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Introduction 
Percutaneous trans luminal coronary angioplasty (PTCA) is an accepted treatment for 
coronary artery disease. However, angiographical restenosis is reported in 40-60% of patients 
after a successful PTCA. 1,2 Mechanisms involved in the restenosis process are elastic recoil of 
the artery, local thrombus formation, vascular remodeling with shrinkage of the vessel and an 
overact healing process with neointimal hyperplasia. 2-5 Neointimal hyperplasia develops by 
migration and proliferation of smooth muscle cells and myofibroblasts after balloon induced 
trauma of the arterial wall and by deposition of an extracellular matrix by the smooth muscle 
cells. 5-8 The introduction of the stent ~ the arsenal of the interventional cardiologist has reduced 
9·]0 II 
the restenosis rate to 15-20%, by preventing elastic recoil and negative remodeling. 
However, the occurrence of restenosis after stent implantation remains unresolved, especially in 
12 
small vessels and long lesions, where it may exceed 30% of the cases. It is primary caused by 
neointimal hyperplasia, which occurs due to trauma of the arterial wall by the stent-struts. The 
treatment of in-stent restenosis with conventional techniques (balloon angioplasty or debulking) 
is rather disappointing with restenosis rates of 27-63%, which increases with the number of re-
. ,13-17 
mterventIOns. 
Since radiotherapy had proven to be effective in treating the exuberant fibroblastic activity of 
keloid scar formation and other non-malignant processes such as ocular pterygia 18·19 it was 
assumed that this adjunctive therapy would also inhibit coronary restenosis. 
mSTORY 
The first experimental study in this field was carried out in 1964 by Friedman et aI, by the 
use ofIridium 192 e92!r) in the cholesterol-fed rabbit.'o In 1992, in Frankfurt, Liermann and 
colleagues performed the first 4 cases of brachytherapy, in patients who had undergone a 
femoral percutaneous angioplasty21 A second wave of experimental work was carried out in the 
United States by Wiedermann and Weinberger in New York/2 Waksman and Crocker in 
Atlantan and Mazur and Raizner in Houston.24 In parallel, Verin and Popowski in Geneva 
conducted experimental studies with the pure B-emitter Wy in carotid and iliac arteries of 
rabbits. 25 The first clinical experience in coronary arteries in humans was performed by 
Condado et al using a hand-delivered 192Ir wire into a non-centered, closed end lumen cathete~6 
and by Verin et al using a B-source and a centered device.27 Both studies demonstrated that the 
delivery of radiation in the coronary artery is feasible and safe, although the restenosis rate 
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remained relatively high. The positive results of the first randomized trial aimed to determine 
the effectiveness of y-radiation for the treatment of in-stent restenosis28 encouraged the 
investigators to design an extraordinary number of studies that will quickly shed light on the 
utility ofbrachytherapy for the prevention of rest enos is. 
BASIC PRINCIPLES 
Radioactive disintegration.- Radioactivity is the process in which atomic unstable nuclei, 
spontaneously change their configuration and energy content to reach a stable state (ground 
state). This event normally brings a change in the basic element itself, that is known as 
radioactive disintegration or radioactive decay. This process is usually associated with the 
emission of particulate or electromagnetic radiation. The particulate radiation is either ct- or 8-
emission. Alpha particles are heavyweight charged particles, which can travel very short 
distances within tissues. Beta particles are lightweight high-energy electrons, with either 
positive or negative charge. A third type of emission originated from the nucleus, known as y-
emission or photon emissio~ takes the form of electromagnetic radiation. An alternate way for 
an unstable nucleus to reach ground state is to capture an electron orbiting just outside the 
nucleus. This process called electron capture, makes the outer shell where electrons are orbiting 
become unstable. To fill the void of captured electrons, other electrons from nearby orbits jump 
to the innermost orbit, which also leads to the emission of photons, called X-rays, which take 
the form of electromagnetic waves. Gamma and X-rays are both high-energy photons, without 
charge or mass. The only distinction between gamma and X-rays lies in its origin: y-rays are 
emitted by the nucleus, whereas the X-rays emanate from electrons jumping to innermost 
orbits. Most often an unstable nucleus will emit an alpha or beta particle followed by gamma 
radiation. Only a few radioisotopes, e.g. Phosphorous-32 (a pure beta-emitter). only emit 
. I . h d· . 29-31 partlc es, Wit out gamma ra latIon. 
The process of radioactive decay is a spontaneous, random event. In a sample with large 
number of atoms, the decay follows exponential behavior. The radioactivity of a sample is 
defined as the number of disintegrations per unit time. The units in which radioactivity has been 
conventionally measured are: 
I becquerel CBq) ~ I disintegration Isecond 
I curie CCi) ~ 3.7 * IOIOBq 
I millicurie CmCi) ~ 3.7 * I07Bq 
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As the nuclei of radioactive material disintegrate, the number of nuclei available for decay 
decreases. The rate of decrease varies among radioisotopes. This value is unique to each 
isotope. This rate of decay follows the exponential formula: 
A(t) ~ A(O) e -{)693' tlT1I2 where, 
A(O) is the known activity of the isotope at a certain time we call zero; A(t) is the activity 
remaining at time t and Tl/2 is a constant called half-life, The half-life of an isotope is the time 
during which its activity reduces to half its original value. 29-31 
Tissue damage indnced by radiation and effective dose.- When radiation is absorbed in a 
tissue, it can either cause direct damage to a critical target by ionization or it can indirect 
damage a critical target by interacting with other molecules to produce free radicals, which will 
subsequently damage the critical target. Approximately 80% of the radiation damage is caused 
by these free radicals, The most critical target that could be damaged by radiation is DNA. The 
consequence of this chromosomal damage, specifically the formation of exchange-type 
aberrations, is that the cell lose its ability to proliferate, which will ultimately lead to its 
death,32 This mode of cell death leads to a dose-response relationship where the fraction of cell 
surviving (S) is a linear-quadratic function ofthe dose (D): 
S = e -u* D -il* D2 where, 
ex and B are constants that are characteristic of a given cell type. At low doses, the linear 
component dominates, but at higher doses (such as the single doses that are proposed for 
intravascular radiation) the term that is quadratic start to dominate. Theoretically, a single 
acute dose of 12 to 20 Gy, would result in a depopulation of smooth muscle cells about 10-3 to 
10--6, that is, only in about 1 cell in 1000 to 1 million would survive. These survivors cells 
would need to double between 12 to 20 times to produce sufficient progeny to block the artery. 
Considering that smooth muscle cells are not malignant and therefore do not have the capacity 
for indefinite proliferation, it may be that a dose of this magnitude could result in a permanent 
inhibition of restenosis. 22,32,33 
Target tissue.- Experimental models have suggested that myofibroblasts in the adventitia 
proliferate after angioplasty and may migrate into the intima where they appear as smooth 
muscle actin-containing cells. 34,35 The effect of radiation on myofibroblasts proliferation in the 
adventitia as well as on the vessel remodeling have been recently reported,36 Endovascular 
radiation after balloon overstretch injury of porcine coronary arteries significantly reduced the 
number of proliferating cells in the adventitia and medial wall compared to controls at a dose of 
14 or 28 Gy prescribed at 2 I1ml into the vessel wall. The higher 28 Gy dose resulted in a much 
-12-
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greater inhibition of cell proliferation in the adventitia compared to 14 Gy.36 In the same study, 
it was observed a sigificant reduction in the extent of adventitial a-actin staining in the 
irradiated vessels as compared to controls, suggesting an inhibition of adventitial fibrosis by the 
radiation treatment, leading to a significant increase in the vessel perimeter (inhibition of 
constrictive vascular remodeling).36 These findings support the concept that the adventitia is the 
target tissue of the intracoronary radiotherapy. 
Radiation Therapy Systems 
Radiation therapy can be delivered to the coronary arteries by external radiation or by 
brachytherapy methods either by catheter-based systems or by radioactive stents. Catheter-
based systems can use both B- or y-emitters, which can deliver the prescribed dose in either 
high or low-dose rate, manually or automatically. Radioactive stents utilize mainly pure B-
emitters in a very low-dose rate. The dosimetry requirements for intraluminal treatment via the 
temporary insertion of radioactive sources can be summarized as follows37: 
I) single fraction acute dose of 10 to 30 Gy to a length of 2 to 4 em of arterial wall, 
approximately 2- to 5 mm ioner diameter, 0.5- to 3 mm wall thickness. 
2) high dose volume confined to the region of angioplasty, with minimum dose to 
normal vessels and myocardium. 
3) dose rates greater than 2 Gy/min (to keep treatment times <15 minutes) thus 
reducing complications (i.e. thrombosis, ischemia). 
4) the radioactive source must have dimensions, stiffness and flexibility compatible 
for use with angioplasty catheters. 
5) source diameter must be less than 0.5 mm, yet stiff enough to be pushed through 
greater than 100 em of artery, and flexible enough to negotiate multiple bends in 
the coronary tree. Source integrity is of great importance, as dislodgement into a 
coronary artery could be fatal. 
The isotopes currently used for intraluminal brachytherapy are depicted in the table: 
Isotope Emission Maximum Energy (MeV) Average Energy (MeV) Half-life 
1921r gamma- 0.6 0.37 74 days 
32P beta- 1.7 0.60 14 days 
90 Sr beta- 0.5 0.20 28 years 
90Y beta- 2.3 0.90 64 hours 
188 Re beta- 2.2 0.79 17 hours 
188 W beta- 0.5 0.17 60 days 
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Overview of thesis 
This thesis is aimed to determine the potential of intracoronary brachytherapy as a new 
technique to prevent restenosis after percutaneous interventions. To that purpose, it has been 
divided in 5 parts. In part I the structural and functional changes that radiation therapy induces 
in coronary tissue are described. In part n dosimetry considerations of this treatment modality 
are discussed. In part m, new methodological concepts derived from the effect of this therapy 
are defined. In part IV, the potential complications secondary to the use of this technique are 
described. And, finally, in part V, the results of clinical trials carried out in our Institution and 
in the rest of Europe are reported. Specifically, we can summarize the aims of this thesis as 
follows: 
1) To define the morphological changes of vessel structures after intracoronary radiation 
therapy by means of either catheter-based systems or radioactive stent following 
percutaneous coronary interventions. This is addressed in chapters 1,2 and 3. 
2) To determine the long-tenn coronary vasomotion of the segment which has been irradiated 
by means of a catheter-based system. This is addressed in chapter 4. 
3) To establish the minimal effective radiation dose to be delivered to the adventitia. This is 
addressed in chapter 5. 
4) To define the dosimetric implications between centering and not centering the radiation 
source into the vessel lumen. This is addressed in chapters 5 and 6. 
5) To determine the intravascular ultrasound predictors of plaque volume at 6-month follow-
up. This is addressed in chapter 5. 
6) To define a new methodology to study the clinical and angiographic implications of this 
new technique. This is adressed in chapters 7 and 8. 
7) To determine the potential limitations of this technique. This is addressed in chapters 9, I 0 
and 11. 
8) Finally, to report on the clinical trials which has been carried out in our Institution and in 
the rest of Europe by the use of intracoronary radiation therapy. This is addressed in 
chapters 12, 13 and 14. 
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Part I 
Mechanism of Action of Intracoronary Radiation Therapy 
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Chapter 1 
Geometric vascular remodeling after balloon angioplasty and beta 
radiation therapy: a three-dimensional intravascular ultrasound study. 
(Circulation 1999;100:1182-1188) 
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Geometric Vascular Remodeling Afier Brachytherapy 
Geometric Vascular Remodeling After Balloon Angioplasty 
and f3-Radiation Therapy 
A Three-Dimensional Intravascular Ultrasound Study 
Manel Sabate, MD; Patrick W. Serruys, MD, PhD; Willem J. van del' Gicssen, MD, PhD; 
Jurgen M.R. Ligthart, BSc; Veronique L.M.A. Coen, MD; I. Patrick Kay, MBChE; 
Anthonie L. Gijzel, MD; Alexander J. Wardeh, MD; Ad den Boer, ESc; Peter C. Levendag, MD, PhD 
Backgroulld-Endovascular radiation appears to inhibit intimal thickening after overstretching balloon injury in animal 
models. The effect of brachytherapy on vascular remodeling is unknown. The aim of the study was to determine the 
evolution of coronary vessel dimensions after intracoronary irradiation after successful balloon angioplasty in humans. 
Methods alld Reslifts-Twcnty-one consecutive paticnts treated with balloon angioplasty and J3-radiation according to the 
Beta Energy Restenosis Trial-l.5 were included in the study. Volumetric assessment of the irradiated segment and both 
edges was performed after brachylherapy and at 6-month follow-up. Intravascular ultmsound images were acquired by 
means of EeG-triggered pullback, and 3-D reconstruction was performed by automated edge detection, allowing the 
calculation of lumen, plaque, and external elastic membrane (EEM) volumes. In the irradiated segments, mean EEM and 
plaque volumes increased significantly (451± 128 to 490.9::!:159 mm l and 201.2±59 to 241.7±74 mm); P=O.OI and 
P=O.OOl, respectively), whereas luminal volume remai11Cd unchanged (250.8::!:91 to 249.2::!: 102 111111J; P=NS). The 
edges demonstrated an increase in mean plaque volume (26.8::!: 12 to 32.6± 10 mm\ P=O.OOO I) and no net change in 
mean EEM volume (71.4±24 to 70.9±24 mny', P=NS), resulting in a decrease in mean luminal volume (44.6± 16 to 
38.3± 16 mmJ , P=O.Ol). 
COllclIlSiof/s-A different pattern of remodeling is observed in coronary segments treated with f3-mdiation after successful 
balloon angioplasty. In the irradiated 'segments, the adaptive increase of EEM volume appears to be the major 
contributor to the luminal volume at follow~up. Conversely, both edges showed an increase in plaque volume without 
a net change in EEM volume. (Circulatioll_ 1999;100:1182-1188,) 
Key Words: balloon. angioplasty. ultrasonics. remodeling. radioisotopes 
RestenoSis after balloon angioplasty (HA) is the major limitation of the technique, occurring after 30% to 40% 
of procedures despite excellent acute results.l Excessive 
neointimal proliferation and extracellular matrix synthesis by 
modified smooth muscle cells in response to injury have been 
suggested as the main mechanisms of reslenosis. 2•J However, 
recent studies identified geometric vascular remodeling after 
SA as a concomitant contributor to the process of 
restenosis."·5 
Endovascular radiation appears to be a novel teChnique, 
which, by use of either 13- or 'Y-isotopes, has inhibited intimal 
thickening after overstretch balloon injury in experimental 
models.~-K The theoretical benefit of radiation in preventing 
ncoinlimal proliferation resides in its killing effect of more 
rapidly dividing smooth muscle cells.9 Two randomi7,ed 
studies demonstrated substantial reduction.~ in restenosis rate 
after treatment of in-sten! restenosis. lo.
" 
The use of either f3-
or 'Y-radiatioll for treatment of de novo coronary lesions has 
been sur:cessfully tested in hUlllans. '2.D 
The effects of hrachytherapy on geometric vascular remod-
eling of de novo (relllcu le.~iolls are .~tiIJ unknown. By 
allOWing direct measurement of the ve~sel wal!, intravascular 
ultrasound (lVUS) imaging hlls been used to study the 
remodeling process in coronary arlerie.~.].1 -,~ Recently, 3D 
IV US reconstruction systems have been introduced, allowing 
the quantitative analysis of a particular segment of interest 
during an automated puHback,17 Furthermore, to prevent 
artifacts caused by systolic-diastolic dimension changes of 
the coronary vessel wa!!, the pullback of the IVUS catheter 
can be performed with ECG gHting.l~ 
The purposes of this llrtic!e were to (I) qwmtify the 
volumes of vessel structures by means of 3D reconstruction 
ofIVUS images of coronary segll1ellL~ succe.~sful1y treated by 
BA followed by f3-radiation therapy, (2) determine the 
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Distal 
Figure 1. Overview of the applied analysis software package.,s.21 A, Schematic presentation of the NUS catheter pullback. B, Two 
computed longitudinal perpendicular views. Corresponding CUi-planes in A are represented by the lellers A and B. C, Outcome 01 mea-
surements. GSA indicates cross-sectional area; h, distance between 2 consecutive catheter positions (0.2 mm). Gray boundary lines 
represent lotal vessel contours; white lines, luminal conlours. 
evolution of these vessel parameters to define the pattern of 
vascular remodeling after coronary irradiation, and (3) eval-
uate the potential effect of brachytherapy on the remodeling 
at both edges of the irradiated area. 
Methods 
Patient Selection 
Patients eligible for the study were those treated successfully with 
BA fullowed by intracu[Unary irradiation according to the !leta 
Energy Restenosis Trial (BERT)- I .5. The purpose of this trial was to 
evaluate the safety and efficacy uf low-t!ose irradiation after BA with 
or without stent implantation in patients with single de novo lesiuns 
of native coronary arteries. The isotupe selected was the pure 
/l-emitting strontium 90, and patients were rant!omly assigned to 
receive doses of 12, 14, or 16 Gray. The inclusiun and exclusion 
criteria of this trial have been previously reportet!.I.l The delivery of 
the rndiatiun was perfonned by the usc of the Beta-Cath System 
(Nuvu.>te Corp).!? The radiation suurce train of this system consists 
of a series of 12 independent cylindrical seeds that contain the 
rndioisotope sources and is burt!ered hy 2 gold ratlio·opaque markers 
separatet! by 30 mm." 
IVUS Image Acquisition Analysis System 
The segment suhjee! to 3D reconstruction was exmninet! with a 
mechankal IVUS system (ClearView, CV1S, Boston Scientific 
Corp) with a sheath·based JVUS catheter incorporating a 30-MHz 
single-element transducer rotating at 1800 rpm (Uilracross, CVIS). 
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The transducer is placed insitle a 2.91', 15-em-long sOlloluccnt distal 
sheath that alternatively houses thc guide wire (during the catheter 
introduction) or the transducer (tluring imaging). The IV US trans-
ducer was withdrawn through the stationary imaging shcath by an 
ECG-triggered pullback device with a stepping motor developed m 
the Thoraxcenter, Ro\terdnrn.20 The ECG-gated im,lge acquisition 
and digitization was performed by a workstation t!esignet! for the 3D 
reconstruction of echocardlugraphie images10 (EchoScan, Tomtec). 
This workstatiull received input from the IVUS machine (video) and 
the palienl (ECG signal) and controlled the motorized transducer 
pullbad tlevice. The steering logic of the work51ation considered the 
heart rale variability and unly acquired images f10m cydes meeting 
a predeterll1ined range; premature beals were rejected. IV US images 
were acquired coinciding with the peak of the R wave. If 1111 R-R 
interval failed to Illeet the preset range, the JVUS catheter remained 
at the S31lle site until a cardiac cycle met the predetermined R-R 
range. Then, the IVUS transducer was withdrawn 200 jim to acquire 
the next image. 17.,".2Cl Given the slice thickness of 200 JLm and the 
length subjett to the analysis of 40 mm (distance between thc 2 gold 
markers uf the mdimion suurce antl 5 mm both edges), 200 
cross-sectiunal images per segment were digitized and analyzed. A 
Microsuft Windows-basetl contour detection program develuped at 
the Thoraxeenter was used for the 3D analysis. 1! This program 
constructs 2longitutlinal scctiuns from the tlata set and itlentifies the 
contours correspont!ing to the iumcn·intima antl media·adventitia 
boundaries (Figure j). Corrections could be performetl interactively 
by "forcing" the contour through visunlly idemified ]loints, and then 
the entire t!ata set was updated.?! Cmeful checking and editing oflhe 
contours of the 200 planar images was performcd with an average oj 
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Figure 2. Longitudinal reconstruction of the NUS cross-sectional images and subsequent volumetric calculations (middle charts) aller 
irradiation (A and A') and at 6-monlh follow-up (8 and B'). Nole increase in scale at follow-up chart reflecting increase in total vessel 
volume. 
60 minutes (or complete evaluation. The area encompassed by the 
lumen-intima and media"advcntitia boundaries defined the lumina! 
and the external clastic membrane (EEM) volumes, respectively. The 
difference between EEM and luminal volumes definetl the pl3ljUe 
volume. Vuiumelril" data were call'U],lled by the formula 
where V is vulume, A is area of EEM or lumen or plaque in a given 
cross-sectional ultrasound image, H is thickness of the coronary 
artery slice reported by this digil'zed cross-sectional IVUS image, 
and n is the number of digitized cross-sectional images encompass-
ing the volume to be measured," The feasibility and intraobservcr 
and interobserver variabilities of this system have been previously 
reported,17,,, The 3D analysis was performed by I investigator. 
Intraob,crver variability was asscssed by analyzing a series of 15 
IVUS volumetric studics at least 3 months apart. Differences in 
EEM, plaque, and lumen volumes were as follows: -0.4±1,0%, 
-0.3 ± 1.3%, and -0.2±0.9%, and the intraclass correlation cocffi-
cicnts were r=0.97, r=O.97, and r=O.98, respectively. 
To dcfine the treatcd segment, a few steps were followed. First, an 
angiogram was performed after positioning the delivery catheter and 
the relation between anatomic landmarks and the 2 gold markers 
were noted. Typically, the aorto-ostial junction and the side branches 
were used as landmarks. The anatomic lamlmark closest to either of 
the gold markers was used as a reference point. During the IVUS 
analysis. this referencc point was identified during a contrast 
injection with the IVUS imaging clement at the same position as the 
gold marker of the source. At the same time, during the contrast 
injection, the image from the IVUS imaging element was recorded 
and the reference point identified, During the subsequent pullback, 
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this reference point was recogniled and used for selecting the area 
subject to the analysis: 30 mnl for the irradiated segment analysis and 
5 mm at both cdges for the "edge erfect" evaluation. In cascs in 
which there were no angiognlphic lamlrn"rks h,wdcring either or thc 
2 gold markers of the delivery catheter, the mininml luminal 
diameter idemiJ1ed during the IVUS pullback lVas used as thc 
reference point. Then, the irradimed segment was defincd by 
selecting slices encompassed within 15 mm pruximal and 15 mm 
distal to the minimal luminal diameter. This approach was necessary 
only in 2 cases. At follow-up, correct matching of the region of 
intcrest was performed by wmparing the longitUdinal rcconstruction 
wilh Ihm aFter trcatmcnt (Figure 2). 
Procedure 
The medical ethics committee of our institution approved the 
study, and all patients signed a wrillen infurmed consent form. The 
patients received aspirill (250 mg) and heparin rio 000 IU IV) before 
the procedure. If the duration or the entire interventiunal procedure 
exceeded 1 hour, additional heparin was given 10 rnaitllain the 
activatcd clotting time >300 scconds. In BERT-I.5, BA was 
pcrformed acconJing to standard c1inic;11 pmctice. Aftcr successful 
angioplasty, intracoronary /3-radiation was perfonncd as previously 
described,Ll and afterward, repeat angiography and IVUS pullback 
were carried out. On average. IVUS pullback lVas performed at 
12±2 minutes (9 to 15 minutes) after BA. A cOlJtinuuu, motorizcd 
pullback at a speed of 0.5 mm/s was lirst carried out, followed by an 
ECG-gated pullback at a step size of 0.2 mrnlstep. Intracorunary 
nitrates were administered immediately before each of the IVUS 
pullbacks. A final angiogmm after the lVUS study concluded the 
procedure. At 6-munth follow-up, further IVUS analysis or the 
trealed area wm; performed. 
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TABLE 1. Baseline Characleristics, (":=:21) 
Male sex, n (%) 
Mean age, y 
Coronary risk faclors, n (%) 
Smoking 
Hyperclloiesteroiemia 
Family history 
HYpertension 
Diabetes 
Treated vessel, n ('/oj 
left anlerior descending 
left circumflex 
Righi coronary artery 
Prescribed dose, n ('/0) 
16 Gy 
14 Gy 
12 Gy 
Statistical Analysis 
16(76%) 
56±9 
14(67%) 
11 (52%) 
11 (52%) 
10(48%) 
4(19%) 
11 (52%) 
6 (29%) 
4 (19%) 
9 (43%) 
4 (19%) 
8 (38%) 
Quantitatil'e data ar~ pr~~~IH<,d ;1>; Illcan±SD. Volumelric data 
deril'etl from the 3D I"ccon>lfudion uf the IVUS imaging were 
cumpared iUlinedimciy after treatment and ut follow-up by use oflhe 
2-lailed, paired Student's I lest. Linenr regression analysis was 
performed to assess the relation hetween lhe change in EEM, lUmen, 
nod plaque dimellsion~ A v,llue of P<O.05 was consitlered slalisti-
cully ~jgllificaill. 
Results 
Baseline Characteristics 
Thilty-one patients were included in BERT-l.5 at our insti-
tution. Eight patients who received stent implantation for 
important recoil or dissection after BA were excluded from 
the volumetric assessment. At foHow-up, the 3D IVUS 
analysis was not performed in 2 patients: 1 patient refused 
and the other returned prematurely with unstable angina 
pectoris secondary to severe restenosis, and only a manual 
IVUS pullback preintervention was possible. Therefore, 21 
patients with volumetric IVUS analysis after treatment and at 
follow-up formed the study population. The baseline charac-
teristics of the patients are presented in Table L 
Clinical and Angiographic Follow-Up 
At follow-up, 14 (66%) patients remained asymptomatic. Six 
patients had stable angina pectoris: Canadian Cardiovascular 
Society dass I (n= 1), class 2 (n=I), and class 3 (n=4). One 
patient was admitted prematurely because of unstable angina 
pectoris. The follow-up angiography demonstrated restenosis 
(>50% diameter stenosis on quantitative coronary angiogra-
phy) in 5 (24%) patients. One restenotic patient demonstrated 
aneurysmatic formation within the irradiated area (Figure 3). 
The prescribed dose in reslenotic patients was 12 Gray (n= I), 
14 Gray (n=I), and 16 Gray (n=3). 
Figure 3. Angiography and 3D reconstruction of an irradiated segment (A, B, and C) that demonstrated restenosis and aneurysmatic 
formation at 6-month follow-up (A', S', and C'). Contour tracing has been manually corrected for distal side branch (black arrowheads 
in bottom charts). prox. indicates proximal. 
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TABLE 2. IVUS Volumetric Analysis 
Patient 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
Mean 
SO 
Artery 
LAD 
LAD 
LC, 
LAD 
RCA 
RCA 
LC, 
LAD 
LAD 
LC, 
LC, 
LAD 
LC, 
LAD 
LAD 
LAD 
LC, 
RCA 
LAD 
LAD 
RCA 
Dose, 
Gray 
12 
14 
16 
12 
14 
12 
12 
16 
14 
16 
16 
12 
12 
12 
16 
16 
16 
16 
16 
14 
12 
14.1 
'8 
LV 
Post 
143.2 
297.6 
206.2 
201.6 
281 
22B.l 
192.1 
169.6 
231.2 
333.2 
392.5 
272.6 
326.4 
154.8 
237.6 
341.2 
2.10.1 
176.6 
234.2 
119 
501.4 
250.8 
91.8 
LV 
Follow-Up 
148.4 
289.2 
222.B 
186 
213.4 
197.9 
257 
176.8 
246.3 
278,9 
490.9 
193 
321.2 
187.8 
216.6 
229 
278.2 
219.3 
225 
108.5 
548 
249.2 
102.5 
dLV 
5.2 
-6.4 
16,6 
-15.6 
-67.6 
-30.2 
64.9 
7.2 
15.1 
-54.3 
98.4 
-79.6 
-5.2 
33 
-21 
-112.2 
68.1 
42.7 
-9.2 
-10.5 
46.6 
-1.6' 
51.5 
EEM 
Post 
321.4 
605.5 
399.3 
313,' 
493.5 
458.7 
352.5 
323.9 
470 
487.2 
718.5 
452.9 
578 
276.8 
332.1 
605.3 
412.6 
415.1 
446.9 
315.7 
694.4 
451.1 
12B.1 
EEM 
Follow-Up 
371.9 
634.8 
426.1 
315.4 
486.1 
442.4 
439.5 
359.3 
489.8 
470.3 
806 
498.2 
676 
337.1 
334.2 
520.4 
600.7 
430.1 
463.2 
296.1 
912.2 
490.9 
159.3 
IlEEM 
50.5 
29,3 
26.8 
2.3 
-7.4 
-16.3 
87.0 
35.4 
19.6 
-16.9 
87.5 
45.3 
98.0 
60.3 
2.1 
-84.9 
188.1 
15.0 
16.3 
-19.6 
217.8 
39.8t 
68.7 
PV 
Post 
178.2 
307.8 
193.2 
111.5 
212.5 
230.6 
160.4 
154.3 
238.8 
154 
325.9 
180.3 
251.6 
122 
94.5 
264.2 
205.7 
238.5 
212.7 
196.7 
193 
201.2 
59.3 
PV 
Follow-Up 
223.5 
345.5 
203.2 
129.5 
272.4 
244.5 
182.4 
182.5 
243.5 
191.4 
315.1 
305.2 
354.8 
149.3 
117.6 
291.4 
322.5 
210.8 
238.3 
187.6 
364 
241.7 
74.0 
dPV 
45.3 
37.7 
10 
18 
59.9 
13.9 
22 
28.2 
4.7 
37.4 
-10.8 
124.9 
103.2 
27.3 
23.1 
27.2 
116.8 
-27.7 
25.6 
-9.1 
171 
40.5* 
49.4 
LAO indicales left anterior descending artery; lCx, left circumllex artery; RCA, righl coronary artery; lV, luminal volume; EEM, external elastic membrane volume; 
PV, plaque volume; and post, after treatment. All values in mm'. 
'P=NS; tP<O.OI; *P<O.OOl. 
Irradiated Segment IVUS Analysis 
Volumetric cakulations of the EEM, lumen, and plaque at the 
site of irradiated coronary segments are presented in Table 2. A 
significant increase in mean EEM volume was observed at 
follow-up (451::'::128 to 490.9::'::159 mm J ; P=O.Ol) parallel to 
that in plaque volume (201.2::'::59 to 241.7::'::74 mm·'; P=O.OOI). 
As u result, mean luminal volume remained um.:hanged 
(250.8::'::91 mml after treatment vs 249.2::'::102 mm~ at follow-
liP; P=NS). Patients as.~igned to receive a dosage of 16 Gray 
showed no differences in teOllS of EEM, lumen, and plaque 
A B 
.,,, 0.'", l"'" v., 
p ........ .. ...... ,u .. 
.. H. ~ ... "" . 
'JI '" 
changes as compared with those a~signed to receive 12 and 14 
Gray. Changes in EEM and plaque volumes showed a signifi-
cant and positive condation (r=O.66; P=O.OOI). Similarly, 
changes ill luminal volumes correlated ~ignificantly with those 
in EEM volumes (/"=0.69; P=O.O(5) hut nol with those in 
plaque volumes (r=0.07, P=NS) (Figure 4). Sixteen (76.2%) 
patients showed a global increase in EEM volume 
(+61.3::'::60 mm'), whereas 3 (14.3%) patients showed a reduc-
tion in plaque volume (-IS.7::':: 10 mm)). Five (23.8'}l» patients 
demonstrated angiographic rcstenosis. In 2 of them, despite the 
c 
G.,,.," HM VOl 
.... 0.'.' ....... , 
............ 
p"."'" 
·11. _. .... -.. 
Figure 4. Unear regression analysis between changes in plaque and luminal volumes (Al, EEM and luminal volumes (6), and EEM and 
plaque volumes (C). EEM Vol indicates EEM volume; PI Vol, plaqoe volume; and Lum vol, luminal volume. 
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Figure 5. Comparison between patterns of remodeling in irradi-
ated area and at edges. 
3bsolutc increilse in EEM volume, a focal increase in plaque 
volume led to restenosis, The remaining 3 patients showed an 
increase in plaque concomitant to a decrease EEM volume. 
Ten (47.6%) patients showed a global increase in luminal 
volume (+4O.1±30 mm\ In 8 of them, the increase in EEM 
volume (+85.7±75 111111') overcame the increase in plaque volume 
(+53.2::':::59 mm'). In the other 2 patienL~, enlargement of EEM 
valum!;: was observed collcomillIDtly to decrease in plaque volume. 
"Edge Effect" IVUS Measurements 
Significant angiographic reduction in luminal diameter in-
volving the proximal edge of the irradiated area was observed 
in I patient at foHow-up. Volumetric calculations demon-
strated a significant mean increase in plaque volume 
(26.8::':: 12 to 32.6::':: JO mm'; "=0.0001) ~ltld no net change in 
mean EEM volume (71.4::'::24 to 70.9::'::24 mmJ ; P=NS), 
resulting in a significant decrease of mean luminal volume at 
follow-up (44.6::':: 16 to 38.3::':: 16 mnl"'; P=O.OI). Changes in 
luminul volumes correlated significantly with those in EEM 
and plaque volume (1-=0.87; P<O.OOO[ and r=-0.51; 
P=O.03; respectively). Conversely, change~ in plaque did not 
cOiTeiate with those in EEM (r=-0.03; P=NS). At the 
edges, percentage of change in EEM and in luminal volume 
differed significantly from those within the irradiated seg-
ment (Figure 5). No differences in volumetric changes were 
observed regarding the 3 ranges of doses. 
Discussion 
Previous studies with y-radiation for the treatment of in-stent 
restenosis have demonstrated a reduction in the restenosis 
rate mainly as the result of a reduction in Ileointimul forma-
tion, as assessed by IVUS.IO.II Our study provides the 
mechanistic interpretation of J3-radiation on remodeling of de 
novo lesions treated with BA. On average, adaptive vessel 
enlargement is the main contributor to luminal volume at 
follow-up by accommodating the increase in plaque volume. 
The importance of geometric remodeling ufter BA has 
been studied both in experimental models5.J).~4 and in hu-
lllans.I~-16 Di Mario et al 15 reported that shrinkage of the 
vessel accounted for 68% of the late loss after BA. Similar 
results were obtained by and Mintz et al,'~ who reported 73% 
of late loss caused by chronic: vessel constriction. A serial 
IVUS study l6 described a biphasic time course of the geo-
metric remodeling after BA. Thus an initial adaptive vessel 
enlargement was observed lip to the first month, followed by 
a late constriction phase during the next 5 months. 
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Only 5 (23.8%) patients demonstrated shrinkage of vessel 
volume 6 months after radiation, whereas the remaining 16 
(76.2%) patients showed vessel enlargement. Furthennore, 
luminal volume appeared to increase in 10 (47.6%) patients. 
These results are in concordance with those obtained by 
Condado et al,'2 who reported a negative late loss in 10 (45%) 
of 22 patients treated with y-radiation. We demonstrated that 
the increuse in luminal volume was mainly due to vessel 
enlargement rather than plaque reduction, which was ob-
served only in 2 patients. 
The ~everity and depth of the arterial wall injury caused by 
the balloon overstretching might induce adventitial inflam-
mation and subsequent fibrosis, which, in tum, might lead to 
contraction of the vesseLH25 The beneficial effect of intra-
vascular radiation on the mtcrial remodeling after angioplasty 
may be explained by a reduction of either cell proliferation in 
the media and adventitia or the expression of a-smooth 
muscle actin in the adventitla, which is responsible for 
fibrotic scar formation after BA."; A potential concern 
regarding coronary brachytherapy is the fact that initially 
favorable adaptive remodeling would lead to late undesired 
aneurysm formation. The incidence of coronary aneurysm 
after BA or stent implantation, as defined as a coronary 
dilatation that exceeded the diameter of normal adjacent 
segments by L5 timcs?7 ranges between 3.9% and 5.4% and 
has not been associated with angiographic restenosis or 
unfavorable clinical outcome.2R •29 Tbe incidence and progno-
sis of aneurysm formation after radiation is unknown. In our 
cohort, I patient demonstrated this complication at 6-month 
follow-up. Condado et al 12 reported 4 (20%) cases of aneu-
rysmatic foonation within 2 months after ,,-radiation. In 2 of 
them, a further increase of the size was observed at 6 and 8 
months, respectively.';' 
An interesting finding was the concurrent vessel enlarge-
ment and focal plaque increase, as observed in 12 patients, 
resulting in restenosis in 2 of them. Inhomogeneity of dosing 
caused by the lack of centering might account for this 
paradox. Therefore the actual dose to the luminal surface and 
adventitia appeared to be highly variable between patients as 
calculated by means of dose-volume histograms. JO A more 
homogeneous dose distribution might be achieved by use of 
a centering catheter or a y_source. JO 
As opposed to the pallern of remodeling within the 
irradiated area, the edge segments demonstrated a significant 
decrease in mean luminul volume. A lack of adaptive remod-
eling concomituntly to an increase in plaque volume ac-
counted for the residua! luminal volume at the edges. The 
edge of the radiation source represents an area receiving 
low-dose radioactivity_ It is hypothesized Ihal a low activity 
could have a proliferative effect, especially when associated 
with injury induced by BA.]I 
Sfudy Limitations 
This study was not placebo-controlled. Consequently, no 
conclusion about the effectiveness of f3-irradiation in prevent-
ing neointimal formation can be extrapolated. 
A potential source of error is germane to the presence of 
the IVUS catheter in the lumen. In relatively small vessels, 
this can result in vessel stretching, resulting in volumetric 
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overestimation. Alternatively, the distending pressure on the 
vessel may be substantially decreased by the presence of the 
catheter that fiUs a significant parI of the lumen. This 
limitation could be especially relevant in studies evaluating 
only 1 cross-section at the narrowest part of the segment. 
However, in our cohort, none of the segments showing 
aduptivc remodeling demonstrated any area in which the 
lumen were occluded by the IVUS catheter. 
The method of selection of the area of interest is the best 
available. However, despite the meticulous procedure followed, 
a small inaccurncy cannot be completely ruled out. Ideally, ncw 
systems incorporating the IVUS imaging element on the deliv-
ery catheler would resolve this drawback. 
llle follow-up period of our cohort might be shoJ1, considering 
the fact that va~ular irradiation may delay restenusis by I to 3 
ye:m.·n Therefore the observed vessel enlargement might represent 
an early pha'>e of the effect of ,B-rarlialion therapy afler BA. 
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Chapter 2 
The effect of p32 beta-radiotherapy on both vessel remodeling and 
neointimal hyperplasia after coronary balloon angioplasty and 
stenting. A three-dimensional intravascular investigation. 
(J In vas CardioI2000;12:1l3-120) 
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Abstract 
lntracoronary radiation is a promising therapy to decrease restenosis after percutaneous intervention. The 
aim of this pilot study was to determine the mechanism of intracoTonaJY beta-radiation after halloon 
angioplasty and stenting in a double-blind placebo-controlled randomized fashion. Twenty-six patients were 
randomized to either placebo (n = 6) or 3 doses (28, 35 and 42 Oy) of beta-radiation (n = 20) using the 
Guidant brachytherapy system (27-mm long p32source wire). Of these, 21 patients underwent post-procedure 
and 6-month follow-up three-dimensional IVUS assessment. Volumetric quantification was performed by 
means of a semi-automated contour detection system after an ECG-gated motorized pullback lVUS imaging 
and three-dimensional reconstruction. We compared the volumetric changes (A) of total vessel volume 
(TVV), plaque volume (PV) and lumen volume (PV) after 6 months between placebo (dummy wire) and 
irradiated patients. In addition the volume of neointimal hyperplasia was quantified within the stented 
segments. There was an opposite behavior ofTVV and LV change between placebo (ATVV = - 24 mm3 and 
L!L V = - 42 mm3) and irradiated (ATVV = + 18 mm3 and L!LV = + 5 mm3) patients. The mean neointimal 
fonnation within the stented segment in the in-adiated patients (n = 7) was 1.9 mm3 (1.5%). Our results 
suggest that beta-radiation affects vessel remodeling after percutaneous intervention and inhibit neointimal 
formation in stented patients. 
Key words - Brachytherapy, remodeling, neointimal hyperplasia 
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Introduction 
Restenosis after percutaneous intervention has been reduced with the advent of coronary stents (1, 
2). However, further reduction in the incidence of restenosis appears to be difficult using conventional 
approaches. 
The introduction of intravascular ultrasound (IVUS) in the clinical practice has refined our 
knowledge about the mechanism of restenosis. Thus, the restenotic process can be divided in two 
components: vessel remodeling and neointimal formation. The former predominates after bal100n 
angioplasty (BA) whereas the latter is the main cause ofin-stent restenosis. (3, 4) 
Intracoronary radiation is a promising therapy to decrease restenosis after percutaneous intervention. 
Stimulated by animal studies showing inhibition of neointimal formation by radiation (5-7), two 
randomized trials have shown the reduction of restenosis by treating restenotic lesions with gamma 
radiation.(8,9) 
Furthermore, a non-randomized study has shown the safety and feasibility of beta radiation, with a 
satisfuctory (15%) rate of rest enos is in de novo lesion treated with balloon angioplasty (10). Recent 
lVUS investigations have shown that beta radiation after BA may affect vessel wall remodeling (11-
13). Experimental studies have corroborated these findings. (14,16) 
Thus, the relative contribution of radiation on vessel remodeling and neointimal fonnation remains 
to be elucidated. The aim of this pilot study was: 1) to assess the effects of beta-radiotherapy on 
coronary segments successfully treated by BA or stenting, 2) to compare the behavior of irradiated and 
non-irradiated (sham) coronary segments 6-month after treatment by means of a volumetric three-
dimensional (3-D) NUS assessment. 
Methods: 
Patient selection 
In this double-blind feasibility and safety study, 26 patients (pts) were randomized to either sham 
(placebo) or 3 different doses of beta-radiation (28, 35 or 42 Gy, as calculated at 0.5 mm into the 
vessel wall). The Medical Ethic Committee of University Hospital Dijkzigt has approved the use of 
intracoronary radiation. All patients gave written infonned consent. 
Radiotherapy system 
The Guidant Brachytherapy System used in this study includes a O.OIS-inch nitinol wire with 27-
mm of p32 source at its tips. The use of a centering spiral balloon (27 mm long) allows the 
administration of prescribed dose homogeneously in the vessel wall as well as distal vessel perfusion 
during balloon inflation at a maximum inflation pressure of 4 atmospheres. Automated source delivery 
unit controls dose delivery and source withdrawal, providing "hands-off" radiation delivery (17). The 
duration of the treatment and dose necessary to reach 0.5 mm into the vessel wall are calculated using 
the mean reference vessel diameter by IVUS immediately prior to radiation delivery. 
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NUS Analysis System 
The segment subject to 3-D reconstruction was examined with a mechanical lVUS system 
(ClearView, CVlS, Boston Scientific Corporation, Maple Grove, MN) with a sheath-based IVUS 
catheter incorporating a 30 MHz single-element transducer rotating at 1800-rpm (Ultracross, CVIS). 
An EeG-gated image acquisition and digitization was performed by a workstation designed for the 3-
D reconstruction of IVUS images (EchoScan, Tomtec, Munich, Germany) (18). IVUS images were 
acquired coinciding with the peak of the R wave, which eliminates. the artifacts caused by the 
movement of the heart during the cardiac cycle. Then, the IVUS transducer was withdrawn every 0.2 
mm to acquire the next image coincident to the R-wave. (18) 
A Microsoft Windows™-based contour detection program, developed at the Thoraxcenter, was used 
for the 3-D volumetric quantification,(19) The feasibility and intra- and inter-observer variability of 
this system have been validated in clinical protocols.(20,21). Briefly, this program constructed 
longitudinal sections from the data set and identified the contours corresponding to the lumen and 
media and stent boundaries, Careful checking and editing of the contours of the planar images were 
perfonned by two independent experts who were blinded to the treatment assignments, 
Volumetric data were calculated by the formula: V= :L\ol Ai * II, where V = volume, A = area of 
EEM, lumen, stent or plaque in a given cross-sectional ultrasound image, H = thickness of the 
coronary artery slice, that was reported by this digitized cross-sectional lVUS image, and n = the 
number of digitized cross-sectional images encompassing the volume to be measured. (19) 
The methodology to define the treated segment has been previously described (13). Angiogram was 
performed after positioning the radioactive source in the centering balloon and the relationship 
between anatomical landmarks and the two radiopaque markers of the radiation source were noted 
after contrast injection (figure 1). Typically, the aorto-ostial junction and the side-branches were used 
as landmarks. The anatomical landmark closest to either of the source markers was used as a 
reference point. During the subsequent IVUS imaging pullback, this reference point was recognized 
and used for selecting the area of interest: 27 mm for the irradiated segment analysis. In addition, in a 
separate analysis we selected only the segment covered by stents within the irradiated area. This was 
facilitated by the high echogenic characteristics of the stent struts. At foHow-up, correct matching of 
the region of interest was performed by comparing the longitudinal reconstruction to that post-
procedure (figure 2). 
Procedure 
All patients received aspirin (250 mg/day) and heparin IV (10.000 ill) before the procedure and stented 
patients also received ticlopidine (25Omglday). Heparin was given to maintain the activated clotting time 
>300 sec. BA and stenting were performed according to standard clinical practice, In the stented patients, 
high-pressure post-balloon inflation was performed guided by lVUS, The diameter of the centering balloon 
was chosen based on IVUS mean reference vessel size (average of the mean distal and proximal reference 
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diameters}. 1his measurement was pelfolIDed after optimization the results of balloon angioplasty or 
stenting. Thus, the centering ba11000 was placed in the target segment and inflated to 4 atmospheres. After 
testing the perfusion of the distal coronary segment and checking the correct placement of the centering 
balloon by contrast injection (figure I), the radioactive or «dummy" source wire (27 mm) was placed in the 
centering balloon by means of the automatic delivering system. Afterwards, repeat angiography and IVUS 
pullback were carried out. A continuous motorized pullback at a speed of 0.5 mmlsec was first carried out, 
followed by an ECG~gated pullback at a stepwise of 0.2 mmistep. Intracoronary nitrates were administered 
immediately prior to each of the IVUS pullbacks. At 6-month follow-up, further IVUS analysis of the treated 
area was perfOITIled. 
Quantitative 3-D NUS Analysis 
The following volumetric measurements were obtained: total vessel (External Elastic Membrane - EEM) 
and lumen. Plaque volume was automatically calculated by subtracting lumen volume from the total vessel 
volume. 
In stented patients, after selecting only the segment covered by stent, we also calculated neointimal 
hyperplasia, which was calculated by subtracting lumen volume from stent volume. In-vivo measurement of 
neointimal fonnation after stenting has been previously validated (22). Plaque volume outside the stent was 
also calculated by subtracting stent volume from total vessel volume within the stented segments. The 
assessment of EEM in stented patients has been reported (23). Although, in this previous report the 
delineation of EEM was not possible in some patients due to the stent shadowing, in our study the 
delineation ofEEM boundary was possible in all stented patients. When the EEM boundary was not visible 
in a single cross-sectional view, the computer interpolated it from the contours of the immediately previous 
and following cross-sections. In addition, the use of three-dimensional reconstruction with multiple 
longitudinal views facilitates the visualization of vessel structures outside the stent. In all cases, the stented 
segment was covered by the radiation or dummy source wire. 
In order to assess the volumetric changes of the vessel structures after 6 months, the delta value for each 
measurement was calculated (delta (.6.) = follow-up - post-procedure). 
Statistical a"alysis 
Quantitative data are presented as mean ± standard deviation. The comparisons between the volumetric 
data of placebo versus irradiated patients and stent versus BA patients (in the irradiated group) were 
perfonned using an unpaired Student's t-test. A value of p<O.05 was considered statistically significant. 
Results 
An patients have completed 6-month clinical follow-up. Of these, 5 patients (1 placebo) did not undergo 
IVUS at 6 months: 2 irradiated patients presented sub-acute thrombosis, one presented late (3 months after 
the procedure) thrombotic occlusion and another irradiated patient had a severe restenotic lesion 
demonstrated by angiography. The lesion was located in an area not covered by radiation, proximal to the 
irradiated site where a balloon was inflated to treat a proximal dissection. Thus, only a manual IVUS 
-37-
Remodeling AJier Balloon Angioplasty or Stent and Brachytherapy 
pullback was perfonned in this patient prior to reintetvention. The non-irradiated patient was asymptomatic 
with a negative stress test at the time of follow-up but refused angiographic restudy. 
Thus, the results of this study consisted of a cohort of 21 patients with successful post-procedure and 
6-month three-dimensional IVUS assessment. Sixteen patients were actually treated with radioactive 
source, while 5 patients received placebo treatment. In the radiation group, 6 pts received 28 Gy, 5 pts 
35Gy and 5 pts 42 Oy. Additional stent was implanted after BA in 7 pts (44%) in the irradiated group 
and 3 pts (60%) in the placebo group (p = NS). All patients were discharged on day 2 after the 
procedure without complication. The medication at discharge consisted of: aspirin (2S0mg/day) and 
ticlopidine (250 mg/day, only for stented patients). The dwell time for delivering the prescribed 
radiation dose ranged from 1.5 to 8 minutes. There was no complication related to the radiation 
treatment protocol. Clinical and demographic characteristics were similar between placebo and 
irradiated patients (table 1). Post-procedure and follow-up IVUS measurements are summarized in 
table 2. At 6-month follow-up, we observed a smaller minimal lumen area (MLA) and greater 
percentage of plaque area in the placebo group compared to irradiated group. 
Volumetric Changes (A) After 6 Months Placebo versus Irradiated 
As illustrated in figure 3, the volumetric change of the total vessel volume (ATVV) occurred in an opposite 
direction between irradiated and placebo patients. While the irradiated patients demonstrated a positive 
A TVV (increase of the TVV at follow-up), placebo patients demonstrated a negative A TVV (decrease of the 
TVV at follow-up). Equally, an opposite behavior was observed regarding the volumetric changes of the 
lumen volume (AL V). The placebo group demonstrated a negative ALV, whereas irradiated patients showed 
a positive ALV (p = 0.01). However, plaque volume (APV) increased in both groups in a similar degree 
(positive APV). There was no relationship between prescribed doses and volumetric changes. 
Irradiated Patients - Stent versus BA 
In the analysis of the entire (27 mm) irradiated segment, stented patients (n=7) demonstrated 
similar volumetric changes after 6 months compared to BA patients (n=9) as illustrated in figure 4. it 
is of interest to note that, in the stented patients, PV consists of the total amount of plaque outside and 
inside the stent. In addition, this analysis quantified the entire irradiated segment including segments 
covered and uncovered by stents. 
Analysis of the Stented Segment (Irradiated Patients) 
In this analysis, only the segments covered by stent were selected for volumetric quantification. The 
average stent length (segment analyzed) was 18.1 ± 6.36 mm. Post-balloon dilation was perfonned in 
all cases at a mean pressure of 14.6 ± 3.2 atmospheres. At follow-up, we observed a neointimal 
hyperplasia volume of 1.89 ± 2.99 mm 3 with a mean percentage neomtimal fonnation of 1.47 ± 2.49 
%. The TVV within the stented segment demonstrated a non-significant increase after 6 months 
(post-procedure TVV of 260 ± 68 mm3 versus 272.2 ± 97 mm3 at follow-up, p = NS). The plaque 
volume outside the stent also demonstrated a non-significant change at follow-up (post-procedure PV 
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of 131 ± 32 mm 3 versus 141 ± 63 mm 3 at follow-up, p = NS). Stent volume remained unchanged (no 
recoil) after 6 months (129.5 ± 39 mm3 post-procedure versus 131 ± 39 mm3. at follow-up, p = NS). 
Discussion 
This pilot investigation demonstrates that beta-radiation affects vessel remodeling after 
percutaneous intervention. In addition, neointimal formation within the stented segment was almost 
absent in our irradiated population. However, the small size of our stented population should be taking 
into account before drawing any defmitive conclusion. 
Considering that vessel shrinkage accounts for about 50-70% of the mechanism of restenosis after 
conventional BA (3) and radiation has been shown to reduce the restenosis rate in the setting ofBA (10), the 
conclusion that radiation affects vessel remodeling seems logical. Clinical (13) and experimental data (14-
16) have already suggested the influence of radiation on vessel remodeling. 
IVUS analysis of patients enrol1ed in the BERT trial has also suggested that radiation may prevent 
vessel shrinkage after BA (I 1,12). The use of single cross-section planar lVUS images limited the 
study of Meerkin et al to assess the influence of radiation on vessel remodeling. The 4 coronary 
aneurysms reported by Condado et al exemplified the extreme expression of this phenomenon in a 
series of patients receiving high doses of gamma radiation. (24) 
Tn accordance to the findings of the present study, a recent clinical investigation from our group using the 
same methodology has demonstrated that beta-radiation using a 90SrIY -source influence vessel wall 
remodeling after BA. (13) In 21 patients analyzed, there was a significant increase of the total vessel volume 
after 6 months in patients enrolled in the BERT 1.5 trial.(13) However, the exclusion of stented patients in 
this previous study did not allow further insights into the mechanism of radiation on the inhibition of 
neointimal proliferation. 
The opposite pattern of change in total vessel volume between the irradiated population (positive A TVV) 
and placebo (negative ATVV) observed in our study may confinn the influence of radiation on vessel wall 
remodeling. In addition, the combination of a smaller total vessel volmne and bigger plaque volmne at 
follow-up accounted for the reduction of lumen observed only in the placebo group. Similar patterns of 
structural vessel changes have been previously reported after conventional percutaneous intervention in non-
irradiated coronary segments. (3) 
On the other hand, gamma radiation has been shown to decrease the incidence of restenosis in stented 
patients treated for in-stent restenosis (8,9). Once again, another logical conclusion may rise in favor of 
radiation inhibiting neointimal fonnation. Clinical and experimental reports have emphasized the effect of 
gamma radiation on inhibiting neointimal formation (5-9). In our stented population, the amount of 
neointimal formation was only 1.89_rrun3, which suggests that beta-radiation also inhibits neointimal 
formation after conventional stenting. 
The assessment of plaque growth outside the stent is a novelty in the setting of brachytherapy. A previous 
NUS study (25), has demonstrated the progression of plaque mass within and surrounding conventional 
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stents. However a recent report investigating 15 non-irradiated stented coronary segments did not 
demonstrate plaque growth outside the stent. (23) In our study, the plaque volrnne outside the stent and TVV 
showed a non-significant increase of 10- and 12-mm3 after 6 months, respectively. Further IVUS studies 
should investigate the influence of radiation on neointimal formation, plaque growth (outside the stent) as 
wen as vessel remodeling in stented patients. 
This pilot study contributes to a better understanding of the complex interaction between radiation and 
vascular structures. By comparing, for the first time, three-dimensionallVUS parameters of beta-irradiated 
and non-irradiated coronary segments our study demonstrates that radiation affects vessel remodeling after 
percutaneous intervention. In addition, this seminal study suggests that beta-radiation may also inhibit 
neointimal formation after stenting. It is nevertheless of interest to note that to date only few reports using 
serial IVUS investigation after either beta-radiation in the setting ofBA or gamma radiation in the setting of 
stenting are available. Thus, the confirmation of these findings by a large population study with volumetric 
IVUS assessment is required. 
Limitations 
The size of the population is the major limitation of this pilot study, which has insufficient statistic power 
to demonstrate some differences. However, this is a pioneering investigation using 3-D IVUS to assess the 
effects of beta-radiation after either BA or stenting. In addition, this is the first study to compare irradiated 
versus non-irradiated coronary segments by means of a volumetric assessment in a randomized fashion. The 
similarity between our findings and those previously reported on either irradiated (13) or non-irradiated 
coronary segment (3) may endorse our conclusions. 
The difficulty to assess patients with severe restenotic lesions is a limitation of the methodology used in 
this study_ Thus, the assessment of the mechanism involved in an '''aggressive'' vessel wall reaction after 
intervention, as observed in one patient ofthis study, cannot be performed. 
Although the prescribed dose was not related to any vessel structural change after 6-month the actual dose 
received by the target segments was not calculated in this study, limiting any dosimetric consideration. 
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Table 1. Baseline and demographic characteristics 
Variable Irradiated (n - 16) Placebo (n - 5) P value 
Age, years 59.2 ± 9.6 56 ± 10.9 NS 
Gender, male II (79%) 4 (80%) NS 
Diabetes 0 0 NS 
Smoking 6 (38%) 2 (40%) NS 
Hypercholesterolemia 9 (56%) 3 (60%) NS 
Hypertension 5 (31%) 0 NS 
Family History ofeAD 6 (38%) 2 (40%) NS 
Previous MI 7 (44%) 3 (60%) NS 
Angina Status, CCS 3/4 12 (75%) 5 (100%) NS 
Treatment site at LAD 7 (34%) 3(60%) NS 
Restenotic lesion 4 (25%) 1 (20%) NS 
CAD means coronary artery disease, MI means myocardial infarction, CCS means Canadian Class 
Society, LAD means left anterior descending coronary artery. 
Table 2. Post-procedure and follow-up 3-D NUS measurements. 
TVV,mrr? PV,mmJ LV,mm.1 MLA,mm2 Plaque burden 
atMLA, % 
Post FU Post FU Po. FU Po. FU Post FU 
Irradiated 385± 110 403± 133 J 98± 63 214± 74 185± 60 190± 63 4.8±2 4,7± 1 63± 9 64±9 
(n= 16) 
Placebo 415± 101 39l± 98 210± 58 228± 69 205± 62 163± 44 4.7± 1 3.3± I 60± 16 76± 14 
(n = 5) 
P value NS NS NS NS NS NS NS 0.Q46 NS 0.042 
TVV indicates total vessel volume; PV indicates plaque volume, LV indicates luminal volume; MLA 
indicates minimal luminal diameter; post indicates post-procedure; FU indicates follow-up. 
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Figure 1- A M Pre-procedure angiogram of the left anterior descending attery (LAD) 
B - Angiogram to veritY the COlTect position of the spiral centering balloon and 
source wire. Distal perfusion is also confirmed as well as the anatomical landmarks 
for 3-D IVUS reconstruction of the irradiated segment. 
C - Post-procedure angiogram of the LAD demonstrates good angiographic result. 
D - Six-month follow-up angiography without restenosis. 
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Figure 2- A -Post-procedure 3D-lVUS imaging and volumetric quantification. Left panel -
one planar cross-section view is displayed and the lumen (inner line) and EEM 
( outer line) area are delineated. Right panel - In the top~ one longitudinal view is 
displayed with the anatomical landmark (side branch - arrowhead) used to 
detennine the segment for volumetric quantification. Lumen and EEM boundaries 
are delineated in the segment of interest. In the bottom, a graphic displays the 
consecutive areas of the entire set of planar images - used for volumetric 
quantification. The values of the plaque area are shown as a gray field between two 
lines (vessel and lumen areas). The absolute value of the plaque area can be derived 
from this field, but is also displayed as single black line. 
B -3D-IVUS imaging and volumetric quantification at follow-up. The correct match 
is determined on longitudinal and planar views using the anatomical landmark 
(arrowhead). Lumen and vessel boundaries are delineated in both planar and 
longitudinal views. The graphic of the vessel, lumen and plaque areas is also 
displayed. 
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Figure 3- 3D-IVUS analysis of stented coronary segments. Longitudinal (post-procedure [AJ 
and follow-up [BD and planar (A' and B') views are displayed. Lumen and stent 
(white lines), and vessel boundaries (black line) are delineated in the planar image 
and in one of the longitudinal views. At follow-up (8, B') we can observe the 
delineation of neointimal hyperplasia between the lumen and stent boundaries 
(white lines). The visualization of the EEM boundary behind the stent and 
neointimal hyperplasia are illustrated in the longitudinal views without contours as 
well as the anatomical landmark (side branch with a spot of calcium in the ostium) 
used for correct match between post-procedure and follow-up analyses. 
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Figure - 4 Volumetric Changes (d) of the total vessel (TW), plaque CPV) and lumen (LV) in 
the target (27-mm long) coronary segments after 6 months. Comparison between 
irradiated and placebo patients. 
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Figure - 5 Volumetric Changes (d) of TVV, PV and LV within the irradiated coronary 
segment (27-mm long) after 6 months. Comparison between balloon angioplasty and 
stent patients. 
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Chapter 3 
Positive geometric vascular remodeling is seen after catheter-based 
radiation followed by conventional stent implantation, but not after 
radioactive stent implantation. 
(Circulation (in press)) 
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Positive Geometric Vascular Remodeling is seen after Catheter - Based Radiation 
Followed By Conventional Stent Implantation, But Not After Radioactive Stenl 
Implantation 
I. Patrick Kay, MBChB, Manel Sabate, MD, Marco A Costa, MD, Ken Kozuma, MD, Mariano 
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.Abstract 
Background. Recent reports have shown that intracoronary radiation affects not only 
neointimal formation but also vascular remodeling. Given the different way in which 
radioactive stents and catheter - based techniques deliver radiation one may expect different 
mechanisms of remodeling after each technique. 
Methods and Results. We analyzed remodeling III 18 patients after conventional stent 
implantation (C), 16 patients after low activity (LA) radioactive stent implantation, 16 patients 
after higher activity radioactive stent implantation (HA) and finally 16 patients who underwent 
catheter - based radiation followed by conventional stent implantation (CBS). Intravascular 
ultrasound with 3 - dimensional reconstruction was used post stent implantation and at 6 -
month follow - up to assess remodeling at the stent edges and within the margins of the stent. 
Baseline, vessel and procedural characteristics were similar between groups. In - stent 
neointimal hyperplasia was inhibited by HA (+9.0mm3) and by CBS (+6.9mm3 (compared with 
LA (+2I.2mm3) and C (+20.8mm'), p<O.05. No difference in plaque or total vessel volumes 
was seen behind the stent in the C , LA or HA groups. However a significant increase in 
plaque (+15%) and TVV (+7%) was seen in the CBS group (p<O.05). At the stent edges, no 
edge restenosis was witnessed in the C, LA or CBS groups. Edge restenosis was seen after HA 
implantation and appeared to be due mainly to an increase in plaque and to a lesser degree to 
negative remodeling. 
Conclusions. Distinct differences in the patterns of remodeling exist between conventional, 
radioactive and catheter - based radiotherapy with stenting. Users of radiation need to be 
alerted to the deleterious remodeling seen at the stent edges after higher - dose radioactive stent 
implantation and behind the stent after catheter - based radiation and stenting. 
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In our enthusiasm to control vessel recoil and remodeling after balloon angioplasty (BA), 
stent implantation has become increasingly popular. With conventional stenting we have 
eliminated recoil and remodeling as components of the restenotic process. However this has 
been at the cost of exacerbating neo intimal proliferation secondary to chronic vessel wall 
irritation, leading to in - stent restenosis!,2. Intracoronary radiation has been developed in an 
attempt to decrease restenosis after BA and stent implantation. Two parallel technologies, one 
employing radioactive stents3-7, the other catheter - based radiation8-lO, have been the subject of 
both animal and human studies. Given the different dose rates and total doses delivered by 
each method, intuitively one may expect different patterns of remodeling subsequent to each 
approach. 
Whereas the effect of catheter-based radiation after BA on vascular remodeling has been 
described II, the response of the arterial wall to catheter-based radiation and subsequent stent 
implantation is not described. Preliminary studies have reported the effect at the stent edge 
after radioactive stent implantation4• These reports do not encompass the response behind the 
stent in the arterial wall however. 
The aim of this study was to describe the response of the coronary artery to radiation and 
stenting, by looking at the stent and its edges after radioactive stent implantation and also after 
catheter - based radiation with stent implantation. 
Methods 
Patient Selection 
We analyzed geometric vascular remodeling in 4 groups of patients: 
1. those who had undergone implantation of 32p - emitting radioactive stents at activity levels 
ofO.75-1.5/lCi (Isostent'M Inc., San Carlos, CA, USA) 
2. those who had undergone implantation of 32p radioactive stents at activity levels of 6.0-
12/lCi (IsostenFM Inc., San Carlos, CA, USA) 
3. those who had undergone conventional stent implantation after suboptimal BA (clinically 
significant dissection or residual stenosis> 30%) and catheter - based radiation. 
4. those who had undergone conventional stent implantation after suboptimal BA. 
Stents analyzed were from patients with single native vessel coronary artery disease, normal 
left ventricular function and objective evidence of ischemia. All groups were matched for 
patient baseline characteristics, vessel size, lesion and stent length (mean stent length 15rrun) 
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Stents placed in the ostial position or adjacent to major side - branches, such that the stent 
edges were unable to be analyzed, were excluded from analysis, Only patients who had 
completed 6 - month angiographic and IVUS follow - up were included. 
Implantation technique 
The same group of cardiologists, using a similar technique implanted all stents. 
Predilation of the lesion was performed, followed by stent implantation using either a pre -
mounted stent or the Johnson & Johnson Intervention Systems delivery system (Johnson & 
Johnson Interventional Systems Co, Warren NJ, USA). Higher - pressure balloon inflation to 
ensure good strut apposition to the vessel wall then occurred. At this time we used a shorter 
balloon to ensure that the edges of the balloon did not extend beyond the limits of the stent. 
Intravascular ultrasound was used to ensure optimal stent deployment. 
Medication 
Patients received 250 mg aspirin and 10000 international units heparin at the initiation of the 
procedure and the activated clotting time was maintained at > 300 seconds. All patients received 
aspirin 80mg daily indefinitely and ticlopidine 250 mg BID for 2 weeks (C) or 4 - 12 weeks 
(LA, HA and CBS), after stent implantation. 
Radioactive stenls 
The BX'" stent (Isostent'" Inc., San Carlos, CA, USA) was the only radioactive stent 
implanted in this trial. It was 15mm in length and available in diameters of3.0 & 3.5 mm. The 
BXTM stent was made radioactive by Phosphorus-32 e2p). The initial activity of the stents was 
measured and thereafter it was calculated at what date the activity had decreased to 0.75-1.5 
f!Ci or 6-12 f!Ci, suitable for implantation. The dose delivered over 100 days at 1 mm from the 
stent surface was calculated for each implanted stent. 
Catheter - based radiation delivery system 
The Beta-Cath System (Novoste Corp., Norcross, GA) was used to deliver localized /3-radiation 
('osrfx'Y) to 2mm depth from the center of the source at the site of coronary intervention. The 
device consisted of 3 components: (l) the transfer device which stores the radiation source train and 
allows the positioning of these sources within the catheter; (2) the delivery catheter, which is a 5 
French (F) multilumen over-the--wire non-centered catheter which uses saline solution to send and 
return the radiation source train; and (3), the radiation source train consisting of a series of twelve 
independent cylindrical seeds which contain the radioisotope 90Sr sources and is boundaried by 2 
gold radiopaque markers separated by 30 mm. Other device and procedural details have been 
previously published by this group. 11 
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Definitions 
Stent Edges: Stent Edges were defined as those volumes axially 5rnrn proximal and distal to the 
fmal stent strut. An edge restenosis was defmed as an angiographic restenosis >50% at 6-
month follow - up located at either stent edge. An edge - effect was defined as any stent - edge 
renarrowing. 
Patients with balloon - injured edges which failed to receive radiation in the catheter - based 
radiation group were excluded. In other words no stents implanted in areas of geographical 
miss were included in this study. 
IVUS image acquisition analysis 
After the fmal balloon inflation and administration of intracoronary nitrates, ECG - gated 
IVUS pullback was performed. This was repeated at 6 month follow-up. 
The segment subject to 3-D reconstruction was examined with a mechanical IVUS system 
(ClearView, CardioVascular Imaging System, CVIS, Sunnyvale, CAl with a sheath-based IVUS 
catheter incorporating a 30 MHz single-element transducer rotating at 1800 rpm. The IVUS 
transducer was withdrawn througb the stationary imaging sheath by an ECG-triggered pullback 
device with a stepping motor.!2 IVUS images were aquired coinciding with the peak of the R wave, 
which eliminates the artefacts caused by the movement of the heart during the cardiac cycle. After 
each image acquisition the transducer was withdrawn O.2mm to aquire the next image coincident 
with the R - wave. The ECG-gated image acquisition and digitation was perfonned by a 
workstation designed for the 3-D reconstrnction of echocardiographic images 12 (EchoScan, Tomtec, 
Munich, Germany) A Microsoft Windows™-based contour detection program, developed at the 
Thoraxcenter, Rotterdam was used for the automated 3-D analysis of up to 200 lVUS images.13 
This program constructs two longitudinal sections and identifies the contours corresponding to the 
lumen-intima and media-adventitia boundaries using a minimum-cost based software algorithm. The 
feasibility, reproducibility and the inter- and intraobserver variability of this system have been 
previously validated in clinical protocols!!. 
Quantitative IVUS analysis 
At the stent edges the area encompassed by the lumen-intima and media-adventitia boundaries 
defined the luminal and the total vessel volumes, respectively. The difference between luminal and 
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total vessel volumes defined the plaque volume. Within the boundaries of the stent total vessel 
volume (TVY), stent volume, neointimal hyperplasia (NIH ~ stent volume -lumen volume) plaque 
behind the stent (pBS ~ TVY - stent volume) and lumen volumes were obtained. NIH presented is 
a measured value at follow - up and not derived from subtraction of the post and follow - up 
measures. 
The assessment ofTVY or EEM in stented patients has previously been reported l4• Although, 
in this previous report the delineation of TVVIEEM was not possible in some patients due to 
stent shadowing, in our study the delineation of EEM boundary was possible in all stented 
patients. When the TVY IEEM boundary was not visible in a single cross - sectional view, the 
computer extrapolated it from the contours of the immediately previous and following cross -
sections. In addition the use of 3 - dimensional reconstruction with multiple longitudinal views 
facilitates the visualisation of vessel structures outside the stent. 
Statistical analysis 
Quantitative data are presented as mean ± standard deviation. Volumetric data derived from the 3-
D reconstruction of the IVUS imaging were compared immediately after treatment and at follow-up 
using the two-tailed paired Student's t-test. Comparison between groups was performed using one-
way analysis of variance (ANOVA) and the Tukey - Kramer multiple comparisons test. A value of 
p<0.05 was considered statistically significant. The Medical Ethical Committee of the University 
Hospital Rotterdam approved the study and all patients signed a written informed consent 
before the procedure. 
Results 
Baseline Characteristics 
Eighteen patients were emolled in the conventional group (C), 16 patients in both the 0.75-
1.5J.LCi (LA) and 6.0-12J.LCi (HA) radioactive stent groups and finally 17 in the group 
employing catheter - based radiation plus a stent (CBS). In the conventional group 10 
Multilink and 8 NIR stents were implanted. Baseline characteristics are similar between all 
groups and are described in Table I. Lesion and procedural characteristics are described in 
Table 2. No statistically significant differences were seen between groups in the parameters 
described in Table 2. A comparison of volumetric data is presented in Tables 3 and 4. 
-56-
Vascular Remodeling After Catheter-Based Brachytherapy versus Radioactive Stent 
In stent inhibition of NIH 
Intra - stent NIH was decreased after radioactive stent implantation and catheter - based 
radiation plus stent implantation (C ~ 20.8mrn3. LA ~ 18.0mrn3, HA ~ 8.9mrn3, CBS ~ 
6.9mm3 , p<O.05). Lower activity radioactive stents had an effect similar to that of conventional 
stents. 
Behind stent 
Conventional stents and both low and higher activity radioactive stents demonstrated an 
absence of remodeling behind the stent, with no significant changes in TVV or plaque volumes. 
This is in contrast to the catheter - based / stent group which demonstrated a significant 
increase in plaque (+15%) and an increase in TVV (+7%), (Table 3, p < 0.05). 
No chronic recoil of the stent was seen in any group. 
Stent edge 
At the stent edges remodeling is similar after both conventional and low - activity radioactive 
stent implantation. In these groups there is evidence of a decrease in TVV, (C~ 7%, LD ~ 8%) 
with little change in plaque as a cause of late lumen loss. At higher activity levels of 
radioactive stent the presence of both stent edge - effect and stent edge restenosis becomes 
apparent. In the 32p group a target segment restenosis (angiographically > 50%) was observed 
in 7 patients at the stent edges. This was more common at the proximal edge (6/7). 
If only edge restenosis is considered, then the major mechanism of restenosis appears to be due 
to an increase in plaque at the stent edge. In non - restenotic patients the edge effect appears 
due to a decrease in TVV and an increase in plaque (Figure 3) 
After catheter - based radiation / stenting the edge effect is largely due to an increase in plaque, 
with no negative remodeling seen (CBS Vs LA, HA, C, p< 0.05). No patients with edge 
restenosis after catheter - based radiation was seen in our series of patients. 
Stent activity and dose prescribed 
Mean stent activity at implantation (LA) was 1.1 +/- 0.3 uCi. Mean stent activity at 
implantation (HA) was 8.6 +/- 1.6 uCi. For CBS mean dose prescribed was 16.7 +/-2.0 Gy. 
Discussion 
The development of NIH within the stent witnessed at 6 - month follow - up is well 
appreciated l5, however the changes that occur at the stent edges or indeed behind the stent 
struts have not been the focus of attention until recentl/. This paper is the first describing the 
difference in vascular remodeling seen after radioactive stent implantation and catheter - based 
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radiation plus stenting, using modern conventional stents as a benchmark. The key findings of 
this paper are as follows: 
a. Similar inhibition of NIH occurs after radioactive stent implantation and catheter - based 
radiation and stenting. 
h. There was no significant remodeling behind the stent is after conventional or radioactive 
stent implantation; however the combination of catheter - based radiation and stenting 
leads to both an increase in plaque outside the stent and TVY. 
c. At the stent edge three patterns of remodeling are seen at 6 - month follow - up: fIrstly a 
shrinkage in TVV and LV after C and LD radioactive stent implantation. These two 
subgroups were not associated with sterrt edge restenosis in this series. After HD stent 
implantation a pattern similar to C and LD is seen in those edges that remain non -
restenotic, however in restenotic edges plaque increase is the major contributor to lumen 
loss (p<O.05). In the CBS group a similar lumen loss to the other groups is seen, however 
this occurs secondary to an increase in plaque (p<O.05) and without a loss in TVY, 
suggesting that some degree of positive remodeling is occurring to accommodate plaque 
increase. 
Neointimal Hyperplasia 
In our study neointimal formation was inhibited after higher dose radioactive stent implantation 
and after catheter - based radiation plus stenting. The former contrasts with the recent study by 
Carter et al. using 32p stents in the porcine model 16, but is in keeping with earlier studies of 
Hehrlein6 using the rabbit model and recent reports by Albiero4 in which a dose - dependent 
inhibition of NIH was noted. 
Mechanism of remodeling behind the stent 
Catheter - based 
After conventional and radioactive stent implantation_little remodeling is witnessed behind the 
stent. In stark contrast to this, is the considerable increase in plaque seen after catheter - based 
radiation and stenting. Part of the key to understanding this process may be aquired from 
understanding the healing process after SA. Wilcox and co - workers 17 describe the presence 
of early proliferation of myofibroblasts expressing contractile proteins in the adventitia 
surrounding the porcine coronary artery after BA. Tracing studies have indicated that the same 
cells migrate and form part of the neointima. Wilcox hypothesizes that the adventitial 
myofibroblasts constrict the artery at the angioplasty site much in the same way that 
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myofibroblasts participate in scar retraction in dennal healing. The source of these 
rnyofibroblasts may he distant to the immediate site of injury including pericardial, adipose and 
intramyocardiallayers. 
Radiation treatment of porcine coronary arteries after BA up - regulates p21 synthesis in 
adventitial celis, inhibits the expression of growth factors, reduces proliferation of adventitial 
myofibroblasts, decreases the production of IX - actin by the adventitial myofibroblasts, 
preventing the formation of the myofibroblast scar around the angioplasty site and inducing 
positive vascular remodeling. Data from Fareh and co - workers 18 suggest that inhibition of 
migration hut not of cellular proliferation occurs at lower doses of radiation. Therefore cells 
may remain in situ, unable to migrate but able to grow in the presence of positive vascular 
remodeling. After one week the effect of the radiation diminishes and cellular proliferation, 
possibly as a reaction to the presence of the stent, occurs behind the stent in the context of 
positive vascular remodeling. In our cohort of patients no cases of stent malapposition were 
seen at follow - up although our group has described this as a risk of ongoing positive vascular 
remodeling19,20. 
Radioactive stent 
The objective of using the radioactive stent is not to neutralise myofibroblasts in the adventitia. 
Rather it is the prevention of the migration and invasion of myofibroblasts from the adventitia 
through the stent struts and into the lumen. As is seen in the HA group this is accomplished due 
to the continuous and low dose rate provided by the radioactive stent. Due to the range of the 
'radioactive fence' created, adventitial cells remain intact without upregulation of growth 
factors and inhibition of contractile proteins. Consequently no remodeling is seen behind the 
radioactive stent. 
Edge Remodeling 
Hoffmann15 has previously described negative remodeling at the stent edge and of the 
stent/vessel wall after conventional stent implantation. In our study we have been able to 
precisely describe the decrease in TVV as the dominant contributor to non - restenotic lumen 
loss at the stent edge and to confirm the absence of recoil and remodeling in modern stents at 6-
month follow - up. Recent reports suggest that the edge effect and edge restenosis may be due 
to an increase in plaque at the edge and to a component of negative remodeling as one moves 
axially from the stent4• However, the edge response after catheter - based radiation and 
subsequent conventional stent implantation were undefined until the current paper. 
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Edge restenosis: is this the result of low - dose radiation? 
Radioactive stents have a limited radioactive range of effect. Whereas those cells behind the 
stent struts may be well fenced at the doses discussed, cells proximal and distal to the 
extremityof the stent, in injured areas treated by the balloon (up to 3mm outside the stent)2I, 
may not be effectively covered by the range of the stent radiation. The latter phenomenon is a 
further example of geographical miss22• Whether there is a proliferative effect on tissue 
secondary to low - dose radiation at the edge of the radioactive stent has yet to be proven in 
clinical trials. Certainly there is evidence from animal work that low dose radiation may induce 
a proliferative effect on tissue23. If the edge restenosis is the result of an aberrant response by 
non-injured healthy or diseased tissue subjected to radiation, then this may suggest that low-
dose radiation has a stimulatory effect on non-injured tissue. This would be the worst possible 
scenario, as clearly non-injured healthy or diseased tissue will always be irradiated at some 
stage. 
Implication for the future: Dealing with the edge effect 
If the edge effect is the result of balloon-induced trauma and low dose radiation then limiting 
the trauma outside the stent and expanding the irradiated area beyond the injured area should 
be attempted. For radioactive stents conceivably the most practical approach may be to extend 
the area of irradiation beyond the injured area using a 'hot-end stent'. This involves literally 
concentrating the greatest activity of the stent at the stent edges; such stents are already 
undergoing multicentre trials. 
If the edge restenosis were purely the result of negative remodeling induced by low-dose 
radiation in an injured area, then the lengthening of the stent by a non - radioactive, cold - end 
would be a logical solution to prevent remodeling at the extremities. If plaque constitutes a 
large percentage of the healing process manifested by the restenosis then cold-end stent 
implantation is unlikely to work as neointimal proliferation may occur at the edges of the 
radiation within the stent (an in-stent candy-wrapper). In the event that excessive vascular 
remodeling is present after catheter - based radiotherapy, then a self - expanding stent may 
playa useful role, The appeal here is that via direct stenting the injury caused by balloon pre -
dilation will be avoided and the self expanding stent would be permitted to expand, minimizing 
geographical miss and stent malappositionI9•2o• 
Limitations This was a retrospective, non - randomised study of individuals who had 
completed 6 - month follow - up and in whom lVUS examination was possible, Individuals 
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who had total occlusion or whom IVUS catheter could not be passed under acceptable clinical 
circumstances were not included. Although no edge restenosis was seen in the CBS group, 
both the CBS and the HA groups reflected the larger parent populations from which they were 
selected in all other features. The dosimetry described in this paper relates to prescribed doses 
only and does not necessarily reflect the dose delivered 2mm from the source in the adventitia. 
Description of the dosimetry is beyond the scope of this paper, however previous work by the 
authors suggest that delivered dose, residual plaque burden and tissue composition playa 
fundamental role on the volumetric outcome at 6-month follow-up after catheter - based .6-
radiation therapy and BA24. 
Conclusion 
Distinct differences in the patterns of remodeling exist between conventional, radioactive and 
catheter - based radiotherapy with stenting. Users of radiation need to be alerted to the 
deleterious remodeling seen at the stent edges after higher - dose radioactive stent implantation 
and behind the stent after catheter - based radiation and stenting. 
Radiation, whether it be catheter or stent - based has forced the interventional community to 
look closely not only at effective inhibition of intimal proHferation but also the adverse 
response of the artery to the combination of injury and radiation. 
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Table 1. Clinical Characteristics 
Conventional LA !fA CBS 
Patient No 18 16 15 17 
Age (mean) 58 (42-76) 60 (43-74) 59 (42-75) 57 (45-74) 
Male(%) 70 66 70 60 
PriorMl (%) 40 40 45 40 
Unstable angina (%) 60 50 65 55 
Smoking(%) 40 55 40 40 
Hypercholestrolemia (%) 60 62 65 55 
Family history (%) 33 42 30 40 
Hypertension (%) 40 42 30 33 
Diabetes (%) 5 5 10 6 
Table 2 Procedural characteristics 
C LA !fA CBS 
Vessel 
LAD 10 9 9 9 
LCx 4 3 4 4 
RCA 4 4 3 4 
Lesion length (mm) 9.6±3.3 12.l±3.8 1O.1±3.3 11.9±4 
Stent length (mm) 14.6±3.8 15.0 15.0 15.2±4.1 
Balloon length-post 14.8±3.4 14.4±2.8 14.1±2.6 15.l±3.6 
Final balloon size (mm) 3.2±0.4 3.l±0.6 3.4±0.5 3.2±0.5 
Max inflation pressure' 11.5±2.4 11.6±2.6 1O.2±2.8 12.2±2.6 
Max inflation pressure2 14.6±3.2 15.2±2.4 15.8±1.7 15.4±3.3 
Balloon-t(}-artery ratio 1.04±O.05 1.12±0.06 1.l0±0.06 1.12±0.05 
Max inflation pressure! - balloon at time of stent implantation 
Max inflation pressure2 = balloon inflation within stent 
Table 3: Mean volume for the edge proximal and distal to the stent (lOmm length) 
Edge (mm') LV post LVF/UP TVV post TVV F/UP Plaque post Plaque 1'/lJ~ ... 
C 67.7 58.3* 124.4 116.5* 56.7 58.2 
LD 75.2 67.3* 126.6 116.4* 51.4 49.1 
HD 74.9 63.0* 126.2 117.6* 51.3 54.6 
CBS 72.6 61.1 * 133.2 138.9 60.6 77.8* 
* - p< 0.05 Post Vs Follow-up 
No significant difference between groups seen at baseline (post). 
Table 4 
Mean volumes fo! tI:e stent (15mm length) 
Stent (mm') LV LV F/UP TVV post TVVF/UP PBS PBS F/UP NIH 
post post 
C 113.9 92.8* 256.1 257.3 142.2 143.7 20.8 
LA 127.3 105.5* 266.6 264.5 139.3 137.8 21.2 
HA 122.4 111.7* 267.8 265.3 145.4 144.6 9.0 
CBS 128.6 121.8' 258.9 278.0* 130.3.0 149.3* 6.9 
* ~ p< 0.05 Post Vs Follow-up 
No significant difference between groups seen at baseline (post). 
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Figure 1 
Figure Legend: 6.0-12.Oj1.Ci activity level stents. Restenotic edges Vs Non - Restenotic. 
+ =p < 0.05. g LV= change in lumen volume (post- follow-up). 0 TVV= change in total 
vessel volume (post - follow-up). I) PV = change in plaque volume (post - follow-up). 
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Figure 2 
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Figure Legend: Remodeling within the stent 
* =p < 0.05; baseline Vs follow-up 
l~p <0.05; ANaVA 
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Figure 3 
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Figure Legend:StentEdge 
A LV for all groups: p<O.05, baseline VS follow~up; between groups:p=NS, ANOVA. 
A TVV for C, LA, HA,:p<O.05, baseline VS foUow~up;between groups: p<O.05, ANOVA. 
A PV for LA&C Vs HA(trend only) &CBS; p<:O.05, ANOVA 
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Chapter 4 
Preserved elldothelium-depelldellt vasodilatioll ill corollary segmellts 
previously treated with ballooll allgiopiasty ami illtracorollary 
irradiatioll. 
(CirculatioIl1999;IOO:1623-1629) 
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Preserved Endothelial Function After Brachytherapy 
Preserved Endothelium-Dependent Vasodilation in Coronary 
Segments Previously Treated With Balloon Angioplasty and 
Intracoronary Irradiation 
Manel Sa bate, MD; I. Patrick Kay, MBChB; Willem 1. van der Giessen, MD, PhD; 
Angel Ccquier, MD, PhD; Jurgen M.R. Ligthart, BSc; loan Antoni Gomez-Hospital, MD; 
Stephane G. Carlier, MD; Veronique L.M.A. Caen, MD; Johannes P.A. Marijnissen, PhD; 
Alexander 1. Wardeh, MD; Peter C. Levendag, MD, PhD; Patrick W. Serruys, MD, PhD 
Backgrollnd-Abnormal endothelium-dependent coronary vasomotion has been reported after balloon angioplaslY (BA), 
as well as after intracoronary mdialion. However, the long-term effect on coronary vasomotion is not known. The aim 
of this study was to evaluate the long-term vasomotion of coronary segments treated with BA and brachytherapy. 
Methods alld Results-Patients with single de novo lesions treated either with BA followed by intracoronary /3-irradiation 
(according to the Beta Energy Restenosis Trial-I.5) or with BA alone were eligible. Of these groups, those patients in 
stable condition who returned for 6-month angiographic follow-up fanned the study population (n= 19, irradiated group 
and n=11, control group). Endothelium-dependent coronary vasomotion was assessed by selective infusion of serial 
doses of acetylcholine (ACh) proximally to the treated area. Mean luminal diameter was calculated by quantitative 
coronary angiography both in the treated area and in distal segments. Endothelial dysfunction was detlned as a 
vasoconstriction after the maximal dose of ACh (10- 6 mollL). Seventeen irradiated segments (89.5%) demonstraled 
normal endothelial function. In contrast, 10 distal nonirradiated segments (53%) and 5 control segments (45%) 
demonstraled endothelium-dependent vasoconstriction (-19::!:17% and -9.0::!:5%, respectively). Mean percentage of 
change in Illean luminal diameter after ACh was significantly higher in irradiated segments (P;:O.Ol). 
COJiclusio1/S-Endothclium-dependcnt vnsomotion of coronnry segments treated with BA followed by J3-radiation is 
restored in the majority of stable patients at 6-month follow-up. This functional response appeared to be better than those 
documented both in the distal segments and in segments treated with BA alone. (Circulation, 1999;100:1623-1629_) 
Key Words: balloon a angioplasty a radioisotopes a endothelium a acetylcholine 
A bnormal endothelium-dependent coronary vasomotion has been reponed both immediately after and up to 6 
months after coronary balloon nngioplasty (BA).H The 
preservation of endothelial function is of the utmost impor-
tnnce to maintain the delicate balance betwcen inhibition and 
promotion of vascular growth, vasoconstriction, and vasodi-
1M inn, us well as antithromboli,; and hemostatic mecha-
nisms.5 lnlnlCoronnry rndiation appears to he a promising new 
technique \0 prevent restenosis after BA."-~ Experimental 
studies have demonstrated an impairment of endothelial 
function in the short term Olfter high-dose intracoronary 
l'-irradiution, which wus restored ut follow-up.~ However, the 
effect of brachytherapy after hOlJioo!l·induced injury on VOlSO-
motor function in patients remains unknowll. The aim of the 
prescnt study was to assess the long-term effect of intracor-
onary radiation therapy after successful BA on coronary 
vasomotion. 
Methods 
Patient Selection 
Two groups of patiems were compared: pmiems with single de novo 
le~i{Hb .w~~e",fully tr~ul~d with BA follow~d by intracoronury 
f:J-irradimion (n=2J) and patients with single de novo le~ion~ 
>lI(:(;~ssfully treated olily with SA (n= (6). Patients receiving radia-
tion wer~ induded in the Beta Energy Reslenosis Trial (BERT-1.5). 
Patiellts ill the control group were individuals treated with BA alone 
and matched for age, sex, and vessel size. Those patients in stable 
(;ondition who returned for 6-month angiogr~phi(; fullow-up formed 
the :;tudy populntion (n=19, irradiated group and n=II, control 
group). BERT-I.5 lVas a prospective multicenter feasibility ~tudy. 
The isotope selected was pure .B-emilling ""Sr/'"'Y, and patients were 
randomized to receive 12, 14, or 16 Gy nl 2 mm from the source. The 
Re(;eived April 13, 1999; revision received June 21. 1999; accepted June 2H, 1999. 
From th~ Th()r~~(;enter. Hean~enter> RUllerdum. Dijkligt A~~demi,~h Ziekenhuis ROllerdam, The Netherlands (M.S., I.P.K., W.J.v.d.O., J.M.R.L.. 
S.O.C .. A.J.W., P.W.S.): Daniel den lIoed Cancer Center, ROllerdam, The Netherlands (V.L.M.A.C., J.P.A.M., P.C.L.): and Hospital de BeJivilge, 
Ulliv~r>itat de B~,,:d"'m. Ban:eiunu. Spain (A.C., J.A.G.-H.) 
Corre~pondence !O P.W. Sentlys, MD, PhD, pror~ssor of Intcrvemional Cardiology, Head of Department of !Ilterventional Cardiology, Btl 412. 
Heartcenler, AClitlemi,(;h Ziekellhllis Rotterdam, Erasmus University, PO Box 1738, Dr MolewJtel1'lein 40, 3000 DR Rotterdam, Netherlands. E-mail 
seml),>@cnrd.aLr.nl 
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Figure 1. Dose-volume histogram showing cumulative dose 
received at level of luminal surface and adventitia layer. Minimal 
dose received by 90% of lumen {D""" Lumen) and adventitia 
(D""o Adv) was calculated. 
inclusion and exclusion criteria of this trial have been reported 
previously. I" 
Radiation Delivery System 
The Bela-Calh System (Novoste Corp) was used to deliver localized 
Il·radiation to a coronary artery at the site of corollary intervention, 
The device cOllsists of 3 components; (I) the transFer device, which 
stores the radiation source tmin and allolVs lhe positioning of lhese 
sources within the catheter; (2) the delivery catheter, which is a 5F 
multi lumen. over-the-wire. noncemered catheter that l!se~ saline 
solution to send and return the radiation source tmin; and (3) the 
rat.lintion source train. which consists of a series of 12 independent 
2.5-mm-Iong cylindrkal seeds that contain the radioisotope "'Srf"Y 
sources and is bordered by 2 gold radiopaque markers at the distal 
and proximal parts of the 3D-mm source train." 
Dose Calculation 
The actual dose received by the luminal surface was retrospectively 
calculated by means of dose-volume hbtograms. 12 This method is 
based on quantitative intravascular ultrasound OVUS) under the 
a<,wmption that the mdiation source is pm;itioned at the same place 
a<, the IVUS cntheter. The method of selection ofthc area of interest 
on IVUS has been reported previously. I.' The IVUS system used was 
a sheath-based IVUS catheter (ClearView, CVIS, Boston Scientific 
Corporation) incorporating a 30-MHz single-element transducer 
rotating at .1800 rpm (Ultmcmss, CVIS). Image ,lcquisition and 
digitization were performed by means of an ECG-gnted pullbnck at 
a step size of 0.2 mnl/step. 1~.I5 Volumetric analysis of the irradiated 
area was performed by a semiautomatic contour detection pmgram 
developed at our institution.'" The feasibility and intraobserver and 
interobserver variabilities of this system have been reported previ-
ously.'HO The distallce between the center of the catheter and both 
the 111men·intima and media-adventitia interfaces was caku!atell in 
24 pi~ slices (15° each) in all cross sections correspunding to the 
irradinted area (30-mm length of the train source). Considering the 
prescribed dose and the accurate geometric data obtained from 
the IVUS, the cumulative curve of the dm;e·volume histogram for a 
predefined volume (ie, intima or adventitia) can be ohtained (Figure 
I). hom this curve, for exumple. the minimal dose received by 90% 
of either the intimal volume {D"1ll lumen) or the adventitial volume 
(D,,,,, Adv) was calculated. 
Endothelial Function Study 
Long-acting \'asoactive drugs were discontinued 2:48 hours before 
the study. A pcrcutaneous femoral artery approach and 8F guiding 
catheter were used in all cases. Endothelium-dependent and 
-independent coronary vasomotion were studied as described previ-
ously in detaipD: after the administration of IU 000 IU of heparin, a 
3F infusion catheter (Transit, Cordis) was advanced over a guidewire 
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and placed proximally to the irradiated segment. To avoid wire-
induced coronary spasm, the wire was removed. The irradinted 
segment was identitled 011 the busis of the anatomic landmarh 
vj~ible on the angiogram performed m the time of the plucement of 
the radiation sOllf~e. To ensure that the segments were fully bathed 
by the infusion of acetykholine chloride (ACh). the lip of the 
infusion catheter was placed 2 to .3 mm proximul to the proximal 
border of the irradiated area. To determine the baseline vasomotion, 
an initial infusion ufsaline solution lor I minute through the infusion 
catheter was performed and a baseline angiogram taken. This was 
followed by infusiun of serial doses of imracomllary ACh, with final 
estimated imracoronary concentrations of 10' to 10-(' mollL, to 
assess endothelium-dependent coronary vasomotion. The duration of 
ench infusion was 2.5 minules, followed immediately by nngiogru-
phy. All angiograms were taken with identical views and radiogmph-
ic characteristics. All infusions were delivered at a rate of 2 mLlrnin 
by usc of a precision pump injector (Mark V, Medrau. Europe BV). 
The finnl blood eonccntratiolH; of ACh were estimllteu with (he 
assumption thaI blood !low in the corunary artery was 80 mUmin." 
Finally. to evaluate endothelillm-inuependcnt v'lso!llotion. a nitro-
glycerin (NTG) bolus (2 mg) was administereu through the guiding 
catheter, after which an angiogram identical to those performed 
previously was done.,n Throughout each infusion, the hean rate, 
systemic arterial pressure, and ECG were 111onitOl'ed continuously. 
Because ACh causes endothelium-dependent vessel rdaxation in 
experimental models and in humans, ".2,' a paradoxi~al vasoconstric-
tion after the infusion of this substance is un indicator of endothelial 
dysfunction.2u 
The study was approved by the Medical Ethics Commillee of uur 
institution. and written informed consent wns obtained ti-orn all 
patiel11s in accordance with the guidelines established by the Com-
mittee for the Protection of Human Subjects. 
Quantitative Coronary Angiography 
Quamitnlive coronary angiography was performed after the infusion 
of saline ;olmion, at the ellu of ea~h ACh infusion. ami after NTG 
bolus. Angiograms were performed in the 2 orthogonal projections 
that best showed the artery of interest, without uverlapping of side 
bf«nchc~ ;md with jess foresh()rtening. Online analysis wa~ [11'1'-
rOlmed by mealls of the CAAS II ~ystell\ (Pic Medical BV). 
Calibration of the system was based on dimensiolls of the catheters 
not filled with contrast medium. The intraobserver and interobserver 
variabilities of this method of analysis have been reported previous-
ly/4-26 Mean luminal diameter was determined after the infu~ion of 
each substance in the irradiated area. in a 15- to 20-mm-long 
segment distal to the irradiated area ~nd in a contralateral nontreuted 
artery that served as II control. Melin luminal diameter was averaged 
for the 2 projections, and the percentage of change relative to 
baseline was noted. All 4uantitative measurements were performed 
by the same investigator (MS.). Intraobserver variability was as-
~essed by reOllulysis of the quumiwtil'c ~{)rollary lIllgiography of a 
series of 15 ,tullies (150 repeated measures in total) ::0:;\ months 
apart. Intruobserver tli!ferell~e~ (meun±:2 SD) in mean luminal 
diameter were as follows: 0.7:<:::2.7'11.' ror baseline values. 0.8±:2.9% 
after maxinwl dose of AC'h, amt 0.7 ±:2.6'7r arter NTG. The intra~lass 
correlation coefficicnt (R') for repeated measures was (),97 for 
baseline I'alues, 0.96 for maximal-tiose ACh valub. and 0.98 rot 
NTG values. We ~onsidercd endothelial dy~rllnclion a \'a,o~ollstfic­
tion of the ,egment studied after the maximal dose of ACh beyond 
the variability of the method of analy~is (>3%). 
Statistical Analysis 
Data are presented as mean±:SD or proportions. To compare 
contilluoll" variable,. 2-tailed Student's I test. ANOVA lur repented 
measurements, and linear regression analy~is were performed when 
appropriate A value of P<O.05 was considereu statistically 
significant. 
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TABLE 1. Baseline Characteristics 
Irradiation Group 
(0"'19) 
Age. y 55:<::8 
Male sex, n (%) 14 (74) 
Treated artery. n (%) 
Left anterior descending 10 (53) 
left circumflex 6 (31) 
Right coronary 3 (IS) 
Coronary risk tactors, n (%) 
Systemic hypertension 9 (47) 
Diabetes mellitus 2 (IO) 
Smoking 14 (74) 
Hypercholesterolemia 11 (58) 
Family history 11 (58) 
Minimalluminai 1.7:<::0.6 
diameter, mm 
Diameter stenosis, % 39:<::17 
Continuous data are presented as mean:!:SD. 
Results 
Baseline Characteristics 
Control Group 
(n=11) 
58±5 
10 (91) 
10 (91) 
1 (tl) 
0(0) 
5 (45) 
1 (9) 
7 (63) 
6(54) 
5 (45) 
1.6:<::0.3 
34:!:7 
Baseline charucleristics of both irradiated and control patients 
are presented in Table J. Angiographic restenosis (diameter 
stenosis >50%) was observed within the irradialed area in 3 
patients (16%), Fourteen patients (74%) remained asymptom-
atic, whereas 5 (26%) presented with angina pectoris Cana-
dian Cardiovascular Society (CCS) class I (n= 1),2 (n= I), or 
3 (n=3). None of the patients in the control group showed 
ungiographic restenosis, und only 2 presented with angina 
pectoris CCS class I. No differences were observed between 
groups regarding age, sex, coronary risk factors, Of minimal 
luminal diameter and diameter stenusis in the diagnoSli(; 
lIngiogram performed at the lime uf the functional study. The 
left anterior descending (;oronary artery was assessed more 
often in the conlrol group. 
Coronary Vasomotion Study 
No signifi(;ant changes in meun aortic pressure and heart rate 
were ubserved during Ihe ACh infusion in either group. Mean 
luminal diameters after infusion of ellch substance in irradi-
ated and distal nonirradiated segments and in the control 
group are presented in TlIble 2. Seventeen irradiated segments 
(89.5%) Qemonstrated normal endothelium-dependent coro-
nary vasomotion (16 segments with a vllsodilatory response 
[5,O::!:3% of change in mean luminal diameter after Ach] and 
I with nn t:hange in Illean IUlllinal diameter [-0.1 % of c!Jange 
after Ach infusionD. On the other hand, endothelial dysfunc-
tion WllS dcmonstrated in 2 irradiated segments (10.5%): I 
with angiographic restenosis anu angina pectoris CCS dass 3 
and lhe other wilh angina pectoris CCS class I without 
restenosis (-5.2% anu --7.8% of vasoconstriction after max-
imal dose of ACh, respectively). In contrast, 10 (53%) of the 
distul nonirradiated segments demonstrated endothelia! dys-
function (-!9.5± 17% of vasoconstriction aftcr maxima! dose 
of ACh). No significant de novo stenosis was observed at 
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TABLE 2. Coronary Vasomotor Response (Mean 
luminal Diameter) 
Distal Control 
Irradiated Segment Segment Group 
(n=19) {n=19) (n=ll) 
Baseline 2.46±0.4 2.20±0.4 2.38±0.3 
ACh 10-1 2.49±0.4 2,19±0.5 2.35±0,3 
ACh 10-1 2.52±0.4 2.13±0.5 2.33±0.5 
ACh 10-' 2.55±0.5' 2.07±0.7 2.31 ±0.3 
NTG 2.62±OAt 2.33±0.6:1: 2.58±0,5:f: 
Data are presented as mean±SO (in mm). 
·P=0.03, tP=0,0004, :f:P=O,OI with respect to baseline values, 
distal segments. No significant correlation was demonstrated 
between the degree of stenosis at follow-up and the vasomo-
tor response. Five patients in the control group (45%) showed 
endothelial dysfunction in the treated area (-9.0::!:5% of 
vasoconstriction at ACh 10-6 mollL). Mean percentages of 
change in mean lumina! diameter after infusion of Ihe 
different substances between the irradiated and control pa-
tients and between irradiated and distal nonirradiated seg-
ments are presented in Figures 2 and 3. Mcan percentage 
change in diamcter after ACh was 3.8±:7.1 % in the irradiated 
segments compared with -3.2±:7% and -6.6±:1O% in the 
control group and in thc distal nonirradiated segments, 
respectively (P=O.OI). No significant differences in percent-
age of change in mean luminal diameter either in irradiated or 
in distal segments were observed between the 3 coronary 
vessels after either ACh or NTG. Examples of ·(;OfOnary 
segments with vasodilation of the irradiated area and vaso-
(;onstri(;tion of the distal nonirradiated segment after ACh 
infusion are depicted in Figures 4 and 5. All of the segments 
experienced vasodilation after NTG, which is indicative of 
normal smooth muscle vasomotion (Fignres 2 and 3). 
Radiation Dose Calculation 
Mean prescribed radiation dose was 14::!: 1.9 Gy at 2 mill to 
the source. However, when dose-volume histograms were 
applied, the calculated minimal dose received by 90% of the 
!I, c ..... ge/<l m .. n 1...,!,..ldl.met<o, 
, 
, 
~~:=; 
.. 
., L __ -""·~"' __ -"""'-_~""''--~'C·:J'" 
ACh 10" ACh 111-7 ACh 10" NTG 
• Irradi.,led.,rua(N"'1&) 0 CofrtrolgroupIN-l1) 
Figure 2. Percentage of change in mean luminal diameter after 
infusion of each substance in irradiated segments and in control 
group. Irradiated segments showed, on average, an increase in 
mean luminal diameter after infusion of ACh, which is indicative 
of normal endothelial function, whereas controt group demon-
strated on average vasoconstriction, which is indicative of endo-
thelial dysfunction. Endothelium-independent coronary vasomo-
tion was preserved in both groups. Bllndicates baseline. 
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Figure 3. Percentage of change in mean luminal diameter after 
infusion of each substance in irradiated and in distal nonirradi-
aled segments. Irradiated segments showed, on average, an 
increase in mean luminal diameter atter infusion of ACh, which 
is indicative of normal endothelial function, whereas distal nonir-
radiated segments demonstrated, on average, vasoconstriction, 
which is indicative of endothelial dysfunction. Endothelium-
independent coronary vasomotion was preserved in both 
groups. BL indicates baseline. 
luminal surface was 8.2±3.8 Gy, whereas Dwn Adv was 
5.2± 1.9 Gy. Only 6 patients (31.5%) received on average 
>10 Gy at luminal surface, and only 2 patients (l0.5%) 
received on average >8 Gy at the adventitial layer. No 
significant correlation WHS found between endothelium-
dependent coronary vasomotion and the calculated D0JO lu-
men (r= -0.03; P=NS). Similarly, no significant correlation 
was observed between the coronary vasomotor response to 
NTG and D,'I{I Adv (r=O.03; P=NS). 
Discussion 
This study demonstrates for the first time that the endotheli-
um-dependent vasomotor function of coronary segments 
treated with BA followed by J3-radiation is restored in the 
majority of stable patients at 6-month follow-up. This func-
tional response observed in irradiated segments appeared 10 
be better than that documented both in distal nonirradiated 
segments and in segments treated only with BA. 
An impairment of endothelial function h[ls been reported [It 
up to 3 to 6 months after BA.4 It has been demonstrated that 
soon after balloon-induced injury, there i~ a release of von 
Willebrand factor27 and endothe!in1s as markers of endothe-
lial injury. Experimental studies have demonstrated .that the 
endothelium regenerates at follow-up. However, the endothe-
lium appeared to still be dysfunclional,29.JO which may cause 
the release of endothelium-dependent contracting factors and 
the alteration of endothelial muscarinic receptors. J1 - JJ 
Endothelial dysfunction in distal nontreated segments is a 
common finding in atherosclerotic coronary arteries after 
percutaneous interventions.] An alteration of autoregulation 
due to chronic hypoperfusion may be implicated in the distal 
abnonnal responsiveness to ACh.2 Furthermore, the presence 
of coronary risk factors may have a deleterious effect on 
distal coronary vasomotion.3us 
In contrast, most of the irradiated segments exhibited 
nonnal endothelium-dependent vasomotion, and all of them 
presented a nonnal response to NTG. Wiedermann et al 9 
demonstrated restoration of endothelial function after high-
dose (20 Gy) y-radiation in a non-balloon-injured animal 
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model. However, a diffusc fibrosis of the smooth musclc 
layer, probably responsible for the loss of response to NTG, 
was detccted on histological analysis. Y Our findings con-
firmed these experimental observations in terms of endothe-
liutn-dependent coronary vasomotion. The lack of paradoxi-
cal vasoconstriction may be explained by an alteration of the 
muscular media, whieh may demonstrate an impairment in 
responsc to endothelium-dependent vasoregulatory signals. 
However, vasodilation rather than lack of constriction was the 
vasomotor response demonstrated in all but I of the irradiated 
segments with normal endothelial function. The vasomotor 
response to NTG remained unaltered and comparable be-
tween groups, which suggests an abscnce of radiation-
induced impairment of the medial layer. In an experimental 
model, endothelial celis as well as vascular smooth muscle 
cells were inhibited in a dose-dependent manner. However, at 
a moderate range of J3-particle delivery (0.4 to 6 Gy), but not 
at a high dose (10 Gy), endothelial cells appeared to be more 
radioresistant than vascular smooth muscle cel1s.·1~ Thc rela-
tively low dose of radiation received by the treated segments 
may Hceount for this normal functional behavior. In fact, none 
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Figure 5. Coronary angiogram showing moderate vasoconstriction of distal nontrealed coronary segment after infusion of maximal 
dose of ACh, which Is indicative of endothelial dysfunction. 
of the patients actually received on average> 10 Oy at the 
level of the adventitia, us assessed by dose-volume 
histograms. 
On the other hand, an experimental model of porcine 
coronary arteries subjected [0 balloon overstretch injury and 
either placebo or radiation with 18 Gyn demonstrated that 
expression of enzyme-inducible nitric oxide synthase (iNOS), 
responsible for NO production, was enhanced, whereas ex-
pression of the cYlokine transforming growth faclOf-f3, (TGF-
(3,) was suppressed in the irradiated group. iNOS is poten-
tially responsible for inhibitiun of neointirnal hyperplasia and 
stimulation of reendOlhelialization, whereas TGF-J3, would 
enhance intima! hyperplasia and fibrosis by negatively mod-
ulating the expres~ion of iNOS.)] Moreover, it has been 
demonstrated in e;>;;perimental models that radiation causes 
dose- and time-dependent impairment of endothelium-
dependent relaxatjon·l~ and that low-dose radiation would 
induce an anti-infiammatory reactiun through specific duse-
dependent modulation of the NO pathway.39 It remains to be 
seen whether this chain reaction after radiation would result 
in a late reduction in the re~tenosis rate. However, restoratiun 
of endothelial function may play an important role in this 
regard. 
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Study Limitations 
Because the use of ACh in unstable patients is not exempt of risk 
of wronary ocdusion, only stable patients were evaluated. 
This study assessed patients receiving l3-radiation by 
means of a noncenteling device. The actual dose received by 
the treated segment was rather low; thus, the effect of a higher 
dose or of different devices that allow a more homogeneuus 
dose distribution remains to be evaluated. 
We assessed the vasomotion of the 3 coronary arteries in 
the irradiated group, which h(lve a potential!y different degree 
of vasureactivity to ACh. However, the 3 arteries demon-
strated comparable vasomotor responses to ACh and NTG 
both at the irradi<lted and the distal segments, which over-
comes thb potential limitation 
We as~umed that coronary vasomotion immediately after 
treatment is markedly impaired, as demonstrated in experi-
mental models and in humans. I- 4.9 Taking into account the 
risk of coronary occlusion in such situation, it was considered 
unethical tu determine endolhelium-dependent vasomotion 
immediately after the coronary intervention. Thus, the degree 
of recovery of coronary vasomotion could not be evaluated. 
We also assumed that the IVUS and delivery catheters 
were lying in the same position in the treated coronary 
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segment. The size of the IVUS catheter is smaller (2.9F, 
"'" 1 mm) than the bracbylherapy device (SF), which is thus to 
some extent more centered in the lumen. Allbough the 
catheters should be on the shortest 3D path in the lumen, 
curomuy arteries have a complex curved geometry in space 
and can be partially deformed by the catheters. Thus, cathe-
ters with different rigidity may occupy different positions. 
The development of new systems that incorporate the IVUS 
imaging element on the delivery catheter might resolve this 
drawback. 
During irradiation, the position of the delivery catheter 
inside the lumen is not fixed and may vary during the cardiac 
cyde because of ventricular contradions, which may lead to 
some degree of inhomogeneity not assumed by data derived 
from the static end-diastolic IVUS images. 
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Chapter 5 
Residual plaque burden, delivered dose and tissue composition 
predict the 6-month outcome after balloon angioplasty and 8-
radiation therapy. 
(Circulation 2000 (in press)) 
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ABSTRACT 
Background. Inhomogeneity of dose distribution and anatomical aspects of the atherosclerotic 
plaque may influence the outcome of irradiated lesions after balloon angioplasty (BA). We 
evaluated the influence of delivered dose and morphological characteristics of coronary 
stenoses treated with beta-radiation following BA. 
Methods and results: Eighteen consecutive patients treated according to the BERT-1.5 Trial 
were included in the study. The site of angioplasty was irradiated using a B-emitting 9OSrf"'Y 
source. Using the sidehranches as anatomical landmarks, the irradiated area was identified and 
volumetric assessment was performed by three-dimensional intracoronary ultrasound imaging 
after treatment and at 6-months. The type of tissue, the presence of dissection and the vessel 
volumes were assessed every 2mm within the irradiated area. The minimal dose absorbed by 
90% of the adventitial volume (D,wAdv) was calculated in each 2mm-segment. Diffuse 
calcified subsegments and those containing sidebranches were excluded. Two-hundred and six 
coronary subsegments were studied. Of those, 55 were defined as soft, 129 as hard and 22 as 
normal/intimal thickening. Plaque volume showed a less increase in hard segments as compared 
to soft and normaVintimal thickening segments (p<O.OOO I). D".Adv was associated with 
plaque volume at follow-up following a polynomial equation with linear and non-linear 
components (FO.71;p~0.0001). The multivariate regression analysis identified the independent 
predictors of the plaque volume at follow-up: plaque volume post-treatment, D"",Adv and type 
of plaque. 
Conclusion: Residual plaque burden, delivered dose and tissue composition playa fundamental 
role on the volumetric outcome at 6-rnonth follow-up after B-radiation therapy and BA. 
KEY WORDS: baUoon, angioplasty, radioisotopes, dosimetry, ultrasonics, restenosis. 
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Endovascular radiation therapy is a promising new technique aimed to prevent restenosis 
after percutaneous coronary intervention. 1~3 Although its effectiveness has been proven in the 
treatment of instent restenosis,4,5 the value of intracoronary irradiation in "de novo" coronary 
lesions remains to be established. Radiation delivered to the coronary artery by means of 
catheter-based systems can use both gamma and beta emitters. 6 Long-term results after 
treatment may be influenced by absolute dose and by the homogeneity in dose distribution. 
Beta-emitters demonstrate a more rapid dose fall-off than gamma emitters because of the short 
range of electrons. 7 This feature may lead to a less homogeneous dose distribution when 
treating coronary segments with variable degree of curvature, tapering, remodeling and plaque 
extent. The lise of dose-volume histograms allows one to evaluate the cumulative dose received 
by a certain specified tissue volumes and has been recently implemented in the field of 
intracoronary brachytherapy as a tool for dosimetry. 9 Aims of the study were (I) to determine. 
by the use of dose-volume histograms, the dose distribution of the beta-emitter Strontium 90 I 
Yttrium 90 ('oSrJ'JOy) along the coronary irradiated segment when delivered by a non-centered 
device, (2) to establish the dose which could be predictive of efficacy in intracoronary 
brachytherapy, and, (3) to detennine the intravascular ultrasound (IVUS) predictors of the 
plaque volume at 6-month follow-up, of coronary segments treated with balloon angioplasty 
(BA) followed by beta-radiation therapy. 
METHODS 
Patient selection 
Eighteen consecutive patients presenting with single "de novo" coronary stenosis, successfully 
treated with BA followed by intracoronary beta-radiation therapy were included in the study. 
Patients receiving a stent were excluded from the analysis. Beta-radiation was delivered according to 
the Beta Energy Restenosis Trial 1.5. The isotope selected was the pure beta-emitting 9OSrI"'Y, 
and patients were randomized to receive 12,14 or 16 Gray (Gy) at 2mm from the source axis. 
The inclusion and exclusion criteria of this trial have been previously reported. 10 The delivery 
of the radiation was performed by the use of the Beta-Cath System™ (Novoste Corp., Norcross, 
GA)." The radiation source train of this system consists of a series of twelve independent 2.5mm-
long cylindrical seeds which contain the 9OSr!''"Y sources and is bordered by 2 gold radiopaque 
markers at distal and proximal part separated by 30mm." 
Intravascular Ultrasound analysis 
The treated coronary segment was evaluated by means of throo-dimensional IVUS imaging, which 
allowed volumetric calculations of the irradiated area. The selection of the area of interest has been 
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reported elsewhere. 12 In brief, a few steps were followed: first, an angiogram was performed after 
positioning the delivery catheter and the relationship between anatomical landmarks and the two gold 
markers were documented. The anatomical landmark closest to either of the gold markers was used 
as a reference point. This angiographic reference point was identified during a contrast injection with 
the IVUS imaging element at the same position as the gold marker of the source. The image from the 
lVUS imaging element was recorded and the reference point identified. During the subsequent 
pullback, this reference point was recognized and used for selecting the area subject to the analysis: 
30mm for the irradiated segment12• The system used for imaging was a mechanical IVUS system 
(ClearView, CVIS, Boston Scientific Corporation, Maple Grove, MN) with a sheath-based lVUS 
catheter incorporating a 30MHz single-element transducer rotating at 1800 rpm (Ultracross, CVIS). 
The transducer is placed inside a 2.9 French I Scm-long sonolucent distal sheath which alternatively 
houses the guidewire (during the catheter introduction) or the transducer (during imaging). The 
lVUS transducer was withdrawn through the stationary imaging sheath by an ECG-triggered 
pullback device using a stepping motor. l3 The ECG-gated image acquisition and digitization was 
performed by a workstation desigued for the 3-D reconstruction of echocardiographic imagesl3 
(EchoScan, Tomtec, Munich, Germany). Description of this system has been previously reported in 
detail. 13- 15 In brief, the steering logic of the workstation considered the heart rate variability and only 
acquired images from cycles meeting a predetermined range and coinciding with the peak of the R 
wave. If an R-R interval failed to meet the pre-set range, the IVUS catheter remained at the same site 
uotil a cardiac cycle met the predetermined R-R range. Then, the IVUS transducer was withdrawn 
0.2 nun to acquire the next image. ]]·15 This system assures the segment to segment independence by 
avoiding taking images during the axial movement of the IVUS catheter which occurs during the 
cardiac cycle. Given the slice thickness of 0.2 mm and the length subject to the analysis of 30 mm 
(distance between the two gold markers of the radiation source), 150 cross-sectional images per 
segment were digitized and analyzed. A semiautomatic contour detection program, was used for the 
3-D analysis. 16 This program constructs two longitudinal sections from the data set and identifies the 
contours corresponding to the lumen-intima and media-adventitia boundaries. Corrections could be 
performed interactively by "forcing" the contour through visually identified points, and then the 
entire data set was updated." Careful checking and editing of the contours of the 150 planar images 
was performed with an average of 45 minutes for complete evaluation. The area encompassed by the 
lumen-intima and media-adventitia boundaries defined the luminal and the total vessel volumes, 
respectively. The difference between total vessel and luminal volumes defined the plaque volume. 
Because media thickness cannot be measured accurately, we assumed that the plaque volume 
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included the atherosclerotic plaque and the media. 17 Volumetric data were calculated by the fonnula: 
V=}: ~ * H, where V = volume, A = area of total vessel or lumen or plaque in a given cross-
j= I 
sectional ultrasound image, H ~ thickness of the coronary artery slice, that is reported by this 
digitized cross-sectional IVUS image, and n ~ the number of digitized cross-sectional images 
encompassing the volume to be measured 16 At follow-up, meticulous matching of the region of 
interest was perfonned by comparing the longitudinal reconstruction to tbat after treatruent as 
previously described. 12 (figure I) The feasibility and intra- and inter-observer variability of this 
system bave been previously reported. 12•l4•I,,, For the purposes of the study, the computed volume of 
the irradiated segment was divided in 2 mm-Iong subsegments. Since the irradiated segment 
measured 30 rum, 15 subsegments were defined per patient, each of them presenting 10 IVUS cross-
sections. (O.2rmn1cross-section). All individual cross-sections were studied by 2 investigators, 
blinded to the dosimetry results. Type of plaque and the presence of dissection were qualitatively 
assessed. Type of plaque was defined in every cross-section, as intimal thickening, soft, fibrous, 
mixed and diJfuse calcified according to the guidelines previously reported.20 Intimal thickening was 
defined when the thickness of the intima-media complex was smaller than O.3mm.20 Soft tissue was 
defined when at least 80% of the cross-sectional area was constituted by material showing less 
echoreflectivity than the adventitia, with an arc of calcium <10°, fibrous plaque when the 
echoreflectivity of at least 80% of the material was as bright as or brighter than the adventitia 
without acoustic shadowing; diffuse calcified plaque when it contained material brighter than 
the adventitia showing acoustic shadowing in >90°; and mixed, when the plaque did not match 
the 80% criterion.20 We categorized the 2-mrn-long subsegments as nonnallintirnal thickening, soft, 
bard (fibrous and mixed) and diffuse calcified, when at least 80% of the cross-sections within the 
subsegment were of the same type. In those cross-sections containing up to 90° of calcium arc, 
the contour of the external elastic membrane was imputed from non-calcified slices. Dissection 
of the vessel was defined as a tear parallel to the vessel wall.'o Cbanges in luminal, plaque and total 
vessel volume between immediately post-treatment and at follow-up, were also computed per 
subsegment. Those subsegments in which the origin of sidebranches involved >90° of the 
circumferential arc in more than 50% of the cross-sections, or were defined as diffuse calcified, were 
excluded from the analysis. 
Dose calculation 
The actual dose received by the vessel was retrospectively calculated by means of dose-
volume histograms8 in every 2mm-long subsegment. This method is based on quantitative 
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IVUS under the assumption that the radiation source is positioned at the same place as the 
IVUS catheter.9 The distance between the center of the catheter and media-adventitia interface 
was calculated in 24 pie-slices (15°) in all cross-sections corresponding to the irradiated area.9 
Considering the prescribed dose and the accurate geometric data obtained from the IVUS, the 
cumulative curve of the dose-volume histogram for a pre-dermed volume (i.e. adventitia as 
calculated at 0.5mm outside the external elastic membrane) can be obtained (figure 2). From 
this curve, the minimum dose received by 90% of the adventitia volume (D,..,Adv) was 
calculated. The methodology and feasibility of this dosimetry approach in vascular 
brachytherapy has been previously reported. 9 
Statistical analysis 
Data is presented as mean ± SD Of proportions. Differences in quantitative IVUS data 
between the types of tissue were assessed by means of one-way analysis of Variance 
(ANOYA). Differences in quantitative IVUS data between subsegments with and without 
dissection and with and without calcium or were evaluated by the use of unpaired Student's t-
test. To determine the relationship between the dose received by the adventitia and the plaque 
volume at follow-up, linear regression analysis was performed first. Then, non-linear 
components were added to the equation (X"l and x-2 were added to describe the steep increase of 
plaque volume at low dose). These components were included in the model if they described a 
the relationship sigoificantly better. Finally, the model was corrected for the plaque volume 
post-treatment. Multivariable regression analyses were perfonned to identify independent 
predictors of plaque volume at follow-up among lVUS-derived (types of tissue, dissection, 
plaque volume post-treatment) and dosimetric variables (D"",Adv). All tests were two-tailed 
and a p value <0.05 was considered statistically significant. 
RESULTS 
Baseline characteristics 
Two hundred and seventy subsegments were defmed in 18 patients successfully treated with 
BA followed by intracoronary brachytherapy. Sixty-four subsegments were excluded from the 
fmal analysis due to either diffuse calcified plaque which precluded the quantification of the 
total vessel volume (n=30) or sidebranches which involved >900 of the circumferential arc in more 
than 50% of the cross-sections (n~34). Therefore, 206 irradiated subsegments were the subject 
of the study. Fifty-five subsegments (27%) were defined as soft, 129 (62%) as hard and 22 
(11%) as normaVintimal thickening. Dissection was observed in 34 subsegments (16.5%). 
Volumetric cbanges and dosimetry 
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On average, total vessel volume increased at follow-up (32.5±9mm3 post-treatment to 
35.5±llmm3 at follow-up; p<O.OOOI), accommodating a parallel increase in plaque volume 
(15.3±6mm3 to 1&.3±7mm3; p<O.OOOI). As a result, mean luminal volume remained unchanged 
(17.1±7mm3to 17.0±7mm3; p~NS). Subsegments with hard tissue demonstrated a less increase 
in plaque resulting in an increase in luminal volume as compared to soft and normal/intimal 
thickening subsegments (figure 3). The behavior of those hard subsegments containing mixed-
calcified tissue (up to 90°; 0=104) was compared to those containing mixed-non-calcified tissue 
(n~25). Mean changes in plaque and total vessel volumes were comparable (delta plaque 
(mm3): +1.3±4.2 in mixed-calcified versus +1.&±5.2 in mixed non-calcified; p~NS; delta total vessel 
volume (mm'): +2.6±6.2 in mixed-calcified versus +4.2±5.& in mixed non-calcified; ~NS), 
resulting in a comparable mean increase in luminal volume at follow-up (+1.3±5.2 mm3 in mixed-
calcified versus +1.9±5.7 mm3 in mixed non-calcified; ~NS). Dissected subsegments 
demonstrated a trend towards a smaller increase in plaque as compared to non dissected 
subsegments (+1.2±3 mm3 vs. +3.3±6 mm'; p~O.O&). Mean of all 3 prescribed doses at 2 mm 
from the source was 14±1.& Gy. The calculated D~dv was 5.5±2.5 Gy (range: 0.2-12.4). A 
wide range of dose distribution was observed in the irradiated coronary subsegments (figure 4). 
The association between D~dv with the plaque volume at follow-up is depicted in figure 5. 
The model appeared to follow a polynomial equation with linear and non-linear components. 
Non-linear components described the increase in plaque volume at lower dose, whereas the 
residual plaque volume post-treatment accounted for the linear relationship of the curve. 
Changes in plaque volume appeared to decrease with dose (figure 6). Four Gy was the 
minimum effective dose to be delivered to 90% of the adventitia since subsegments receiving at 
least this dose, demonstrated a significantly smaller increase in plaque volume as compared to 
those receiving <4Gy (p<O.OO I). As a result, luminal volume decreased significantly less in 
those subsegments receiving at least 4 Gy and even increased when the minimal dose to the 
adventitia was higher than 6 Gy. Multivariable regression analyses identified plaque volume 
post-treatment as a positive predictor of plaque volume at follow-up, whereas Dv90Adv and 
type of plaque (hard) were negative predictors (table). 
DISCUSSION 
This study demonstrates for the first time, the relationship between plaque increase, as 
assessed by IVUS, and the dose received by the adventitia, as calculated by means of dose-
volume histograms. A plot of dose-volume histogram is a standard method used in radiotherapy 
which condenses the large body of information available from conventional three-dimensional 
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distribution data into a plot summarizing graphically the radiation distribution throughout the 
target volume. 8 
The assumption of the adventitia as the target tissue is supported by experimental studies.2t,22 
Scott et aI, localized the proliferating cells in the adventitia and their migration into the 
neointirna after angioplasty, using bromodeoxyuridine irnmunohistochemistry.21 Similarly, 
Waksrnan et ai, demonstrated a greater cell proliferation in control vessels 3 days after 
angioplasty in the adventitia at the site of the medial tear as compared to the medial wall in the 
same region.22 In this study, the proliferation was significantly reduced in irradiated vessels 
using either a source of 90SrfOy or 192Tr which delivered 14 or 28 Gy at 2nun into the artery 
wall. 22 
The actual dose received by the adventitia appeared to be rather low as compared to the 
prescribed dose at 2mm from the source. Furthermore, the dose varied considerably between 
coronary subsegments as demonstrated by the dose distribution depicted in the figure 4. The 
use of beta-radiation may account in part for this dose inhomogeneity. As compared to gamma 
radiation, beta-sources have more fall-off because of the short range of electrons. 7 This feature 
may become crucial when treating vessels with a great degree of vessel tapering or, 
alternatively, lesions showing positive remodeling where the distance from the source to the 
surrounding adventitia may be smaller or greater than expected. In this regard, the use of lVUS 
as a tool for dosimetry in beta-radiation therapy may become mandatory. In contrast, gamrna-
sources may present with more homogeneous dose distribution. Therefore, in the SCRIPPS 
trial, a retrospective analysis of dosimetry, demonstrated a mean minimal dose of 7.7±0.7 Gy 
at the target site and only 10.9% of the targets receiving <7Gy.23 Dose unifonnity may also be 
influenced by the source centering in the lumen?4 By the use of dose-volume histograms, 
earlier et ai, demonstrated in 10 patients treated with balloon angioplasty followed by 
intracoronary beta-radiation, that the prescribed dose was administered in only 35% of the 
adventitia. After centering the source in the lumen, up to 60% of the adventitia may have 
received this dose.9 
The remnant plaque burden at the site of angioplasty becomes a powerful predictor of the 
outcome. This is in accordance with other studies which identified, either in non-stented or 
stented coronary segments, postintervention cross-sectional area as a predictor of restenosis. 25,26 
In this regard, the usefulness of a debulking technique prior to radiation therapy should be 
addressed in further studies. 
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D~dv was also identified as an independent predictor of the plaque volume at follow-up. 
The relationship between D"",Adv and plaque volume at follow-up appeared to be polynomial 
with linear and non-linear components. This may model the survival curve of mammalian 
cells.27 The minimal effective dose to be delivered to 90% of the adventitia volume appeared to 
be 4Gy. Further increase in dose resulted in net increase in luminal volume at follow-up. 
Similarly, in a subgroup analysis of the SCRIPPS trial late loss was significantly lower when 
the entire circumference of the adventitial border was exposed to at least 80y. 28 Radiation 
doses greater than 20Gy have been suggested to be able to completely eliminate the smooth 
muscle cell population from the treated area. 29 However, since cells from normal tissue have a 
limited capacity to proliferate30, lower doses would probably be sufficient to pennanently 
prevent restenosis. 
Finally, subsegments containing hard tissue (fibrotic and calcified material up to 90 degrees 
of the circumferential arc) demonstrated a trend to he a negative predictor of plaque volume at 
follow-up. Hard plaque on IVUS, consists of a more mature tissue with low cellularity and high 
content of extracellular matrix. 31,32 These features may induce either a physical barrier for 
migration of smooth muscle cells from the surrounding layers or a reduced capacity to 
proliferate when injured as compared to that of the soft tissue with a high concentration of 
smooth muscle cells.3 !-33 Further, it is hypothesized that tissue composition may potentially 
exert a different degree of shielding effect on radiation and thus, become less effective. 
However, the degree of remodeling was similar between the different types of tissue, suggesting 
that the effects of attenuation of radiation induced by hard material (either containig calcium up 
to 90° of circumferential arc or mixed non-calcified tissue) may be negligible as compared to 
that of soft tissue. 
Study Limitations 
We assumed that the IVUS and the delivery catheters were lying in the same position in the 
treated coronary segment. The size of the IVUS catheter is smaller (2.9 Fr - I mm) than the 
brachytherapy device (5 French), which is thus to some extent more centered in the lumen. 
Although the catheters should be on the shortest three-dimensional path in the lumen, coronary 
arteries have a complex curved geometry in space and can be partially deformed by the 
catheters. Thus, catheters with different rigidity may occupy different positions. The 
development of new systems incorporating the rvus imaging element on the delivery catheter might 
resolve this drawback. 
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During irradiation, the position of the delivery catheter inside the lumen is not fixed and vary 
along the cardiac cycle because of ventricular contractions, which may lead to some degree of 
inhomogeneity not assumed by data derived from the static end-diastolic IVUS images. 
The behavior of diffuse calcified plaques after radiotherapy has not been evaluated because 
the acoustic shadowing would have impeded the reliable analysis of total vessel and plaque 
volumes.20 It has not been possible to differentiate those areas which have been traumatized 
and irradiated from those only irradiated. Thus, no conclusions regarding the effect on radiation 
in irradiated but non-injured segments can be drawn. Further studies will address this problem 
by defIning meticulously the injured and the irradiated areas either on TVUS or quantitative 
coronary angiography. 
Finally, the dose as presented by the use of dose-volume histograms is not a direct 
measurement. The theoretical value obtained at the level of the adventitia is derived from the 
fall-off of the isotope and the geometrical data obtained from the IVUS study. The influence of 
the attenuation of the radiation due to different tissue characteristics has not been taken into 
consideration. Future investigations should address the implementation of dosimetry program 
on-line in order to prescribe the radiation dose in a more refined fashion. 
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Table. Parameters associated with plaque volume at roDow-up (mm'). 
Parameter estimate 
Plaque volume post-treatment (mm') 0.6 
D""Adv (Gy) -4.4 
Type of plaque (hard vs. other) -1.6 
95%CI indicates 95% confidence intervals 
-96· 
95%CI 
'0.8/0.5" 
-5.6/-2.9 
-3.4/0.1 
p value 
0.0001 
0.0001 
0.06 
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Figure 1. Longitudinal reconstruction and volumetric calculations (charts) of irradiated 
coronary segments post-treatment (A and A') and at 6-month follow-up (B and B'). 
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Figure 2. Dose volume histogram showing the cumulative dose received at the level of the 
adventitia layer. The minimal dose received by 90% of the adventitia volume (Dv9(Adv) is 
calculated. 
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Figure 3. Changes between the post-procedure and 6-month measurements in total vessel, 
plaque and luminal volumes regarding different types of tissue. TVV= total vessel volume; 
PV~ plaque volume; L V~ luminal volume. 
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Figure 4. Range of dose distribution in irradiated coronary subsegments as calculated by dose-
volume histograms. 
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Figure 5. Relationship between plaque volume at follow·up and D"", Adv. 
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Figure 6. Changes in total vesseL plaque and luminal volumes regarding 5 ranges of doses as 
calculated by dose-volume 
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Chapter 6 
Comparison of hrachytherapy strategies based on dose-volume 
histograms derived from quantitative intravascular ultrasound. 
(Cardiovascular Radiation Medicine 1999;2:115-124) 
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Purpose. We present in this paper the comparison, by simulation, of differcnt treat~ 
ment strategies hased either on ~- or 'V-sources, both with and without a centering de-
vice. Ionizing radiation to prevent restenosis is an emerging modality in interven-
tional cardiology. Numerous clinical studies are presently heing performed or planned, 
but there is variability in dose prescription, and both 'V- and i3-emittcrs are used, lead-
ing to a wide range of possihle dose distributions over the arterial vessel wall. This 
paper discusses the potential merits of dose-volume histograms (DVH) based on three-
dimensional (3-D) reconstruction of electrocardiogram (ECG)-gated intravascular ultra-
sound (IVUS) to compare brachytherapy treatment strategies. 
Materials alld Met//Ods. DVH describe the cumulative distribution of dose over three 
specific volumes: (1) at the level of the luminal surfacc, a volume was defined with a 
thickness of 0.1 mm from the automatically detected contour of the highly cchogenic 
blood·vessel interface; (2) at the Icvel of the IVUS echogenic media-advcntiLia interface 
(external elastic lamina [EELn, an adventitial volume was computed considering a 
D.S-mm thickness from EEL; and (3) the volume encompassed betwecn the luminal 
surface and the EEL (plaque + media). The IVUS data used were recorded in 23 of 31 
patients during the Beta Energy I{estenosis Trial (HERT) conducted in our institution. 
lkmits. On average, the minimal dose in 90<Y" of thc adventitial volume was 37 ::':: 16% 
of the prescribed dose; the minimal dose in 90% of the plaque + media volume was 58 ::':: 
24% and of the luminal surface volume was 67::':: 31%. The minimal dose in the ]0% 
most exposed luminal surface volume was 296 :.': 42%. Simulations of the use of a 
,,-emitter and/or a radioactive source train centered in the lumcn are reported, with a 
comparison of the homogeneity of the dose distribution. 
Conclusiol1s. It is possible to derive DVH from IVUS, to evaluate the dose dclivercd to 
different parts of the coronary wall. This process should improve our understanding of 
the mechanisms of action of brachytherapy. © 1999 Elsevier Science Inc. 
Keywords: Brachytherapy; Restenosis; Vascular; Intravascular ultrasound (IVUS); Dosimetry. 
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Introduction 
Coronary artery diseases remain the major cause of 
death and disabilities in industrialized countries. The 
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only revascularization procedure available up to 1977 
was bypass surgery. Percutaneous transJuminal coro-
nary angiopla_~ty (PTCA) introduced by Andreas 
Griintzig!J I profoundly modified our therapeutic ar-
senal with a minimally invasive alternative. Presently, 
interventional cardiology consists of several tech-
niques to cut, drill, scrape, burn, and otherwi.~e re-
move atherosclerotic plaque [2]. With more than one 
million interventions undertaken per year worldwide, 
angioplasty is now a cornerstone therapy for coronary 
artery diseases. However, despite a high acute proce-
dural success rate, the long-term benefit is hindered 
by the phenomcllon of Iestellosis. Mechanisms in-
volved in the restenosis process are the elastic recoil of 
the artery, local thrombus formation, vascular remod-
eling- with shrinkage of the ve.~sel, and exuberallt 
healing proc{'ss with neointimal cellular proliferation 
and matrix synthesis n-5]. Stcnt implantation mini· 
mizes elastic recoil and remodeling of vessels, and 
carefully controlled and randomized clinical trials 
have demonstrated a significant decrease in the rate 
of restenosis [6-8J. However, stents increase the pro-
liferative response of tissue to the intervention and, 
depending on the type of lesions treated, a significant 
re_~tenosLs rate of 15-50% remains the key limitation 
of transcatheter procedures. Restenosis is the subject 
of numerous investigations to further improve appli-
cability and cost-effectiveness of angioplasty and to 
reduce the need of reinterventions. Virtually all at-
tempts to limit restenosLs with systemic drugs have 
failed, with the recent exceptions of abciximab, 
probucol, and cHostazol [9-11 J. 
Some investigators have considered restenosis as 
an accentuation of the wound healing process asso-
ciated with the trauma of angioplasty, and because 
radiotherapy had proved effective for the treatment 
of keloid formation and other nonmalignant dis-
eases, radiation therapy for intravascular applica-
tion was attempted. The therapy was introduced by 
Friedman et al. [12] early in ]964, for the preven-
tion of atherosclerosis, and subsequent animal ex-
periments demonstrated a reduction of intimal hy-
perplasia following endovasculelr irradiation. 
Waksman [13) has recently reviewed these early 
studies. Three clinical studi{'s helw been reported 
that confirmed a significant reduction in the resl-
enos is rate using additional brachytherapy 114-16J. 
Currently, the vascular brachytherapy devices 
available for clinical trials are radioactive stenls and 
catheter-based systems using a radioactive wire ad-
vanced with an afterioader, or radioactive seeds 
delivered with a hydraulic delivery system. Other 
systems based on radioactive balloons are in devel-
opment. There is variability in the dose prescrip-
tion, and both 'Y- and [3-emitters are used. These 
variations lead to a wide range of dose distributions 
over the arterial vessel wall requiring a careful intef-
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pretaLion and comparison of the result" of til(' on-
going studies. The typical dose prescriplion distance 
in the coronary artt'ries is in the range of 2 mm from 
the source axis. Because of tlH' steep dose fall-orr, 
particularly for [3-emitlers, accurate dosimetry rc-
quires precise knowledge of geometry. 
In this paper, we describe a dosimetry evaluation 
tool for coronary brachytherapy based on three-
dimensional (3-D) reconstruction of electrocardio-
gram (ECG)-gated intravascular ultrasound (IVUS) 
images. lVUS was developed to overcomc the limita-
tions of x-ray angiography. Its metilodol%'Y and clin-
ical applications have been reviewed extensively [17]. 
IVUS, by its tomographic approach, provides a mcan 
for the evaluation of both lumen and vessel wall 
morphology. Assuming that the catiletE'r containing 
the radioactive SOU Tee is lying in the ",lllle position 
as the IVUS catheter, it is pussible to measure the dis-
tance from the source to any vascular structure in 
one cross-sectional image, and to construct isodose 
plots. rvus recordings can be performed with a con-
stant speed motorized pull-back devic{' (e.g., 0.5 
mIll!s), which permits the evaluation of the length 
of a .~tenosis. Recently, 3-D image reconstIuction 
and analy.sLs sy.stems have been introduced that can 
be used for compkte quantitative analysis of lVUS 
images 118-21]. However, illlage artifacts that result 
from cyelic changes in coronary dimensions and 
from the movement of the IVUS catheter in the arte-
rial lumen limit the accuracy of the 3-lJ boundary 
detection systems [221. This problem led to the de-
velopment of a new approach in otlr institution. To 
limit Lyelic movement artifacts, we use an ECG-
gated image acquisilion workstation that controls a 
dedicated pull-back <-levice. Feasibility, reproducibil· 
ity, and improvement in the quantitative parameters 
analyzed have been reported recently 123, 24]. The 
complete 3-0 data set of the coordinates of the auto-
matically detected lumen corresponding to the 
highly echogenic blood-vessel interface, and of the 
echogenic media-adventitia interface can be used 
for dosimetry {'valuation. 
Dose-volume histograms (DVH) are used every-
day in radiotherapy to condense the large body of 
information of the complete 3-D dose distribution 
data into a plot graphically summarizing the radia-
tion distribution throughout the target volume and 
the anatomical structures of interest 125, 26]. We 
have recently reported prcliminary data on the 
methodology to compute DVH for coronary 
brachytherapy from 3-D rvus data [271. 
Material and Methods 
Stud), poplllntioll 
We used the lVUS data acquired during the Beta 
Energy Restenosis Trial conducted in our institu-
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lion (Bl':lrr 1.5 arm). Thirty-one patients were en-
rolled. We I"eport the data of the 23 patients who 
had an ECG-triggered pull-back available before a 
stenl implantation (18 men, 5 women, mean age: 
58 :!:: 9 years). All were in sinus rhythm. The Medical 
Ethics Committee of our institution approved the 
study and all patients signed a written informed 
consent form. Before catheterization, the patients re-
ceiVl.'d 250 mg aspirin and 10,000 IU heparine 
parenterally. If the duration of the intervention ex-
ceeded 1 h, the activated clotting time was measured 
and intravenous heparin was Llsed to maintain an 
activated dotting time >300 s. The coronary seg-
ments examined were the right (/1 = 7) and left (II = 
10) anterior descending coronary arteries, and the 
left circumflex coronary artery (II = 6). 
IlIte/wl/tiol/al procedllre al/d BERT 1.5 trial 
The BERT 1.5 trial was the European arm of a feasibil-
ity study of coronary radiation therapy with a '){JSr/Y 
source delivered by a hydraulic system (Beta-Cath™ 
System, Novoste Corp., Norcross, GA) [16J. All pa-
tients had a Single de /101'0 coronary stenotic lesion 
>60% with a maximal length of 15 mill and a refer-
ence vessel diameter of 2.5-3.5 111m. After .mccessful 
PTCA, irradiation using a 5 Fr (~1.6 mm) over-the-
wire triple-lumen delivery catheter was performed. 
The catheter has one open lumen and two closed lu-
mens. The open lumen allows for advancement of 
the device over a 0.014-inch guide wire, and position-
ing at the site of the PTCA (Fig. 1). One of the closed 
lumens permits the hydraulic advancement of the ra-
diation source train (12 independent cylindrical 
sealed YOSr/Y sources, total length 30 mm) to the le-
sion site. This advancement is performed manually, 
with a saline-filled syringe connected to tIle delivery 
system. The other closed lumen, in communication 
with the first one at the tip of the delivery catheter, 
permits the opposite fiujd flow direction at the end of 
the irradiation time (~3 min) for the retrieval of the 
sources into the back in the shielded transfer device. 
A randomized dose of either 12, 14, or 16 Gy was pre-
scribed at a distance of 2 mm from the source axis. 
IVUS image acquisitio/1 
IVUS was performed prior to the insertion of the ra-
diation delivery catheter. Intracoronary nitrates were 
administered before the coronary segments were ex-
amined. The ClearView™ (CardioVascular Imaging 
System rCVIS], Sunnyvale, CAl was used with IVUS 
catheter incorporating a 30-MHz single-element ro-
tating transducer in a 2.9 rr sheath (~1 mm). The 
ECG-gated image digitization system (EchoScan, 
TomTec, Munich, Germany) received the video sig-
nal input from the IVUS console, and the ECG signal 
from the patient. This system steered the ECG-gated 
stepping pull-back device by increments of 0.2 mm. 
Images were acquired at end-diastole for heart cycles 
failing within a predetermined range (0.125 s) around 
the heart rate of the patient. Premature beats and 
RR-intervals outside this range were excluded and 
the IV US catheter remained at the same site. Byex-
perience, we have noticed that with these settings, 
on average 1O-159\") of the RR intervals are n~jected, 
and that for a heart rate of 60 beats/min, on average, 
the pull-back speed is 1 cm/min. 
Imaxe aI/a lysis system 
A contour detection program developed in our labo-
ratory !281 was used for the automated 3-D analysis 
of the IV US images corresponding to the irradiated 
segment. Two longitudinal sections (corresponding 
to the A and B lines on the IVUS cross-section in 
Fig. 2) were constructed from the data set. The con-
tours of the lumen-intima (internal contour on rig. 
2, lower left panel) and the media-adventitia (ex-
Jig-lire 1. Angiograms of one patknt included in We Beta Energy Restenosis Trial (BERT). (A) The initial !e~ion in the mid-portion of 
the lE'f1 anterior descending artery at a biruf("atiol! point with a diagonal and a septal ~ide-branclles is indicated by an arrow. {IlJ The 
angiogram after successful percutaneous transluminat coronary angioplasty (PTCA). (C) The triple-lumen deHvery catheter advanced to 
the angioplasty sito:. The ~ealed radioactive cylinders (total length 30 mm) wil! b~ between the two guld markers (small arrows). 
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Figure 2. The three·dimemional intravascul1lr ultr~sullnd (lVUS) data _~el: the bottom left panel deOlOllSlrales an lVUS cross-section 
image, with the catheter in the center, surrounded by bloud. The catheter is against the lumen wall at 2 o'clock. The tirst detected con-
tour th~t corresponds to tile blood-vessel wall interface is highlighted. The second highlighted contour, more ext!:'rnally, corresponds 
\0 the media-adventitia interface, which encompasses tile residual plaque lying between 11 and 4 o'dod.:. Lines A and B correspond to 
the cutting planes of the corresponding longitudinal views Ull tile right panel. The imdoses of 32 and 16 Gy are sU]lcrimpusc(l on the 
longitudinal views and on the IVUS cross-secllon of the upper left panel. 
ternal contour on Fig. 2) boundaries were identified 
using a minimum-cost-based analysis algorithm. 
These longitudinal contours were used to guide au-
tomated contour detection in every planar cross-
sectional image. Scrolling through the entire data 
set is possible in this Windows™-based program, 
for manual corrections of the contours. From these 
tracings, the total ves.sel area (encompassing the 
media-adventitia border) and the lumen area were 
determined for each cross-section. The residual 
plaque burden (%) on each cross-section was calcu-
lated as total vessel area minus lumen area divided 
by the total vessel area. 
DVH 
Selection of the IVUS segment matching the irradi-
ated site was based on anatomical landmarks lying 
next to the treated segment (side branches, bifurca-
tions, etc.). For example, the diagonal artery seen 
on the angiogram of Fig. 1 is marked with an arrow 
on the longitudinal IVUS pull-back of Fig. 2 (right 
panel). The coordinate of the center of the IVUS 
catheter was used as a reference, and was consid-
ered at the same location as the center of the radia-
tion train. This assumption is probably violated 
when looking at the differences in size of the lVUS 
and delivery catheters (2.9 vs 5 Fr), but it has to be 
kept in mind that the source does not occupy the 
center of the delivery catheter, and that no easy 
correction might be applied. The radii of the lumen 
and the media-adventitia contours were calculated 
in 24 pie-slices (lSO), in all the cross-sections corre-
sponding to the irradiated site (3D-mm length of 
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the train source). The number of required slices was 
a function of their thickness, which was on average 
0.2 nUIl. 
DVH describe the cumulative distribution of dose 
over a specific volume, and summarize the dosime-
try that would otherwise have to be interpreted 
from numerous IVUS cross-sections with superim-
posed isodoses plotted (Fig. 2, upper left panel). 
Three volumes have been studied: the first one at 
the level of the luminal surface is arbitrarily defined 
with a thickness of 0.1 mm from the automatically 
detected lumen contour. The second volume, de-
fining the adventilia volume, is computed consid-
ering a thickness of 0.5 mm from the second con-
tour detected, corresponding to the echogenic 
media-adventitia interface. The third volume, cor-
responding to the plaque and media structures, is 
encompassed between the two detected contours. 
The dose distribution over the total vessel wall was 
calculated with 0.1 mm spatial resolution. The 
DVH provided a tool for reporting the actual deliv-
ered dose in different arterial structures, or to detect 
excessive radiation at the luminal level. From the 
complete 3-D IVUS data set, simulations of DVH of 
alternative brachytherapy strategies such as the use 
of a 'V-emitter or a centered radioactive source were 
tested. To compute the isodoses and the DVH for 
the Novoste system, we used the dose distribution 
and dose rate around the source train as provided 
by the manufacturer in the user manual. Calibration 
was performed at the National Institute of Stan-
dards Technology, using both an extrapolation 
chamber and GafChromic Dosimetry media. For the 
",(-source, data were derived frolll Amoh etal. [29). 
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Results 
No complications related to the hrachytherapy and 
lVUS procedures were seen. Figure 1 demonstrates a 
typical procedure on a lesion situated in the mid-
portion of the left anterior descending coronary ar-
tery, at the level of the emergence of a septal and a 
diagonal side branch. These anatomical landmarks 
observed on the angiograms were used for position-
ing both the lVUS catheter and the irradiation de-
vice at the site of the lesion. The angiogram after 
PTCA is shown in Fig. lB. The corresponding ECG-
triggered IVUS pull-back performed at that time is 
illustrated in Fig. 2. The position of the side-branch 
is dearly seen on the mid-portion of the longitudi-
nal view (* and arrow in right panel of Fig. 2). After 
withdrawal of the IVUS catheter, the hrachytherapy 
delivery catheter was positioned at the PTCA site, 
using its two radio-opaque gold markers as land-
mark (Fig. Ie). 
Of the 31 patients included in the BERT 1.5, a to-
tal of 7 required stent implantation. In 3 of these 
patients, the IVUS was performed before stenting. 
Absence of an ECG-triggered pull-back or technical 
problems limited the total number of analyzable 
patients without a stent to 23. Quantitative IVUS 
data analysis of these 23 patients demonstrated a 
mean lumen area of 7.7 :t 3.0 mm2 (~150 cross-sec-
tions per patient). The mean vessel area was 14.8 ± 
3.9 mm2 and the residual plaque area was 7.1 :t 1.6 
mm2, corresponding to a residual plaque burden of 
49 :t 8%. For each patient, the minimal, mean and 
maximal distance (~radius r) between the center of 
the IVUS catheter and the lumen or the media-ad-
ventitia interface were computed along the com-
plete pull-back. The minimal r was 0.51 ± 0.02 
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mm, the mean rwas 1.42 ± 0.25 mm, and the max-
imal r was 3.36 ± 0.70 mm. For the vessel (media-
adventitia interface) minimal r was 0.88 ± 0.17 
mm, mean r was 2.07 ± 0.25 mm, and maximal r 
was 3.80 ± 0.63 mm. Computer simulation of the 
placement of the IVUS catheter in the center of the 
lumen in each cross-section of the pull-back dem-
onstrated a significant increase of minimal r (p < 
0.0001): 0.67 ± 0.17 mm and 1.23 ± 0.25 mm, re-
spectively, for the lumen and the vessel. In parallel, 
there was a significant decrease of maximal r (p < 
0.0001): 2.46 ± 0.42 mm and 3.41 ± 0.41 mm, re-
spectively, for the lumen and the vessel. 
On the longitudinal view (right panel) of the 
IVUS pull-back in Fig. 2, and on one cross-section 
(upper left panel), the isodoses corresponding to 8, 
16, and 32 Gy are superimposed. The derived DVH 
for this patient for the luminal surface and adventi-
tial volumes are plotted on Fig. 3. The minimal 
dose in 90% (DV90adv) of the predefined adventi-
tial volume was 47% (this corresponds to the x-axis 
value of the DVH plot with the y-axis value = 90%). 
Among the 23 patients, the average DV90adv was 
37 ± 16% of the prescribed dose and the minimal 
dose in 90% (DV901Ilm) of the luminal surface vol-
ume was 67 ± 31% of the prescribed dose, and was 
58 ± 24% in 90% of the plaque + media volume. 
The average minimal dose in the upper 10% 
(DV1Oadv) of the adventitial volume exposed to the 
highest dose (the x~axis value of the y-axis value 
10%) was 133 ± 19% of the prescribed dose. For the 
luminal surface volume, DVlOlllm was 296 ± 42%. 
Figure 3 summarizes these data with a plot of the 
mean ± SD of DV95, DV90, DV75, DV50, DV25, 
OVI0, and DVOS for the luminal surface and the 
3 4 5 6 
dose/prescribed dose 
Figure 3. ExampJc of integral dose-volume histograms (DVH) at the level of the luminal surface and adventitial volumes of the patient 
illustrated in Figures I and 2, representing the fraction of volume (y-axis, % volume) receiving greater than or equal to a specific relative 
dose (x-axis, dose/dose prescribed). Por this patient, the minimal dose In 90% of the adventitial volume (DV90Ildv) was 47% of the pre-
scribed dose. The superimposed plots with the enor bars correspond to the average among the 23 investigated patients of the DV9S, 
DV90, DV7S, DVSO, DV2S, DVlO, and DVOS of the predefined luminal surface and adventitial volumes. 
-109-
Dose-Volume Histograms After Intracoronary Brachytherapy 
Table 1. Summary of the computer simulations of the use of a J3 or a ")'-source (with the saille dose prescribed at 2 n11ll from the cenler 
of the cath('ter) or a centering device 
Noncentered Cent('red 
DV90 DVIO DV90 DViO 
~ 
Lum. 0.67 ± 0.31·t 2.96 ± 0.42·t 1.06 ± 0.31 2.03 ± 0.49t 
r + M. 0.58 ± 0.24*t 2.16 ± 0.32*t 0.73 ± 0.20t 1.66 ± O.35t 
Adv. 0.37 ± 0.16*t 1.33 ± 0.19*t 0.49 ± 0.14t 1.05 ± 0.20 
, 
Lum. 0.79 ± 0.21' 2.34 ± 0.31' 1.05 ± 0.21 1.70 ± 0.32 
P + M. 0.72 ± 0.17' 1.78 ± 0.2)' 0.83 ± 0.13 1.45 ± 0.23 
Adv. 0.58 ± 0.12* 1.24 ± 0.13* 0.67 :!: 0.09 LOS ± 0.13 
DV90 == relative minimal dose (dose/dose prescribed) of 90% of the predefined luminal surface (Jum. thickness = 0.1 mill). adventitial 
(adv. thickness = 0.5 mm), and plaque + media (P + M = between luminal and external elastic lamina conlour.~) volumes. Means ± so 
for the 23 available electrocardiogram-triggered pull-backs performed during the Beta Energy Restenosis Trial {BERT} 1.5. Means were 
compared by paired t-test. 
'p < 0.0001, centered vs. noncentered radiation catheter; tp < 0.0001, 13- vs )I-source. 
adventitial volumes. By randomization, the actual 
doses administered were 12 Gy in 8 patients, 14 Gy 
in 6 patients, and 16 Gy in 9 patients. Plots of rela-
tive dose (dose/dose prescribed) allow the pooling 
of data from patients who received different ran-
domized doses. 
The simulations (assuming that the source was 
centered in the lumen and/or the use of a ,,-source 
l192Ir]), with the same dose prescribed at 2 mm from 
the catheter as in the BERT protocol, are summa-
rized in Table 1. A direct comparison of the homo-
geneity of the absorbed dose or of the high dose ab-
sorbed by the upper 10% of the luminal surface and 
adventitial volumes is possible. Figure 4 illustrates 
the improvement of the homogeneity of the dose 
distribution for the case of Figs. 1-3 when simulat-
ing a source situated in the center of the lumen. 
Figure 5 illustrates similar improvement of the ho-
mogeneity when considering a ,,-source. Optimally, 
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Dbcussion and Conclusion 
Restenosis rates of 15-50% after percutaneous an-
gioplasty procedures are the major hindrance to the 
success of transcatheter therapies. Supported by en-
couraging results obtained in animal models of cor-
onary restenosis [13], several clinical trials of vas-
cular brachytherapy have been designed, but with 
different systems and isotopes [30]. The discussion 
below focuses on the catheter-based device like 
the one used in this work. DOSimetry for radio-
active stents has been described recently by Janicki 
etal. [31J. 
In the ongoing clinical trials, there is variability 
in the dose prescribed; the target site for the dose 
prescription, and both 'Y- and J3c-emitters are used. 
-
-
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Figure 4. illustration of the beneficial effect of a centering device on the homogeneity of the dose distribution for the same patient as in 
figures 1-3. The dose-volume histograms (DVH) were recalculated simulating the irradiation source ('XISr/Y) lying in the center of the lumen. 
The DVH curves for the centered position (Lumen c. and Adventitia c.) are steeper. with a DVIO for the lumen decreasIng from Z.9 to 1.8. 
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Figure S. lUuslralioll of the improvement of the dose homogeneity for the same patient as In Fjgures 1-3, simulating the usc of a 
'Y-source for which the same dose would have been prescribed at 2 mm from the center of the catheter (noncentered situation). The 
DYH curves for the 'Y-source (Lumen G and Adventitia G) are steeper, with a DYlO for the lumen decreasing from 2.9 to 2.3. 
The consequence is a wide range of possible dose 
distributions over the arterial vessel wall requiring a 
careful interpretation and comparison of the results 
of these studies. The typical dose prescription dis-
tance in the coronary arteries is in the range of 2 
mm. As the dose fall-off at this close vicinity is 
steep, particularly for ~-emitters, accurate dosime-
try requires knowledge of the exact geometry, 
which can be only partly assessed by coronary an-
giography. 
Among the four published clinical brachytherapy 
studies today, Condado et al. (14] used a manual af-
terloader, noncentered, in 22 lesions, with a InIr "(-
source. The doses were prescribed at 1.5 mm (single 
doses of 18 Gy, n = 1; 20 Gy, n = 11; 25 Gy, n = 9) 
and only angiographic assessment was used. Al-
though reported as positive, an unexplained early 
reduction of the minimal lumen diameter of 0.45 
mm on average after only 24 h might have blurred 
the real efficacy of the applied radiotherapy in 
these patients [32] who presented no additional 
loss in minimal lumen diameter at the 6 months 
follow-up. However, doses of up to 92.5 Gy could 
have been delivered to the lumen wall because of 
the noncentered device. This maximum dose may 
well be over the vascular tolerance limits [32]. This 
finding could partly explain the observation that 
two patients experienced early total vessel occlu-
sion, and four others developed a pseudoaneurysm 
at 2 years follow-up. In Geneva, Verin et al. [33] de-
veloped a mean for /3-irradiation in human coro-
nary arteries using a radioactive wire (90y) in a cen-
tering balloon device_ The dose prescribed was 18 
Gy at the surface of the balloon corresponding to 
the vessel luminal surface. No IVUS was performed. 
The findings were disappointing, with a restenosis 
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rate of 40% among the 15 patients studied. A retro-
spective analysis of the dose prescribed in the vessel 
wall revealed that at a depth of 2 mm, the dose was 
only -2.7 Gy, probably below the nominal effec-
tive dose against the proliferating cells involved in 
the post-angioplasty restenosis process [34]. The 
only placebo-controlled study of coronary brachy-
therapy published to date demonstrated a substan-
tial reduction of the restenosis rate (17% vs 54%) 
among 55 patients presenting with in-stent rest-
enosis [15}. A sealed 192fr ')'-source in a noncentered 
catheter was used. The dosimetry was calculated, 
based on IVUS measurements, to be in the range of 
8-30 Gy. Finally, King et al. [16] recently reported a 
restenosis rate of 15% and a late loss index of 4% 
for the American arm of the BERT, using the same 
hydraulic delivery system as the one we used in this 
study. 
IVUS was developed to overcome the limitations 
of x-ray angiography, which portrays only overlap-
ping shadows of the lumen of the coronary arteries 
(Iuminogram) [35]. In the field of vascular radiation 
therapy it is important to characterize precisely the 
dose prescribed in the vessel wall, IVUS imaging, by 
its angiotomographic nature, can be used to evalu-
ate both lumen and vessel wall morphology. The 
results of our preliminary investigation, using the 
complete 3-D information available from carefully 
recorded ECG-triggered IVUS pull-back, demon-
strate the potential applications for dosimetry and 
the possibilities for the evaluation of doses in spe-
cific target volumes of the vessel wall. DVH appear 
to be a valuable tool and summarize, in a graphic 
form, the large amount of information included in 
the dose distribution of the complete 3-D IVUS data 
sets. DVH cannot be used alone because of the lack 
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of information regarding the spatiality of the dose 
distribution [25J. For the spatiality, two-dimen-
sional isodose displays, such as in rig. 2, superim-
posed on IVUS images will still be required for the 
guidance of a vascular irradiation plan. In our 
study, there was no direct guidance of the brachy-
therapy with IVUS because of the nature of this 
trial, which was a feasibility study in which the pre-
scribed dose was predetermined. However, the data 
set constitutes a preliminary database for the assess-
ment of several radiation strategies, as illustrated in 
Table 1. The homogeneity of the dose distribution 
might be estimated by the difference between the 
DVlO and the DV90. Ideally, a DVH should demon-
strate a steep curve around the desired prescribed 
dose. Flattening reflects that some regiOns are un-
derexposed, whereas others are overexposed. Poten-
tial advantages of a centering device for a i3-source, 
as illustrated in Table 1 and Figs. 4 and 5, are that 
the DV90 increases for the luminal (1.06 ± 0.31 vs 
0.67 ± 0.31, P < 0.0001 by paired t- test), the adven-
titial (0.49 ± 0.14 vs 0.37 ± 0.16, P < 0.(001) and 
the plaque + media (0.73 ± 0.20 vs 0.58 ± 0.24, P < 
0.0001) volumes. In parallel, DVlO decreases for 
the luminal (2.03 ± 0.49 vs 2.96 ± 0.42, P < 
0.0001), the adventitial (1.05 ± 0.20 vs 1.33 ± 0.19, 
P < 0.0001) and the plaque + media 0.66 ± 0.35 vs 
2.16 ± 0.32, P < 0.00(1) volumes. As a conse-
quence, the homogeneity, which can be expressed 
as DVI0 ~ DV90, is improved for the lumm (0.97 
vs 2.29), [he adventitia (0.56 vs 0.96), and the 
plaque + media (0.93 vs 1.58, respectively, for a 
centered and a noncentered delivery system). How-
ever, only one number, such as OV10 - OV90, can-
not summarize a complete OVH curve. The com-
plete shape of the curve, as presented in the figures, 
is important. Several other parameters have been 
proposed [36, 37J, but no definitive one has 
emerged as a gold-standard to assess the dose ho-
mogeneity. Looking at the slope of the DVH, for ex-
ample, is a proposed alternative, but the slope will 
vary with the interval chosen to compute it. The 
DVH presented in this study are cumulative plots: 
this integral formaL shows the fraction of volume 
receiving greater than or equal to a specific dose. 
Another format is the differential DVH constructed 
by dividing the range of dose values into equa! in-
tervals and accumulating partial volumes in those 
bins according to their dose values. Plots of dose~ 
volume distributions have also been proposed [38J. 
Our definition of the thickness of the lumina! and 
adventitial volumes is arbitrary. The intima is 
formed only by a superficial layer of endothelial 
cells and a thin subendothelial layer of connective 
tissue. Its thickness increases with age and reaches 
250 /Lm at 40 years. Diffuse thickening is common 
in older patients, even without atherosclerosis. The 
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adventitia is composed of loose collagen and elastic 
tissue, which merge with the periadventitial tissue. 
The normal thickness of the adventitia is 300--500 
/Lm [17J. However, we evaluated these DVH for an-
other thickness (0.2 mill) and the results are in 
close agreement with the data presented in Table 1 
G.P.A. Marijnissen et Ill., personal communication). 
The differences found with the simulations of the 
use of a 'Y-emitter or a radioactive source train cen-
tered in the lumen are also present for the plaque + 
media volume for which no arbitrary choice has 
been made. 
On average, in the conditions of our study, 
whereas only 10% of the advential volume were ex-
posed to a minimal dose 1.33 times the prescribed 
dose, ] Oq"h of the luminal surface volume absorbed 
at least 2.96 times the prescribed dose. For a pre-
scribed dose of 16 Gy, this corresponds to an actual 
dose of 47.2 Gy, which may well be above the rec-
ognized vascular tolerance limit. The simulations in 
Table 1 demonstrate that the use of a device to 
maintain the source in the center of the arterial lu-
men would decrease this overexposure, which has 
potential deleterious effect such as the develop-
ment of an aneurysm. With centering, the upper 
10(% of the luminal surface volume is exposed to a 
reduced minimal relative dose of 2. Following our 
results, the best strategy could be the use of a cen-
tered ]'-source: the minimal relative dose would 
then be reduced to 1.7 for the upper 10% of the, lu-
minal surface volume. No clinical data presently 
support these potential advantages, and to our 
knOWledge, no trial is planned to address this issue. 
Nevertheless, ]'-sources have other drawbacks, at 
the radioprotection level, for example, because 
these more penetrating radiations require stringent 
shielding precautions [39]. These radiation safety 
issues may be improved if lower energy gamma 
sources can be manufactured. 
There is an interindividual variability related to 
the geometry of the lesion and the morphology of 
different coronary arteries, as demonstrated by the 
rather large standard deviations in Table 1. The 
choice of the brachytherapy modality (centering 
device or not, 13- vs ]'-) cannot be only guided from 
DVH, but must integrate all the information avail· 
able from the angiogram and the 3·0 JVUS pull-
back (such as morphology of the leSion, length, ec-
centricity of the plaque). Potentially, catheters 
combining IVUS and asymmetriC sources might be 
helpful in the guidance of a radiatioll treatment for 
eccentric lesions. Such a device with a C-shape 
shielding screen around a radioactive wire has been 
described recently j40J. 
Another limitation of our approach is that we re-
constructed an artificially straight coronary seg-
ment. However, this limitation might be overcome 
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by image fusion of biplane angiography and rvus, 
as developed in our center, to assess the true 3-D 
geometry of coronary vessels [41]. Presently, we 
also do not implement different dose fall-off char-
acteristics in function of the type of plaque seen (£i-
bro-fatty, calcified, etc.). Although there are proba-
bly differences, no data are available. 
One major assumption made in this work was to 
consider that the IV US and delivery catheters were 
lying in the same pOSition in the treated coronary 
segment. It is important to realize first that because 
the size of the rvus catheter is smaller (2.9 rr ~ = 1 
mm in diameter) than the brachytherapy device we 
used (S Fr ~ = 1.6 mm), it lies in a more eccentric 
position in the coronary lumen. However, no easy 
correction can be applied because the channel 
source in the delivery device is not in the center of 
the catheter. The real average DVlOf11111 in our pa-
tients is thus in the range 2.03-2.96 given in Table 
1. Moreover, even with the use of radiotherapy and 
IVUS catheters of the same size, it is not certain 
that when advanced .~equentially in the arterial lu-
men, they will occupy the same position. Although 
they should be on the shortest 3-D path in the lu-
men, coronary arteries have a complex curved ge-
ometry in space, and are partially deformed by the 
catheter lying in their lumen. Thus, catheters with 
differing rigidity will occupy different pOSitions. fi-
nally, it is important to understand that the posi-
tion of a catheter inside the arterial lumen is not 
fixed and varies along the cardiac cycle because of 
ventricular contractions. These methodological 
limitations could be partially overcome with exist-
ing imaging wires, which could be introduced in 
the lumen of the irradiation delivery catheter itself. 
Presently, another limitation we face in our cathe-
terization laboratory is that DVH are not obtained 
on-line. Further implementations with faster pro-
cessing of the 3-D rvus data set for optimal auto-
matic contour detection are under study. 
In conclusion, we think that the body of addi-
tional information available from IVUS and derived 
dOSimetry parameters such as DVH should improve 
our understanding of the mechanisms of action of 
brachytherapy and be helpful for the comparison 
of trials based on different dosimetry strategies. In 
our center, we systematically assess the lesions 
treated by vascular radiation therapy by IV US. 
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ABSTRACT 
Objectives: The aims of the study were to determine the incidence of relocation of the minimal 
luminal diameter (MLD) after B-radiation therapy following balloon angioplasty (BA) and to 
describe a new methodological approach to define the effect of brachytherapy on treated 
coronary arteries. 
Background: Luminal diameter of irradiated coronary lesions. may increase over time 
following dilatation and irradiatation. As a result, the MLD at follow-up may be relocated from 
its location pre-intervention, which may induce misleading results when a restricted definition 
of the target segment by quantitative coronary angiography (QCA) is performed. 
Methods: Patients treated with BA followed by intracoronary brachytherapy according to the 
Dose-Finding Study constituted the study population. A historical cohort of patients treated 
with BA was used as control group. To be included in the analysis, an accurate angiograpbic 
documentation of all instrumentations during the procedure was mandatory. In the irradiated 
patients, 4 regions were defined by QCA: vessel segment (VS), target segment (TS), injured 
segment (INS) and irradiated segment (IRS). 
Results: Sixty-five patients from the Dose-Finding Study and 179 control patients were 
included. At follow-up, MLD was relocated more often in the radiation group than in the 
control group (78.5% versus 26.3%; p<O.OOO I). The rate of> 50% diameter stenosis differed 
between the 4 pre-dermed regions: 3.1% in the TS; 7.7% in the INS; 9.2% in the IRS and 
13.8% in the VS. 
Conclusions: Relocation of the MLD is commonly demonstrated after BA and hrachytherapy 
and it should be taken into account during the analysis and report of the results of radiation 
clinical trials. 
Key words: intracoronary brachytherapy, quantitative coronary angiography, minimal luminal 
diameter, balloon angioplasty. 
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During the past 10 years the efficacy of percutaneous interventions in preventing restenosis 
after percutaneous interventions has been assessed by the use of quantitative coronary 
angiography (QCA).'-4 This technique of analysis has become the gold standard for the 
assessment of coronary angiograms in the context of scientific research due to its superior 
accuracy and objectivity as compared to visual and hand-held caliper measurements, as well as 
possessing a better inter- and intraobserver variability.5,6 Consequently, the percent diameter 
stenosis has become the usual output of this analysis and the value of 50% has gained 
widespread acceptance to define the presence of restenosis in the treated coronary segment. 7 
Intravascular ultrasound (IVUS) studies demonstrated that restenosis after balloon angioplasty 
(BA) is mainly due to neointimal hyperplasia and vessel shrinkage at the site ofthe injury.~!O 
Pioneers in intracoronary radiation therapy have demonstrated that in a majority of patients 
the luminal diameter at the site of the treated lesion may increase during the follow-up, rather 
than decrease. II Three-dimensionallVUS analysis has shown that this phenomenon is induced 
by positive remodeling of the vessel wall at the site of the irradiated segruent. 12 As a result, the 
minimal luminal diameter (MLD) of coronary segruents treated with brachytherapy following 
percutaneous interventions may be relocated at follow-up from its location pre-intervention. A 
restricted definition of the target segment by QCA could induce misleading results and make 
any comparison to previous non-radiation studies unfair. This study was aimed to (I) determine 
the incidence of the relocation of the MLD after B-radiation therapy following successful BA 
and, (2) describe a new methodological approach to accurately analyze and report the effect of 
brachytherapy on the treated coronary artery. 
METHODS 
Patient selection. Patients eligible for the study were those successfully treated with BA 
followed by intracoronary radiation according to the Boston Scientific/Schneider Dose-Finding 
Study.13 The purpose of this trial was to determine the effect of various doses of B-irradiation 
on coronary artery restenosis after BA with or without stent implantation, in patients with 
single de novo lesions of native coronary arteries. The isotope selected was the pure B-ernitting 
90y and patients were randomized to receive doses of 9,12,15, or 18 Gray (Gy) at Imm tissue 
depth. The delivery of radiation was carried out by the use of the Schneider-Sauerwein 
Intravascular Radiation System. 14 In brief, this system comprises (l) a flexible coil made of 
titanium-coated pure yttrium affixed at the end of a thrust wire between proximal and distal 
tungsten markers, (2) a centering catheter which is a segmented balloon consisting of 4 
interconnected compartments which allows centering of the source lumen relative to the arterial 
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lumen, and (3) a computerized afterloader which allows automated advancement and 
positioning of either the dummy or the active source. 14 
QCA analysis and definitions. QCA analysis was performed off-line by an independent 
corelab (Cardia lysis, Rotterdam, the Netherlands). All angiograms were evaluated after 
intracoronary administration of nitrates. The analysis was performed by means of the CAAS II 
analysis system (Pie Medical BV, Maastricht, The Netherlands). Calibration oflhe system was 
based on dimensions of the catheters unfilled with contrast medium. This method of analysis 
has been previously validated.4,lS-16 The area of interest was selected after reviewing all 
cinefilms performed during the index procedure. Any angiographic sequence showing the lesion 
pre-intervention, positions of angiopJasty balloon, and radiation source may be displayed 
simultaneously on the screen using the Rubo DICOM Viewer (Rubo Medical Imaging, 
Uithoorn, The Netherlands). The ECG tracing is also displayed in any angiographic sequence. 
By selecting frames in the same part of the cardiac cycle. we were able to define the location of 
the radiation source and angiopJasty balloon relative to the original lesion. The analyst defined 
a coronary segment bordered by angiographicaHy visible sidebranches which encompassed the 
original lesion, angioplasty balloon and radiation source. This segment was defined as the 
vessel segment (VS). (figure I) The MLD was determined in the VS pre-intervention by edge 
detection and was averaged from the two orthogonal projections. Reference diameter was 
automatically calculated for the VS by the interpolated method' The percent diameter stenosis 
was calculated from the MLD and the reference diameter.' At the time of the procedure, all 
angioplasty balloons, when deflated, were filmed in place with contrast injection in the same 
projections as were the VS. After successful BA, intracoronary brachytherapy was performed. 
Both the location of the centering balloon and the active wire in place were filmed in the same 
projections as performed previously. The proximal sidebranch within the VS was used as an 
index anatomical landmark. Distances from this proximal sidebranch to: (1) the inner part of 
the proximal tungsten marker; (2) the proximal marker of the angioplasty balloon; (3) the 
proximal margin of the obstruction segment; (4) the distal margin of the obstruction segment; 
(5) the distal marker of the angioplasty balloon; and, (6) the inner part of the distal tungsten 
marker were computed by the CMS software. The target segment (TS) was encompassed by 
the proximal and distal margin of the obstructed segment. The segment encompassed by the 
most proximal and most distal marker of the angioplasty balloon defined the injured segment 
(INS). The segment encompassed by the inner part of the 2 tungsten markers defined the 
irradiated segment (IRS). (figure I) All regions of interest were superimposed on the pre-, 
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post-procedural and follow-up angiograms. Geographical miss was defmed for those cases 
where the entire length of the injured segment was not fully covered by the IRS.l7 
Using the softwear of the CAAS system the analyst is able to perform a subsegmental 
analysis within the VS. The segment is automatically divided into subsegments of equidistant 
length (on average, 5.0±O.3 mm). The subsegment containing the MLD was taken as the index 
segment and enabled relocation of the MLD to be defined (figure 2). Relocation pre-post was 
defined as those cases where the MLD of the VS post-treatment was located in a different 
subsegment in the 2 orthogonal projections from that of the index procedure. Relocation post-
fup was defined as those cases where the MLD of the VS at follow-up was located in a 
different subsegment in the 2 orthogonal projections from that post-procedure. Relocation pre-
fup was defmed as those cases where the MLD of the VS at follow-up was located in a 
different segment in the 2 orthogonal projections from that at the index procedure (figure 2). 
Additionally, the analyst computed the MLD in every region of interest and calculated the 
acute gain, late loss and the frequency of> 50% diameter stenosis on a regional basis. Acute 
gain was defined as MLD post-treatment minus MLD pre-intervention. Late loss was defined 
as MLD post-treatment minus MLD at follow-up. Restenosis was defined as diameter stenosis 
>50% at follow-up. 
Control Group. A historical cohort of consecutive patients treated with BA from the 
BENESTENT II trial lS presenting with matched views and correct angiographic 
documentation, was used as the control group. VS, TS and relocation of the MLD were defmed 
in this cohort as above described. 
Statistical analysis. Data are presented as mean ± standard deviation or proportions. To 
compare qualitative variables, the Chi-square test was carried out. To compare quantitative 
variables, the Student's test was performed. All tests were two-tailed and a value ofp<0.05 
was considered statistically significant. 
RESULTS 
Baseline characteristics. One hundred and eighty one patients were included in the Dose-
Finding study. Of these, 51 patients received a stent. The remaining 130 patients treated with 
BA alone followed by B-radiation were eligible for the study. By comparing the technician 
worksheet with the angiograrns recorded, the analyst was able to identifY those patients in 
whom all balloon inflations and source positioning were filmed and all target views were 
matched. Using this systematical approach, 65 patients who did not accomplish these technical 
requirements to perform an accurate QCA, were excluded from the study. Thus, the study 
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population comprised the 65 patients presenting with complete and correct angiographic 
documentation. All patients, regardless of the dose prescirbed (9,12,15, or 18 Gray (Gy) at 
Imm tissue depth), were pooled together. 
Of 410 patients enrolled in the balloon arm of the BENESTENT Jl trial, 179 presenting with 
all the above mentioned technical requirements constituted the control group. Baseline 
characteristics of both the study population and control group are described in the table 1. No 
differences were observed between the 2 groups. 
Incidence and location of the relocation of the MID. Relocation pre-post of the MLD was 
defined in 36 patients (55.4%) in the Dose-Finding cohort and in 62 pts (34.6%) in the control 
group (p~0.005); relocation post-fup was defined in 37 patients (56.9%) in the Dose-Finding 
cohort and in 59 patients (33.0%) in the control group (p~O.OOl); and, relocation pre-fup in 51 
patients (78.5%) in the Dose-Finding cohort and in 47 patients (26.3%) in the control group 
(p<O.OOOl). Geographical miss was identified in 2 patients (3%). At follow-up, 45 patients 
(69.2%) presented with an increase in the value of MLD at TS, whereas 20 patients (30.8%) 
demonstrated either a decrease (18 patients) or no change (2 patients) in the value of MLD at 
TS. The location of the MLD in cases of relocation is presented in the table 2. This new MLD 
was most commonly located within the IRS and INS, followed by those regions within the VS 
but outside the IRS and the INS. Typically, when the new MLD was located outside the INS 
and IRS, distal subsegments were most often involved rather than the proximal ones (88% VS. 
12%, respectively). 
Methodological implications of the relocation of the MLD. QCA data derived from the 
analysis ofthe pre-defmed regions are presented in the table 3. 
DISCUSSION 
Incidence and causes of relocation of the MLD. This study demonstrates that the relocation 
of the MLD is a conunon phenomenon in coronary segments treated with BA followed by 
intracoronary beta-radiation therapy. Although relocation of the MLD at follow-up was 
significantly more frequent in the irradiated group, control patients demonstrated also a notable 
incidence of relocation. This phenomenon noted after radiation was witnessed in previous 
studies that showed that the restenosis process affected the entire vessel segment which was 
dilated and not just the obstructed segment. 19,20 This may explain the mismatch between good 
angiographic results of previous radiation trials and the poor cHnicaJ outcome (Le., high target 
vessel revascularization rates) observed in these studies21 . 
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Further, as changes in'the reference diameter may occur during the follow-up period, the use 
of the percent diameter stenosis measurements is questioned as an accurate estimate of lesion 
severity.19,20 In this regard, 2 thirds of our study population demonstrated an increase in the 
value of the pre-intervention MLD. In the radiation group, increase of vessel dimensions at the 
site of the index MLD may play an important role in the relocation of the MLD. 
Previous three-dimensional intravascular ultrasound observations demonstrated that the 
vessel wall enlarges after catheter-based radiation therapy either following conventional BA or 
stent implantation. [2,22 This vessel enlargement was able to accommodate the mean increase in 
plaque volume, resulting in a net increase in the irradiated luminal volume at follow-up. 
In our study, the MLD was mainly relocated within the IRS and the INS and outside the INS 
and the IRS (lypically at distal segments). In such regions, the presence of pre-existing plaques 
which became angiographically apparent or progressed after the treatment and tapering of the 
vessel may have accounted for the relocation of the MLD. On top of these causes of relocation, 
we cannot exclude the influence of the natural atherosclerotic process on this phenomenon in 
the context of patients with coronary risk factors by inducing development of new coronary 
lesions in any of the pre-defmed regions of interest. 
Methodological consequences of relocation. When the analysis was restricted to the TS, this 
lumen gain at follow-up resulted in a negative mean late loss and a very low restenosis rate 
(3.1%). The TS represents a region which was injured by the angioplasly balloon and 
theoretically presented with the peak stress and vessel stretch after BA. Further, this segment 
was fully covered by the radiation source in all cases. Thus, the results of the analysis of the 
TS may demonstrate the effect of brachytherapy in optimal conditions. On the other site of the 
spectrum, when the analysis included the entire VS, both the late loss and the restenosis rate 
were significantly higher (table 3). This latter analysis was performed in most of the historical 
trials aimed to determine effectiveness of new therapeutic agents on restenosis process after 
BA.23~26 Since the MLD of the entire treated coronary segment is the flow-limiting lesion for the 
patient, the results of the VS should also be presented in intracoronary radiation trials. Finally, 
analyses of INS and IRS may be helpful to identifY the potential causes of failure after 
brachytherapy (i.e. geographical miss, not-injury related edge effect). 
Limitations. The defmition of relocation of the MLD depends decisively on the accurate 
documentation of all steps followed during the procedure. This was accomplished only in 50% 
of the cases treated with BA in the Dose Finding Study and in 44% of the historical control 
group. 
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The QCA data presented in this study represent only the results of the pooled cohort of 
patients enrolled in the Dose-Finding study and not the entire population. 
Conclusions. Relocation of the MLD is a common phenomenon after successful BA followed 
by intracoronary beta-radiation. This feature may induce controversial results related to the 
methodology used in the QCA analysis and should be considered when reporting the results of 
subsequent radiation studies. The new methodological approach proposed may better detennine 
the efficacy of this technique by defining different regions of interest within the target coronary 
segment. 
Appendix: 
The participating centers and investigators of the Dose-Finding Study Group are listed with the 
number of included patients under parentheses. 
University Hospital, Geneva, Switzerland (57): Verin Vitali, MD, Youri Popowski, MD, Delafontaine 
Patrice, MD, Kurtz John, MD, Papirov Igor, PhD, Sergey Airiian, MD, Philippe Debruyne, MD, 
Ramos de Olival Jose, MD. 
Cardiovascular Center, Onze~Lieve-Vrouw Ziekenhuis, Aalst, Belgium (54): Wijns William, MD, 
(Principallnvestigator), de Bruyne Bernard, MD, Heyndrick:x Guy, MD, Verbeke Luc, MD, Piessens 
Marleen, PhD, De Jans Jo, MSc. 
University Hospital, Essen, Germany (26): Baumgart Dietrich, MD, Sauerwein Wolfgang, MD, Erhel 
Raimund, MD, von Birgelen Clemens, MD, Haude Michael, MD. 
University Hospital, Kiel, Germany (22): Lins Markus, .MD, Simon Ruediger, MD, Kovacs Gyorgy, 
MD, Thomas Martin, MD, Herrmann Gunhild, MD, Wilhelm Roland, l\.1D, Kohl Peter, MD. 
Kings College Hospital, London, United Kingdom (22): Thomas Martin, .MD, Caiman Francis, MD, 
Lewis Niel, PhD. 
Data Monitoring: Thaler Thomas, MD (Boston Scientific) 
Aogiographic Core-Laboratory and Data Analysis: 
Teunissen YVOlme, PhD, (Clinical Trial Manager), Spierings Astrid, Van derWiel Connie, Kloek 
Gitte, MSc, Disco Clemens, PhD 
Critical Events Committee: Oekkers Jaap, MD, Serruys Patrick, MD, PhD. 
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Table 1. Baseline Characteristics (0=65). 
Dose~Finding Group Control Group 
(n~65) (n~179) 
Age, years 64±9 62±10 
Gender, male 46 (70.7%) 137 (76.5%) 
Treated artery: 
Left anterior descending 28 (43.1%) 80 (44.7%) 
Left circumflex 7 (10.8%) 22 (12.3%) 
Right coronary 30 (46.1%) 77 (43%) 
Coronary risk factors: 
Systemic hypertension 35 (53.8%) 89 (49.7%) 
Diabetes mellitus 12 (18.5%) 27 (15%) 
Smoking 33 (66.1%) 123 (68.7%) 
Hypercholesterolemia 38 (58.5%) 98 (54.7%) 
Family history 23 (35.4%) 60 (33.5%) 
Dose: 
9Gy 18 (27.7%) 
12 Gy 11 (16.9%) 
15 Gy 20 (30.8%) 
18 Gy 16 (24.6%) 
An p=NS. Oy indicates Gray_ 
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Table 2. Location of the relocated MLD 
Within INS - IRS 
Outside INS - IRS 
Within lRS-Outside INS 
Within INS-outside IRS 
(geographical miss) 
Relocation pre-post 
(n~36) 
19 (52.9%) 
9 (25%) 
6 (16.6%) 
2 (5.5%) 
Relocation post-fup 
(n~37) 
23 (62.2%) 
10 (27%) 
4 (10.8%) 
0(0%) 
INS indicates injured segment; IRS indicates irradiated segment. 
·131· 
Relocation pre-fup 
(n~51) 
24 (47%) 
18 (35.3%) 
8 (15.7%) 
1(2%) 
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Table 3. QCA data from the 4 pre-defined segments. 
TS INS IRS VS 
MLD pre, rnm I.06±O.2 1.06±O.2 1.06±O.2 1.06±O.2 
MLD post, rnm 2.17±O.S 1.99±OA 2.00±OA 1.91±OA 
MLDfup, mm 2.36±0.5 1.97±0.5 1.97±0.5 1.84±0.5 
%DS fup 20.3±11 33.2±11 33A±11 37.9±1O 
Acute gain, mm 1.12±0.4 0.93 ±OA 0.94±OA 0.85±OA 
Late loss, mm ·0. 18±OA O.OI±OA 0.03±OA 0.07±0.3 
Restenosis rate, n (%) 2 (3.1) 5 (7.7) 6 (9.2) 9 (13.8) 
Segment length, mm 5.0±O.3 18.7±4.2 22.9±3.5 36.9±8A 
TS indicates target segment; INS indicates injured segment; IRS indicates irradiated segment; VS 
indicates vessel segment; J\1LD indicates minimal luminal diameter; DS indicates diameter stenosis; 
pre indicates pre-intervention; post indicates post-intervention; fup indicates follow-up. 
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F1gure 1 
A. Target segment (TS) is between proximal and distal margin of the target lesion 
automatically defined by the quantitative coronary angiography system. Vessel segment (VS) is 
bordered by visible sidebranches, which encompass the target segment (TS), and the position of 
the angioplasty balloon and radiation source. 
A'. Original lesion in the middle part of the right coronary artery before intervention. 
B.lnjured segment (INS) is defined as the segment encompassed by the most proximal and 
most distal marker of the angioplasty balloon. 
S'. Arrows indicate the markers of the deflated angioplasty balloon filmed in place with a 
contrast injection. 
C. The segment encompassed by the inner part of the 2 tungsten markers of the radiation 
delivery system defined as the irradiated segments (IRS). 
C'. Arrows indicate the inner parts of the radiation source tungsten markers filmed with a 
contrast injection. 
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Figure 2 
A. Subsegmental analysis before procedure. Vessel segment (VS) was automatically divided 
into 5-mm subsegments by the CAAS II system. The original lesion is located at segment No.5 
pre-procedure as the arrow indicates. 
A'. Computer defIned analysis pre-procedure. 
B. Subsegmental analysis at post-procedure. Minimum lumen diameter is located at segment 
No.6 (arrow). 
B'. Computer defined analysis post-procedure. 
C. Subsegmentai analysis at follow-up. Minimum lumen diameter is located at segment No.7 
(arrow). 
C'. Computer defined analysis at follow-up. 
PRE POST 
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Late Coronary Occlusion After 
Intracoronary Brachytherapy 
Marco A. Costa, MD; Mane! Sabate, MD; Wim J. van der Giessen, MD, PhD; I. Patrick Kay, MBChB; 
Pavel Cervinka, MD; Jurgen M.R. Ligthart, BSc; Pedro Serrano, MD; Veronique L.M.A eoen, MD; 
Peter C.-Levendag, MD, PhD; Patrick W. Serruys, MD, PhD 
Backgrotwd-Intfacoronary brachylherapy appears to be II promising technology to prevent restenosis. Presently, limited 
d<ll<l <lfe available regarding the lillc safelY of Ihis therapeutic modality. The aim of the study was to determine the 
incidence of lute (> I month) thrombosis after PTCA and radiotherapy. 
Methods alld Results-From April 1997 to March 1999, we successfully treated 108 palients with PTCA followed 
by inlfacoronary J3-radiation. Ninety-one patients have completed at least 2 months of clinical follow-up. Of these 
patienlS, 6.6% (6 patients) presented with sudden thrombotic events confirmed by angiography 2 to 15 months after 
intervention (2 balloon angioplasty and 4 stent). Some factors (overlapping stents, unhealed dissection) may have 
triggered the thrombosis process, but the timing of the event is extremely unusual. Therefore, the effect of radiation 
on delaying the healing process and maintaining a thrombogenic coronary surface is proposed as the most plausiblc 
mechanism to cxplain such late events. 
Conclusions-Late and sudden thrombosis after PTCA followed by intracoronary radiotherapy is a new phenomenon 
in interventiona1 cardiology. (Circulation. 1999;100:789-792.) 
Key Words: thrombosis. angioplasty • radioisotopes 
Thrombotic occlusion nfter PTCA is associated with increased morbidity and mortality rates. I Current tech-
niques of stenting followed by antiplatelet therapy have 
drnll1ntically reduo::ed the incidence of this event to < I .5%.2.3 
See p 780 
intrncoronury radiation is a promising new thempy to 
prevent restenosis. Recent mndomized trinls demonstrnted 
a reduction in the restenosis rate and m3intenance of 
benefits up to 2-year follow-up.~-" Presently, limited data 
are available regun.ling long-term safety nfler intraeoro-
nary brachytherapy.,,·7 Although subacute thrombosis has 
been reported ufler rudiotherapy,U .. " the incidence of late 
thrombotic events has not been determined. 
The aim of this study wu~ to document the ino:.:idence of 
l3Ie {> I month} thrombotic events 3fter elective PTCA 
folJowed by intnlva~cular radiotherapy. 
Methods and Results 
From April 19!}7 to M<lrch 1999, 108 consecutive pUlients 
were successfully treated with catheter-based intracorunary 
j3-radiation <It the Thoraxcenter (Rollerdam, The Nether-
lands). The Medical Ethical Commillec approved the usc of 
mdiation therapy and informed consent was obtnined from 
every patien!. All patients presented with stable angina 
pectoris and single vessel disease. Brachytherapy was per-
formed using the Beta-Calh system (Novoste Corporationl lU 
(n=76 patients, 32 stents and 44 balloon angioplasty [BAJJ. 
or the Guidant intravascular brachytherapy system (Guidant 
Corporation Vasculur Intervention)11 (n=32 palients, 13 
Stents nnd 19 BA). BA and stenting were performed ucconJ-
ing to stnndard techniques. Intravascular ultrasound (lVUS) 
was performed nfter radiation with a mechanical ultrasound 
cutheler (CV1S, Boston Scielltific). Off-line quantitmive cor-
onary angiography was performed using CAAS system (Pie 
Medicn1 [mnging BV). Six-month angiographic and IVUS 
follow-up was scheduled in all patients. 
All pntients were discharged without complications. Ninety-
one p<ltients completed at least 2-month clinical follow-up. We 
observed I case of subacute thrombosis occurring 15 days after 
stenting. This patient reccived an 18-mm long stent (postdilated 
at 10 aIm) with optimal IVUS result. Ticlopidine withdrawal (12 
days after stenting) was the plausible explanation of thrombosis 
in this case. 
Six putients (6.6%) presented with sudden late throm-
hotie coronary occlusion. Twu of them were treated with 
BA and the remaining 4 received un udditiona] stent after 
radiation. Their clinien] characteristics are summarized in 
Rccciwu !I.-lay to. t'oJ'll): revi.,ion re~eived June 12. t999: accepled June 24. t999. 
From Th()ra~L~nlel (M.A.C., M.S., W.J.I'.d.G., I.P.K., P.c., J.M.R.L., P.S., P.W.S.). Oijkzigl Ulli\"er~ity Hmpilal, and Dunie1 den Hoek Cancer 
Cellier lV.L.!I.·I.A.C.. P.CL.). ROllcldam, The NClherlnnds. 
Correspondence to Prof P:llrkk W. Sefllly~, Head of Ihe DepnrlmCnl of tlllervcnlionu) Cardiology. Unil"cr'iily Ho,pit~1 Dijhigl-Thor'l.~cenler 
13d41~, Dr. Motewulerpiein,40-30t5GD l{ollerd~m, The Nelhertands. E·mait ,~rruy,@eard.~lf.nl 
© J 'oJ99 Ameri~un Hearl A>socimion, Inc 
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Clinical and Angiographic Variables 
Variables 
Age, y 57 58 49 73 52 62 
S" Male Female Male Female Female Female 
Pre·procedure 
Targel vessel lCX RCA lCX LAO RCA RCA 
Type of lesion A A 
RD, mm 2.5 2.8 2.67 2.66 2.84 2.6 
MLD, mm 0.9 1.12 0.64 1.09 0.65 0.55 
DS, % 66 60 76 60 77 78 
Lesion length, mm 13 15 18 11.2 9.6 9.7 
Procedure 
Brachylherapy system Bela-Calll Guidanl Beta"Calh Bela-Calil Beta-Cath Beta-Calh 
Source lenglh, mm 30 27 30 30 30 30 
Prescribed dose, Gy ,,' 35j 
'" 
14' 18' 14' 
Slentiangioplasty Stefl! Balloon Balloon Slenl Stent Sten! 
Total stenllength, mm 41 25 25 16 
Postprocedure 
Dissection/type No YestS YestS No No No 
MLD, mm 2.47 2.07 2.15 2.4 2.34 2.4 
OS, % ~1 26 21 9.5 17 
Clinical success y" y" y" y" y" y" 
Follow·up 
Event VF Inferior MI Postlateral MI Anterior MI Inferior MI Inferior MI 
Time, mo 15 10 2.5 
Antiplatelel medication y" y" y" No y" y" 
Associated lactors Long slen! Dissection Dissection at 6-mo Aspirin withdmwal No No 
LCX indicates left clrcumflex artery; RCA, right coronary artery; LAD, left anterior descending artery; RD, reference diameter; MLD, 
minimal lumen diameter; DS, diameter stenosis; VF, ventricular fibrillation; and MI, myocardial infarction 
'AI 2 mm from the source; tat 0.5 mm into the vessel watL 
the Table. No clinical or anatomic characteristic appeared 
to be related to thesc cvents, 
In patient I, overlapping 9- and 32-mm NIR stelllS 
(Medinol Ltd) were optimally implanted as assessed by 
IVUS. Patients 2 and 3 (BA) showed type B dissections 
without compromising flow postprocedure. Patients 4 
and 5 both received a Multilink 25-mm stent (Advanced 
Cardiovascular Systems/Guidantl, and patient 6 received a 
NIR 16·rnm stent with optimal angiographic results. Stent 
patients were discharged on aspirin (250 mg/d) and tido-
pidine (250 mg BID for 15 days in patients 3 and 4, and for 
30 days in cases 5 and 6). BA patients received aspirin 
alone. 
Patient I was readmitted with ventricular fibrillation 2 
months after the procedUre, whereas, patients 2, 5, and 6 
sustained inferior myocardial infarctions (MI) betwecn 2.5 
and 3 months after the treatment. The irradiated segment 
wa,; ocduded at 6-month angiogram in patients I and 2 
(Figure I). Thrombotic occlusion was successfully treated 
by primary angioplasty in patients 5 and 6. 
In patient 3, the 6·month IVUS control revealed a 
persistent (unhealcd) submedial dissection (Figure 2) with 
no signs of re.~tenosis. Nine months later, this patient 
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sustained a posterolateral Mf which was treated with 
thrombolytics. Two weeks aftcr this treatment. an angio-
gram perrormed hecal1';c of recurrent allginn showed the 
occlusion in the irradiated area. Silnilarly. the 6-lllulllh 
IVUS control of patieJlI 4 showed no neointimal hyperpla-
sia. FOllr months after control. she had a strokc and aspirin 
was rcplaced by accnot:oumarol. Ten days later. she 
sustained an anterior ML The thromhotic occlusion in the 
treated site was confirmed by angiography. 
Discussion 
Progression to total ocdusioll al"ter BA i~ a ,table process in 
the general nonirradiated population which occurs in approx-
imately 4% of patients, leading to a MI in <0.5%.12 In 
contrast, our study shows 11 high incidencc (6.6%) of throm-
botic clinical cvents 2 10 15 months al"ter PTCA and 
brachythcrapy. 
Coronary dissection after SA is associated with abrupt 
closure; however, Iype B dissections (NHLBI classifica-
tion). as observed after BA in our patients, have not been 
related to thrombotic e Vents. I.' The normal heal ing process. 
present after di.~sectiolls, may be impaired after intracoro-
Late Thrombosis After Intracoronary Brachytherapy 
nary fadiation.l~ Whether unhealed dissections, us demon-
strated in patient J, is related \0 lale thrombosis remaim to 
be elucidated in a lurger population. Further, the necessity 
of stenting mild di.'iscdions without compromising !low 
after radiotherapy should be investigated. 
The mean time of subacute thrombosis after stenling is 
approximutcly 5 to 6 days.n In a recent study, subacute 
thrombosis occurred within the fir>.( 24 hours in 86% of 
patients treated with llspirin and ticludipine for 14 days, 
with no case of thrombotic events occurring after 15 
daysY Columbo e1 al reported only 2 cases (0.6%) of 
thrombosis uccurring 2 to 6 months after stenting.2 In 
contrast, in our study, 4 patients receiving a stent (8.8%) 
experienced thrombosis late after radiation. 
Experimentally, reendothelialization after injury takes 
>4 weeks to be completed.)" However, the clinical pre-
sentation of subacute thrombosis infrequently occurs later 
than 15 days after stenting, 15 when the reendothelialization 
process lTlay still be incomplete. Delayed reendothcli-
alization as a trigger mechanism of late stent thrombosis 
after antineopll1stic therapy has been hypothesized previ-
ously. ,., Farb et al reported incomplete endothelialization 3 
months after placement of J3-radioactive stent.l~ Neverthe-
less, the same group showed no differences regarding 
endothelial cell growth between radioactive and control 
stents in anothcr experimental model. 19 Further studies 
should address the timing of sten! reendothelialization 
after brachytherapy to determine its role on the pathogen-
esis of latc thrombosis. 
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Figure 1. Patient 1. A, Preprocedure 
angiography shows a significant lesion in 
the mid-third of left circumflex artery. B, 
Radioactive source placed in treated site. 
e, Poslprocedure angiography and IVUS 
images show an optimal result (arrow-
heads). 0, AI2 months, the proximal part 
of stent appeared occluded. 
Although multiple stents have been related to subacute 
thrombosis,20 the significance of multiple stent implanta-
tion (patient I) on late thrombotic phenomena has not been 
demonstrated. 
The use of intracoronary J3-radiation is a common 
feature in our patients. However, the judgment of whether 
radiation is the key faelOr in the pathogenesis of late 
thrombosis should await the analysis of ongoing trial>. 
Concomitantly, the benefit of prolonged antiplatclet ther-
apy with the combination of aspirin, c1opidogre!, or 
liclopidine should be considered. 
Limitations 
Our patients were included in well-controlled J3-radiation 
studies with similar baseline characteristics and inclusion 
criteria (lesion length <15 mm, treatment of single vessel). 
However, 2 different systems to deliver f3-radiation were 
used. 
In addition, it is not possible to rule out the natural 
history of coronary disease as a cause of late thrombosis. 
However, the incidence of total occlusion in the general 
non irradiated population is much lower than that observed 
in our study. In fact, the incidence of late thrombotic 
events would be even higher if, in the interest of complete-
ness, we waited for I-year foHow-up in the total patient 
population. 
Finally, whether late thrombosis is a generic complica-
tion of intracoronary radiotherapy or is restricted to the use 
of J3-sources cannot be eXlrapolated from our findings. 
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Figure 2. Patient 3. A, Postprocedure coronary dissection, demonstrated both on angiography and IVUS, did not c"ompromise flow in 
treated area (arrowhead). S, This dissection persisted unhealed at 6-month control (arrowhead). C, At 15 months, irradiated segment 
appeared occluded. 
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Chapter I} 
The outcome from balloon-induced coronary artery dissection after 
intracoronary Il-Radiation. 
(Heart 2000;83:332-337) 
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Outcome from balloon induced coronary artery 
dissection after intra coronary ~ radiation 
I P Kay, M Sahate, G Van Langenhove, M A Costa, A J Wardell, A L Gijl-el, N V Deshpande, 
S G Carlier, V L M A Coen, P C Levendag, W Van der Giessen, P J de Feyter, P \V Serruys 
Abstract 
Objective-To evaluate the healing of balloon induced coronary artery dissection in individuals 
who have received p radiation treatment and to propose a new intravascular ultrasound (IVUS) 
dissection score to facilitate the comparison of dissection through time. 
Design-Retrospective study. 
Setting-Tertiary referral centre. 
Patients-31 patients with stable angina pectoris, enrol1ed in the beta cnergy restenmis tria! 
(BERT-I.5), were included. After excluding those who underwent stent implantation, the evalu-
able population was 22 patients. 
Interventions-Ba!!oon angioplasty and intracoronary radiation followed by quantitative coronary 
angiography (QCA) and rvuS. Repeat QCA and IVUS were performed at six month follow up. 
Main outcome measures-QCA and lVUS evidence of healing of dissection. Dissection 
classification for angiography was by the National Heart Lung Blood Institute scale. IVUS proven 
dissection was defined as partial or complete. The following IVUS defined charactcristics of dis-
section were described in the affected coronary segments: length, depth, arc circumference, pres-
ence of flap, and dissection score. Dissection was defined as healed when all features of dissection 
had resolved. The calculated dose of radiation received by the dissected area in those with healed 
versus non-healed dissection was also compared. 
Results-AngiographY (type A = 5, B = 7, C = 4) and IVUS proven (partial = 12, com-
plete::: 4) dissections were seen in 16 patients fol!owing intervention. At six month follow up, six 
and eight unhealed dissections were seen by angiography (A = 2, B;;; 4) and rvus (partial = 7, 
complete::: I), respectively. The mean IVUS dissection score was 5.2 (range 3-8) following the 
procedure, and 4.6 (range 3-7) at follow up. No correlation was found between the dose 
prescribed in the treated area and the presence of unhealed dissection. No change in anginal sta-
tus was seen despite the presence of unhealed dissection. 
Conclusion-p radiation appears to alter the normal healing process, resulting in unhealed dis-
section in certain individuals. In view of the delayed and abnormal healing observcd, long term 
follow up is indicated given the possible late adverse effects of radiation. Although in this cohort 
no increase in cardiac events following coronary dissections was seen, larger populations are 
needed to confirm this phenomenon. Stenting of ail coronary dissections may be warranted in 
patients scheduled for brachytherapy after ba!loon angioplasty. 
(Hearl 2000;83:332-337) 
Keywords: dissection; intraVaS~lllar ultrasound; angiography; coronary art~ry; brachythemp),; angiopiasty 
Despite excellent acute results, restenosis at six 
month follow up after coronary artery balloon 
angioplasty remains a serious problem.' Exces-
sive neointimal formation, extracellular matrix 
synthesis, and negative vessel remodelling in 
response to balloon injury have been docu-
mented as the main mechanisms of 
restenosis. ,-, Intracoronary radiation treatment 
has recently emerged as a means of preventing 
and treating restenosis in coronary arteries 
treated by balloon angioplasty. The theoretical 
benefit of radiation in preventing neointima! 
proliferation resides in the destruction of more 
rapidly dividing smooth muscle cells.' H It may 
not be surprising that by inhibiting the above 
deleterious features of healing after balloon 
angioplasty, intracoronary radiation may also 
alter normal healing processes. 
Coronary artery dissection is common after 
balloon angioplasty. This is angiographically 
visible in 20-45% of cases fol!owing balloon 
angioplasty" and present in up to 85% of cases 
when intravascular ultrasound (IVUS) assess-
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ment is used." If further angioplasty of the 
lesion is not undertaken, then it is recognised 
that nearly all angiographic dissection will heal 
over a six month time frame."" \X'hether 
intracoronary radiation will prevent the process 
of natura! healing after balloon induced dissec-
tion has not been documented thus far in 
humans. To exanline this, we retrospectively 
analysed coronary artery dissections using 
angiography and IVUS, at the time of treat-
ment and at six month follow up, in patients 
treated with intracoronary radiation following 
balloon angioplasty. \X'e also aimed to compare 
the prescribed dose received by the treated area 
in individuals with non-healing dissection with 
the dose received bv those individuals with 
healed dissection. -
Methods 
PATIENT SELECTION 
Patients eligible for the study were those 
treated successfully with balloon angioplasty 
followed by intracoronary irradiation according 
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to the beta energy restenosis trial (BERT-l.S). 
The purpose of this trial was to evaluate the 
safety and efficacy of low dose ~ source irradia-
lion following balloon angioplasty with and 
without stent implantation in patients with sin-
gle "de novo" lesions of native coronary arter-
ies. The design of this trial was a prospective 
multicentre non-randomised feasibility study. 
\Ve used a strontium 90 C"Sr) source with 
ynrium as a pure /3 emitter, and patients were 
randomised to receive 12, 14, or 16 Gray (Gy). 
The inclusion and exclusion criteria of this trial 
have been previously reported." 
RADIATION DELIVERY SYSTEM 
The Beta-Cath system (Novoste Corp, Nor-
cross, Georgia, USA) was used to deliver local-
ised j3 radiation to a coronary artery at the site 
of coronary intervention. The device consists 
of three compOnents: (1) the transfer device 
which stores the radiation source train and 
allows the positioning of these sources within 
lhe catheter; (2) the delivery catheter, which is 
a 5 F multilumen over the wire non-centred 
catheter which uses saline solutiofl to send and 
return the radiatiOfl source train; and (3), the 
radiation source train consisting of a series of 
12 independent cylindrical seeds which con-
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tain the radioisotope 90SI' sources and is 
bordered by two gold radiopaque markers 
separated by 30 mm. 18 
IVUS IMAGE ACQUISITION ANALYSIS SYSTEM 
The segment subject to analysis was examined 
with a mechanical lVUS system (ClearView, 
CardioVascular Imaging System (CVIS), Sun-
nyvale, California, USA) with a sheath based 
IVUS catheter incorporating a 30 MHz single 
element transducer rotating at 1800 rpm. The 
transducer is placed inside a 2.9 F 15 cm long 
sOnOlucen[ distal sheath which alternatively 
houses the guidewire (during the catheter 
introduction) or the transducer (during imag-
ing, after the guidewire has been pulled back). 
To assure the correct identification and analy-
sis of the irradiated segment, certain steps were 
followed. First, all angiogram was performed 
after positioning the delivery catheter, and the 
relation between anatomical landmarks and the 
two gold markers was noted. Typically, the 
aorto-ostial junction and the side branches 
were used as landmarks. The landmark closest 
to either of the gold markers was used as a 
guide. During the motorised lVUS pullback, 
all side branches were counted and the guiding 
landmark was identified. The correct selection 
of the marker was confirmed by visualising the 
position of the lVUS probe during a contrast 
injection. Once the acquisition was completed, 
we selected the segment of interest by taking 
the digitised cross-sectional images proximal or 
distal to the guiding landmark up to 30 mm, 
which is the area encompassed by the two gold 
markers of the radiation source. At follow up, 
we selected the same region of interest and 
compared it with that after treatment. 
PROCEDURE 
The medical ethics committee of the Erasmus 
Medical Center, Rotterdam approved the 
study and all patients signed a written in-
formed consent form. In the BERT-I.5 trial 
balloon angioplasty was performed according 
to standard clinical practice. Following suc-
cessful angioplasty, patients were randomised 
to receive 12, 14, or 16 Gy, as calculated at 
2 mm from dle centre of the radiation source. 
The 5 F delivery catheter of the Beta-Cath 
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Figure I JmravasCl/lar u/rrasOI/JId images (lefl <IIld remre) ,hOldug a dUllble III"'eIt bemee" 12 ami 3 0 'dod/ 
poslimervemiml, The right image ,how.< Ihe .<ame {"ioll aI .,ix 1II0011h follow up !~ilh Ihe Ullhealed fal"" fume/! ,een belweell 
Ilwld2a'c/ock. 
system was insened over the guidewire and 
advanced such that the two marker bands 
encompassed the angioplasty site. The 
guidewire was removed and the radiation 
source train containing 12 '"Sr seeds was posi-
tioned between the gold markers using fluoro-
scopic visualisation. The seeds remained in 
place for 25-35 minutes to deliver the 
assigned dose of radiation. Following irradia-
tion, repeat angiography and IVUS pullback 
were performed. Intraeoronary nitrates were 
administered before the treated artery was 
examined with IVUS. The 2.9 F IVUS cath-
eter (CVIS, Sunnyvale) was advanced distal to 
the treated site. A continuous motorised 
pullback at a speed of 0.5 mmls \vas carried 
out, fo!lowed by an angiographic control. At six 
month angiographic follow up, identical quan-
titative coronary angiography (QCA) and 
IVUS examination of the treated area was per-
formed, 
Fig'~I'e 2 Coro"ary allgiogram </uywing: (A) le.<iou pre/l"t!almC!II; (8) ",,/iollelil'e .",wu 
'" "Wi (e) p,milll'I"VennOUia"d (lJ) Ihe .",m" le$l(>IIIII.":~ JIIomhf"lImu up. Nme Ihe 
PI"CSeIICC t>f <III edge effeci and absence of allgiographic disscwoll aI ,ix mOlllh follow up. 
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DEFINITIONS 
Dissection was defmed both angiographically 
and by IVUS. Angiographic dissection was 
defined using the National Heart Lung and 
Blood Institute criteria for the classification of 
dissection. ,0 QCA analysis was performed 
before the intervention, after treatment, and at 
six month follow up using identical gantry 
positions. Coronary angiography \vas per-
formed after intracoronary administration of 
nitrates. The offline analysis of at least two 
orthogonal projections was performed by 
means of the cardiovascular angiography 
analysis sytem (CAAS II, Pie Medical BV, 
Maastricht, The Netherlands). Calibration of 
the system was based on dimensions of the 
catheters not filled with contrast medium. This 
method of analysis has been previously 
validated."'·" The following measurements 
were obtained in each projection: minimal 
luminal diameter (lviLD), reference diameter, 
% diameter stenosis, and lesion length. Lesion 
length was user defined and not done by an 
algorithm using curvature analysis (lfthe diam-
eter function, The reference diameter wns 
obtained h;.' all int<,rpolatl'd mcthod. Acute 
gain \\las defined as J'l'lLD measured after 
tn:atment minus IvlLD prcintcrvcntion. Late 
loss was defined as MLD after treatment minus 
MLD at foHow up. Late loss index was defined 
as late loss diyidcd by acute gain. ReSlenosis 
was defined as > '50%. diameter stenosis at fol-
low up and located within the tr<,ated area. 
IVUS dissection \HIS defined as a longitudi-
nal tear parallcl to the \-esse! wall. r,· III all 
patients with IVUS d<:tected disseClion, length, 
arc, and depth were recoIlkd. For inclusion in 
the study all dissections were located within the 
area treated by radiation. Axial length wa~ 
measured ill millimetres, Circuml~ren[ial ex-
tension was measured as an arc in degrees. The 
maximal depth of wall disruption was defined 
as follows: partial-plaque between tear and 
aUl'entitia; complete - full thickness tear ex-
tending through the plaque w the adl-entitia. ", 
An IVUS dissection score \\'a~ created to 
rank the severity 'llf dissection (table I). This 
score facilitates comparison of dissection after 
the procedure anu at follm\" up. Assuming that 
a dissection is present, the potential f:lnge of 
the dissection score was 3-9. The dissection 
was considered to be healed when an features 
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of dis~ection had disappeared. Partial healing 
was considered to have occurred when at least 
one feature of dissection persisted a[ follow up. 
Absence of healing was defin~d as no change to 
the dissection on follow up. 
The prescribed radiation dose delivered to 
2 mm from the source was recorded and com-
pared between individuals with and without 
healed diss.:uion. 
STATISTICAL ,\NAlSSIS 
Quantitative data are presented as mean (SD). 
The non-paired two tailed Student's ( test was 
Tabl~.J HlS/illlcn'CIIli">I wid ,ix mOil/), fol/ow liP 0/ <fillet/ioll elJaill(lled by IVUS 
used to compare dose levels and healed/non-
healed dissection. 
Results 
HA$JiLlNJi CHARACTERISTICS 
From April to December 1997, 31 patients 
were treated at our institution according to the 
BERT 1.5 triaL Eight patients, who received 
stent implantation because of important recoil 
or angiographic and IVUS proven dissection 
after balloon angioplasty, were excluded from 
the assessment. One patient refused IVUS at 
follow up; the same palient had no evidence of 
dissection following treatment. Therefore Lhe 
study population was 22 patients. The baseline 
characteristics of the patients are shown in 
table 2. 
CLINICAL, ANGJOGRAPHIC, AND IVUS FOLLU\~' L'I' 
At follow up 14 patients (63%) remained 
asymptomatic. Six patients presented with 
stable angina pectoris: one with Canadian 
Cardiovascular Society (CCS) class 1 angina, 
one with CCS class 2, and four with CCS class 
3. The follow up angiography demoustr:Hed 
restenosis (> 50% diameter stenosis on quanti~ 
tative coronary angiography) in five patients 
(24'X,). These included the four patients with 
CCS class 3 angina. One restenotic patient 
showed aneurysmatic formation within the 
irradiated area. The prescribed dose in resten-
otic patients was l2 Gy in one patient, 14 Gy 
in one patient, and 16 Gy in three patients. 
Dissection was seen in 16122 patients (73%) 
after intervention using both angiographic and 
IVUS criteria. At six month follow up dissec-
tion was seen in six patients on angiography 
(38%) and eight patients on NUS (50%) 
(table 3). Disagreement between lVUS and 
angiography was caused by the presence of a 
double lumen in one individual (fig 1) and a 
flap in another (figs 2 and 3), neither of which 
was detected by angiography. Angiographic 
analysis of healed versus non-healed dissection 
is presented in fig 4. No difference was seen in 
the reference diameter, % diameter stenosis, 
and MLD before or after the procedure or at 
follow up for either the healed or the 
non-healed dissection groups (table 3). As 
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expected late loss and late loss index were 
greater in the healed dissection group, but the 
difference was not significant. Eight patients 
had persisting dissection after IVUS 
examination-six had no evidcnce of healing 
and two had partial healing (table 4). Three of 
the healed dissections resulted in restenosis. 
The mean IVUS dissection score was 5.2 
(range 3-8) after the procedure and 4.6 (range 
3-7) at follow up. IVUS healed dissection 
received a mean prescribed dose of 14 Gy and 
non-healed dissection received 13.8 Gy (p 
value not significant). 
Discussion 
We describe coronary artery dissection follow-
ing intra coronary radiation treatment in a 
group of individuals who had dissection noted 
angiographically and with IVUS, but who did 
not undergo stent implantation as the lesion 
appeared stable under standard clinical condi-
tions. These dissections were not associated 
with any significant acute or subacute clinical 
sequelae. What is remarkable is that after six 
month follow up, six of the angiographic 
dissections and eight of the IVUS proven dis-
sections persisted. In a similar patient popula-
tion who had undergone conventional balloon 
angioplasty (n = 183),87 patients (47%) suf-
fered a type A-C dissection aftcr coronary 
angioplasty. Only one dissection persisted at 
six month follow up coronary angiography 
(DEBATE 1 subanalysis, unpublished data, 
1999). 
\Vhy should these dissections fail to heal in a 
predictable manner as previously described in 
conventional angioplasty? In an experimental 
model, a reduction of cell proliferation in the 
media and adventitia has heen observed in the 
early phase after balloon injury and radiation 
treatment. Furthermore, the expression of u 
smooth muscle actin in the adventitia is 
reduced after radiation treatment, suggesting a 
positive effect on vascular remodelling." Con-
sequently it appears that radiation treatment is 
directly implicated in altering the healing proc-
ess after banoon angioplasty, increasing the 
potential for positive remodelling," arterial 
dilatation, and non-healing dissection. 
It remains uncertain as to whether the 
dissections described represent permanent dis-
ruptions to the vessel wall or merely a retarda-
tion in the healing process. The possible 
inhibitory healing effect of radiation may 
diminish with time such that at a critical point 
there may be a further activation of the resten-
otic process associated with the healing of the 
dissection. 
In an animal model, Farb and colleagues 
showed a reduction in neointimal formation in 
"P-emitting radioactive stents three months 
after implantation; endothelialisation was in-
complete, however, with only one third of the 
entire intimal surface showing endothelialisa-
tion with poor formation of cell junctions.25 As 
a result of incomplete or delayed endotheliali-
sation, late thrombosis may \llso occur among 
the described dissections. It therefore would be 
of considerable interest to repeat IVUS assess-
ment of individuals undergoing intracoronary 
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radiation treatment at a later date (12-18 
months postintcrvention) so as to see if there is 
evidence of persisting dissection or of wound 
healinglrestenosis, which may present in a 
delayed fashion.'· 
Although the dissections did not lead to an 
increase of cardiac events in our population, 
Preisack and colleagues rccently described a 
higher event rate in patients who suffered co\"-
onary dissections after balloon dilatation only." 
In this study, the dissection type was highly 
correlated with the probability of a clinical 
event. Other authors have not found a 
diH·erencc in six month clinical event rate in 
patients with stable coronary dissections." 
We feel th\lt additional stent implantation 
may be justificd in patients with dissections 
who are about to receive brachytherapy follow-
ing balloon angioplasty. This approach may be 
warranted even if the dissection is stable. After 
stent implantation in these circumstances, we 
feel that a long tcrm antiplatelet regimen (> 3 
months) may prove helpful in thc prevention of 
late thrombotic occlusion, given re-
endothelialisation seems to be delayed in this 
patient cohort. 
Thcre have been no reports on y radiation 
causing interference with thc healing of dissec-
tion. Compared with y radiation a higher dose 
of J3 energy is rcquired in the near field to 
deliver the prescribcd dose to 2 mm. This 
intrinsic feature of P radiation may be causing 
the deleterious e!Tect witnessed. 
The IVUS dissection score was created to 
obtain a means of ranking and comparing dis-
section between postprocedural and follow up 
features. Up to this point, there has been no 
system that employs the well describcd features 
of dissection (arc, length, depth, and presence 
of flap) to create such a ranking. Clearly, the 
fate at ~ix month follow up of IVUS proven 
postprocedural dissection is not well described 
and we must relv on evidence that is extracted 
from angiograpllic follow up data. An IVUS 
ranking system Jll:'l)' be useful to describe the 
fate at follow up of disscction not only in the 
context of normal balloon angioplasty, but also 
after intracoronary radiotherapy. 
Using the prescribed dose delivcred to thc 
total treated area there was no differencc 
between the dose prescribed and the presencc 
of non-healing dissection. On the {Jne hand this 
relation may be genuine, on the other it may be 
argued that this lack of correlation results from 
the use of the measure of radiation received by 
the total vessel; this Illay not retiect thc 
radiation dose receivcd by thc specific area of 
dissection,'" or the radiation which is poten-
tially transmitted down the disrupted tissue 
planes of the dissection. It is possible dlat such 
tissue planes may permit greater passage of 
radiation with deleterious consequcnces such 
non-healing or aneurysmal change. EqUally, it 
is possible that certain tissue characteristics, 
such as heavy calcification, may interrupt 
radiation dosing to the level of the adventitia. 
Clearly, IVUS provides superior information to 
angiography in describing tissue characteristics 
and is likely to be an integral part in the calcu-
lation of appropriate radiation dose in the 
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future, '" so as to maximise efficacy and 
minimise the complications of over- and 
underdosing. 
Tbe design of lbe radioactive source delivery 
catbeter may also be relevant to its efficacy. A 
non-centred catheter as used in this study may 
lead to inhomogeneous dosing. Alternative 
centred devices arc available; however, the 
issue is as yet unresolved and will he the subject 
of further research. ,,, 
LL\IIT.-\TI()NS 
\'\fe describe the phenomenon of non-healing 
coronary artery dissection after balloon angio-
plasty in a small group of patients. The 
outcome of dissection in those with flow limit-
ing dissection has not been defined, as these 
individuals all had stents implanted. The 
angiographic dissection control group for this 
study is historical and there is no good descrip-
tion in the literature on the long term outcome 
of those with IVUS proven dissection. 
CONCLUSION 
f"\ Radiation alters the normal healing process, 
resulting in unhealed dissection in certain indi-
viduals. In view of the delayed and abnormal 
healing witnessed, long term follow up may be 
prudent. Althougb no increase in cardiac 
events at six months following coronary dissec-
tion was seen in this cohort, larger populations 
ure needed to confirm this phenomenon. 
Stenting of all coronary dissections and the use 
of prolonged courses of antiplatelet agents may 
be warranted in patients scheduled for brachy-
therapy following balloon angioplasty. 
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ABSTRACT 
Background. A recognized limitation of endovascular B-radiation therapy is the development 
of new stenosis at the edges of the irradiated area. The combination of injury and low-dose 
radiation may be the precursors of this phenomenon. We trans lated the radio-oncological 
concept of 'geographical miss' to define those cases in which the radiation source did not fully 
cover the injured area. Aims of the study were to determine the incidence and causes of 
geographical miss and evaluate the impact of this inadequate treatment on the outcome of 
patients treated with intracoronary B-radiation. 
Methods and Results. We analyzed 50 consecutive patients treated with B-radiation after 
percutaneous coronary intervention. Prescribed dose ranged between 12 and 20 Gray at 2 mm 
from the source axis. By means of quantitative coronary angiography, the irradiated segment 
(IRS) and both edges were stndied prior to, after intervention and at 6 month follow-up. Those 
edges which were injured during the procedure constituted the geographical miss edges. 
Twenty-two edges were injured during the intervention mainly due to procedural complications 
which extended the treatment beyond the margins of the IRS. Late loss was significantly higher 
in geographical miss edges, as compared to IRSs and not-injured edges (0.84±O.6 versus 
0.15±0.4 and 0.09±0.4, respectively; p<O.OOOI). Similarly, restenosis rate was significantly 
higher in those injured edges (10% within IRS, 40.9% in geographical miss edges, and 1.9% in 
not-injured edges; p<O.OO I). 
Conclusion. These data support the hypothesis that the combination of injury and low-dose 6-
radiation induce deleterious outcome. 
KEY WORDS: geographical miss, radioisotopes, balloon angioplasty, stents, quantitative 
coronary angiography, restenosis. 
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Endovascular radiation therapy is a novel technique aimed to prevent restenosis after 
percutaneous coronary intervention. \-3 Radiation can be delivered to the coronary artery by 
means of catheter-based systems or radioactive stents.4 A potential drawback of this treatment 
is the development of new stenotic lesions at both edges of the irradiated segment. This so-
called "edge effect" has been originally described after high activity (>3 microCi) radioactive 
stent implantation.5-6 However, this phenomenon is not exclusive to radioactive stents and may 
also affect coronary segments treated by means of catheter-based systems.? The 
pathophysiology of the "edge effect" may be the result of vessel wall injury,8-10 concomitantly 
to low-dose radiation at the edges of the irradiated area. 1\,12 In radio-oncology, the term to 
defme a cause of treatment failure due to low-dose was coined by the Manchester Clinic as 
'geographical miss'. In such cases, a small part of the treatment zone has either escaped 
radiation or been inadequately irradiated because the total volume of the tumor was not 
appreciated and. hence an insufficient margin was taken. 13 This concept is translated in 
interventional cardiology to define those coronary segments which were irtiured but received 
low-dose radiation. Typically, this phenomenon occurs by injuring the edges of the irradiated 
segment where, by definition, the dose is rather low. 
Aims of the study were (1) to determine the incidence and causes of geographical miss in the 
treatment of patients with intracoronary B-radiation using a catheter-based system; and (2), to 
evaluate the impact of this inadequate treatment on the angiographic outcome of these patients. 
METHODS 
Patient Selection 
We retrospectively analyzed 50 consecutive patients treated at our institution with catheter-
based B-radiation by means of the Beta-Cath system™ (Novoste Corp., Norcross, GA). 
Patients included in the radiation protocol were those with objective signs of ischemia and 
presence of significant de novo lesions (n=39) or recurrent in-stent restenosis (n=11). Detailed 
description of the radiation system has been reported elsewhere. 14 The radiation source train 
consists of a series of 12 cylindrical seeds that contain the radioisotope 9OSrfOy sources and is 
bordered by 2 gold radio-opaque markers separated by 30 mm.14 
Procedure 
The medical ethics committee of our institution approved the investigational use of B-
radiation and all patients signed an informed consent form. Percutaneous intervention was 
performed according to standard clinical practice. Typically, coronary_ lesions were treated 
initially with balloon angioplasty (BA). After successful BA, the target coronary segment was 
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irradiated. This could be followed by additional stent implantation when clinically indicated. 
Lesion length measured on average 11.4±4 mm, the mean balloon length was 20.0±3 mm and 
the number of balloon inflations was 2.9±1.6. Patients received aspirin (250 mg) and heparin 
(10.000 IV IV) at the initiation of the procedure and an additional dose of heparin was 
administered to maintain the activated clotting time> 300 seconds. After the procedure, aspirin 
was continued indefinitely. In those patients receiving additional stent implantation tic10pidine 
was initiated and continued at least for 15 days after the procedure. Radiation dose was 
prescribed at 2 nun from the source axis. Prescribed dose for the treatment of de novo lesions 
was randomly assigned to 12, 14 or 16 Gray (Gy) for protocol requirements. For the treatment 
of in-stent restenotic lesions, the prescribed dose was 16 Gy or 20 Gy if the reference diameter, 
by quantitative coronary angiography (QCA), measured <;3.25 mm or >3.25 mm, respectively. 
Mean dwell time to deliver these doses was 143 ± 44 seconds. 
Definitions 
The irradiated segment (IRS) was defmed as the area encompassed by the 2 gold markers of 
the radiation source train. It was identified on angiography by a contrast injection with the 
source in place. The edges of the IRS were defined as the 5 mm-long segments proximal and 
distal from the angiographic location of the gold markers. Those edges which were touched by 
the angioplasty balloon or received new stent implantation during the procedure were defined as 
geographical miss edges since represent injured segments receiving low-dose radiation. Not-
injured edges were those which were not traumatized during the intervention. To determine 
whether the edges of the IRS were injured, a few steps were followed: during the procedure 
every balloon inflation or additional stent implantation were filmed in the same projection as 
was the radiation source. This approach allowed us the correct matching of the cinefilms in the 
off-line analysis. Either cineioop showing balloon inflation, stent implantation and the radiation 
source may be displayed simultaneously on the screen using the Rubo DIeOM Viewer (Rubo 
Medical Imaging, Uithoorn, The Netherlands). ECG tracing is also displayed in either cineloop. 
By selecting those frames in the same part of the cardiac cycle, we were able to define the 
location of the radiation source relative to the injured area. 
QCA Analysis 
The IRS and both edges were analyzed by QCA prior to, after intervention, and at 6-month 
follow-up. All angiograms were evaluated after intracoronary administration of nitrates. The 
off-line analysis of two orthogonal projections was performed by means of the CAAS II 
analysis system (Pie Medical BV, Maastricht, The Netherlands). Calibration of the system was 
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based on dimensions of the catheters not filled with contrast medium. This method of analysis 
has been previously validated. 15·[7 The following QCA parameters were computed in the IRS 
and both edges: minimal luminal diameter (MLD), which was computer defmed; reference 
diameter, which was obtained by an interpolated method; 15·17 and, percentage diameter stenosis. 
Binary restenosis was defined in every area as diameter stenosis >50% a1 follow-up. Acute gain 
was defined as MLD post-treatment minus MLD pre-intervention. Late loss was defined as 
MLD post-treatment minus MLD at follow-up. Relative late loss was defined as late loss 
divided by reference diameter. 18 
Statistical Analysis 
To compare continuous variables between IRS, geographical miss edges and not-injured 
edges, one-way analysis of Variance (AN OVA) with post-hoc analysis for multiple 
comparisons was performed. Unpaired Student's t test was performed to compare continuous 
variables between proximal and distal geographical miss edges and between patients in whom 
the geographical miss was induced by balloon dilatation or stent implantation. To compare the 
binary restenosis between groups the Chi-square test was performed. All tests were two-tailed 
and a p value <0.05 was considered statistically significant. 
RESULTS 
Baseline Characteristics 
Fifty irradiated coronary arteries and 100 edges in 50 patients were eligible for the study. 
However, 26 edges were finally excluded, due to ostial location of the proximal end of the 
source in the right coronary artery (n=12) or overlapping of one of the edges with sidebranches 
(n~14). Thus, finally 74 edge areas and 50 IRS's were studied. Mean age was 55.3±9 and 38 
patients (76%) were male. Smoking was the most frequent coronary risk factor involving 33 
patients (66%) followed by dyslipideruia in 27 patients (54%) and hypertension in 24 patients 
(48%). Eight patients (16%) were diabetics. Left anterior descending artery was treated in 21 
patients, left circumflex in 10, right coronary artery in 18 and saphenous vein graft in 1. 
Twelve patients received a stent due to bailout situation. 
Incidence and causes of Geographical Miss 
Geographical miss was observed in 22 edges (31.9%) induced by balloon dilatation (n~13) or 
additional stent implantation (n~9). The remaining 51 edges (68.9%) were defined as not-
injured edges. Location of the geographical miss was in the proximal edge in 11 patients (50%) 
and in the distal margin also in II patients (50%). The following reasons were responsible for 
this phenomenon: (1) development of procedural complications which extended the treatment 
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beyond the margins of the IRS (unexpected geographical miss, n~9); (2) lack of availability of 
longer radiation source (>30 mm) in the context of patients with diffuse recurrent in-stent 
restenosis in whom radiation was given on a compassionate use basis (n=8); and (3), the 
injured segment from prior balloon inflations was not appropriately covered by the source (lack 
of accurate matching; n=5). An example of a patient with geographical miss induced by a 
balloon dilatation in the proximal margin is depicted in the figure 1. 
QCA Analysis 
QCA data is presented in the table. As expected, IRS demonstrated on average a higher acute 
gain as compared to both injured and not-injured edges. However, geographical miss edges 
presented, on average, with significantly higher late loss and relative late loss. Restenosis was 
demonstrated in 5 cases (10%) within the IRS, in 9 cases (40.9%) in the geographical miss 
edges and in \ case (1.9%) in the non-injured edges (p<O.OO\). No difference in the pattern of 
the late loss between the 3 areas were observed in de novo lesions as compared to recurrent in-
stent restenotic lesions (figure 2). In the geographical miss edges, 4 edge restenosis (44%) were 
located at the proximal edges, whereas, the other 5 (56%) were located at the distal edges. 
Mean relative late loss was comparable between those edges with geographical miss located 
proximally or distally from the IRS (0.3\±0.2 versus 0.34±0.2, respectively; p~NS). Those 
edges in which the geographical miss was due to additional stent implantation presented, on 
average, higher acute gain than those due to balloon dilatation (0.70±0.4 versus 0.21±0.3, 
respectively; p=0.005). However, mean late loss and mean relative late loss were comparable 
between both causes of geographical miss (0.95±0.9 and 0.36±0.3 after stent versus 0.77±0.3 
and 0.30±0.\ after balloon dilatation; both p~NS). 
DISCUSSION 
This study reports on the initial experience of our center with the use of intracoronary 6-
radiation. By means of a careful retrospective angiographic analysis of all patients treated with 
the same radiation system we sought to define the effect of the injury on those areas located at 
the margins of the source where the delivered dose is potentially rather low. Up to 31.9% of the 
cases presented with the pre-defined technical error, tenned as geographical miss. This concept 
requires the concurrence of 2 conditions: low-dose radiation and injury. Any other clinical 
situations which do not include both conditions can not be termed as geographical miss. For 
instance, (\) the effect of injury on coronary segments not being irradiated (proximal or distal 
to an irradiated segment but in areas where the calculated dose is almost 0) should fall into the 
category of normal restenotic process; (2) the effect of low-dose radiation in areas which have 
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not been injured may be defined as the pure radiation edge effect, SInce In intracoronary 
radiation the edges of any irradiated segment will always receive low-dose radiation; (3) finally, 
the effect of full prescribed dose on segments presenting with or without injury is the situation 
where the physician may be able to irradiate (with full dose) the entire injured segment and 
include some not injured margin. A key issue in the definition of geographical miss is to define 
those segments receiving low-dose. These may vary between systems and sources used. With 
the BetaCath™ system the longitudinal distance of the 100% isodose is 26mm. Since the 8-
emitting 9OSrt"Y has an acute fall-off of dose related to the distance, the last 2 mm within the 
markers of the source should be considered as presenting with lower-than-the-prescribed dose. 
In fact, the dose received at 1 nun from the 100% isodose is 86% of the prescribed dose, and at 
2 mm, 60% of the prescribed dose (inner part of the gold marker). Further, at 3mm the dose is 
30% of the prescribed dose, at 4 mm 13% of the prescribed dose and at 5 mm 5% of the 
prescribed dose. We defined the IRS as the segment encompassed by the 2 gold markers, which 
included the last 2 mm within the markers with lower-than-the-prescribed dose (up to 60% of 
the prescribed dose). Using this definition, late loss and restenosis rate were significantly lower 
that those of the injured edges (analyzed from the inner part of the gold marker). Further, the 5 
cases of restenosis within the IRS, were located at the site of the initial MLD. These results 
may reflect the fact that the dose at these last seeds of the source was high enough to avoid 
edge effect after being probably injured during the procedure, especially when 20mm-Iong 
balloon was used. Thus, the region receiving low-dose may be defined, for this system and 
source, as the Srnm-Iong segment located 2 mm further to the 100% isodose boundary, that is 
beyond the inner part of the gold marker. In this regard, we believe that the injury should be 
completely restricted to the segment of the 100% isodose curve of the radiation source (26mrn), 
and that the last 2 nun at both extremities of the source and within the gold markers may be 
considered relatively but probably not completely safe. Finally, any injured segment covered by 
or beyond the gold marker (up to 5mm) must be considered as of high risk offailure at follow-
up. 
From the perspective of these findings and future technical developments in the field, the 
following recommendations are advisable. Filming every single balloon inflation performed 
during the procedure would allow one to define the injured area. More than ever, tenacious 
attention to detail when positioning the radiation catheter encompassing the entire injured area 
must be mandatory. The development of longer sources (>30 mm) would allow one to treat 
diffuse lesions and completely cover those areas in which an extension of the treatment was 
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indicated due to procedural complications. Equally, the use of on-line QCA in the decision-
making, would avoid appreciation errors due to visual assessment of the target area and 
subsequent under- or over-estimation of balloon lengths. Finally, the selection of the most 
suitable fluoroscopic projections (e.g. less· fore-shortening, no overlapping) would avoid errors 
in the quantification of the region of interest. 
The fact that the location of most of the restenosis were in geographical miss edges and that 
late loss in those areas was unexpectedly hi~ must raise the alarm about the deleterious effect 
of the combination of injury and low-dose radiation. This hypothesis may be supported by the 
fact that the late loss observed in those injured edges is higher than that reported in recent 
clinical trials either after balloon angioplasty or stent implantation l9,20 and than that 
demonstrated in the not-injured edges. Balloon overstretching injury has been used as an 
experimental model to study the restenosis process.8-10 The response of the vessel wall to injury 
involves both neointimal hyperplasia8,9 and vessel remodeling. 10)1,22 The stimulatory effect of 
low-dose radiation after balloon angioplasty on smooth muscle cell proliferation has been 
previously reported. II In the low-dose radiation group of this swine model (lOGy), neointima 
was composed of smooth muscle cells with a marked increase in inflammatory cells and less 
medial and intimal fibrosis as compared to higher dose groups (15 and 20 Oy) and control 
group. It was suggested that at low-dose, inadequate fibrosis was induced to prevent effective 
smooth muscle cells migration and to act as a diffuse barrier for mediators of chemotaxis, 
chemokinesis and cellular proliferation. I I Similarly, after low-activity radioactive stent 
implantation (1 IlCi) in a porcine model, neointima hyperplasia was significantly greater than 
that after non-radioactive control stents. 12 If ongoing intravascular studies reveal that edge 
restenosis is mainly due to plaque increase, the former hypopthesis that at low-dose inadequate 
medial and intimal fibrosis to avoid migration and proliferation predominate, may become a 
plausible explanation. On the contrary, if negative remodeling is the main contributor to the 
lumen loss, the excess of inflammatory cells demonstrated at low-dose, may be responsible for 
subsequent adventitial fibrosis and vessel shrinkage. The development of the so-called "candy 
wrapper" after radioactive stent implantationS may represent the clinical paradigm of the 
combined deleterious effect of low-dose radiation and injury. The latter is secondary to the 
angioplasty balloon used for pre-and post-dilatation of the radioactive stent. In this regard, a 
higher balloon-artery ratio was associated with the presence of this phenomenon.5 
Future trials must address the benefit of new technical developments in the field (use of 
square deployment balloons, hot-end, cold-end stents6, longer sources with smaller radiation 
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delivery catheters) to minimize the impact of injury at the edges either after radioactive stent or 
catheter-based systems. 
Study Limitations 
In this study, only one type of radiation delivery catheter usiog the Jl-source 9OSrf'y 
has been evaluated. Thus, the effect of either other catheter-based systems usiog 
centering balloons and different sources or the y-radiotherapy on the geographical miss 
edges cannot be extrapolated from our results. The actual dose at the margins of the 
radiation source has not been calculated. Low-dose at these edges was assuroed by the 
fuct that, the isotope 9OSrf'Y demonstrates an acute fall-off related to the distance 
from the 100% isodose boundary. This angiographic study was aimed to defroe the 
concept and the clinical implications of the geographical miss. To defroe the 
mechanism of the unexpectedly high late loss and the correlation between radiation 
dose and plaque extent at the margios of the IRS, iotravascular ultrasound studies must 
be carried out. The location of the segment receiviog low-dose may vary between 
systems and sources. Thus, the confidence margio to be taken may vary accordiogly. 
The position of the source relative to the various balloon iofIations was assessed by 
compariog still frames at the same part of the cardiac cycle from cioeangiograms 
performed io the same projections. However, small ioaccuracies io the definition of the 
IRS and the edges, derived from the axial movement of the radiation source duriog 
cardiac cycle caonot be completely ruled out. This study is not placebo-controlled. 
Thus, the effect of the sham source on the balloon-iojured coronary segments have not 
been determioed. 
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Table. QCA data. 
IRS Geographical miss edges Not-injured edges p 
(n~50) (n~22) (n~52) value 
MLD pre-intervention, mm 1.20 ± 0.3 2.02 ± 0.6 2.10±0.6 <0.0001 
MLD post-intervention, 2.02 ± 0.4 2.43 ± 0.5 2.12 ± 0.6 0.01 
mm 
MLD at follow-up, mm 1.87 ± 0.5 1.59 ± 0.6 2.02 ± 0.5 0.006 
Reference diameter, mm 2.69 ± 0.6 2.50 ± 0.6 2.55 ± 0.7 NS 
%DS pre-intervention, % 54.9 ± 13 19.8 ± 14 17.9± 11 <0.0001 
%DS post-intervention, % 28.4± 9 19.9 ± 10 20.8 ± II 0.0003 
%DS at follow-up, % 333 ± II 443 ± 22 24.3 ± 10 <0.0001 
Acute gain, mm 0.81 ± 0.4 0.41 ± 0.4 0.01 ± 03 <0.0001 
Late loss, mm 0.15 ± 0.4 0.84 ± 0.6 0.09 ± 0.4 <0.0001 
Relative late loss 0.06 ± 0.1 0.32 ± 0.2 0.02 ± 0.1 <0.0001 
Data is presented as mean ± SO. MLO - minimal luminal diameter; %DS - diameter stenosis 
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Figure 1. Geographical miss induced by balloon dilatation. A: Lesion located in the proximal 
segment of the left anterior descending coronary artery; B: One of the balloon dilatations 
perfonned during the intervention (black arrowheads indicate the area injured by the balloon); 
c: Radiation source train in place. The irradiated area is delimited by the gold markers (white 
arrowheads); D: Final result: proximal traumatized edge presented a residual type B dissection; 
E: 6-month follow-up: obvious reduction in lumen at the geographical miss edge. 
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Figure 2. Difference in late loss between irradiated segment, geographical miss edges and oot-
injured edges. Both de novo lesions and in-stent restenosis demonstrated the same degree of late 
loss between the 3 different segments analysed. 
Late Loss 
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Chapter 11 
Beta particle emitting radioactive stent implantation. A safety and 
feasibility study. 
(Circulation 1999;100:1684-1689) 
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f3-Particle-Emitting Radioactive Stent Implantation 
A Safety and Feasibility Study 
AJ. Wardeh, MD; J.P. Kay, MBChB; M. Sabate, MD; V.L.M.A. eoen, MD; 
A.L. Gijzel, MD; J.M.R. Ligthart, BSc; A. den Boer, BSc; P.e. Levendag, MD, PhD; 
W.J. van del' Giessen, MD, PhD; P.W. Serruys, MD, PhD 
Background-This study represents the Heart Center Rotterdam's contribution to the Isostents for Restenosis Intervention 
Study, a nonrandomized multicenter trial evaluating the safety and feasibility of the rudioactive Isostent in patients with 
single coronary artery disease. Restenosis after stent implantation is primarily caused by neointimal hyperplasia. In 
animal studies, !3-particJe-emitting radioactive stents decrease neointimal hyperplasia by inhibiting smooth muscle 
cell proliferation. 
Methods and Results-The radioisotope J2p, a j3-particle emitter with a half-life of 14.3 days, was directly embedded into 
the lsostent. The calculated range of radioactivity was 0.75 to 1.5 IACi. Quantitative coronary angiography 
measurements were performed before and after the procedure and at 6-l11onth follow-up. A total of J I radioactive stents 
were used in 26 patients; 30 (97%) were successfully implanted. and I was embolized. Treated lesions were in the left 
anterior descending coronary artery (n=12). the right coronary artery (n=8). or the !eft cirellilltlex coronary artery 
(n=6). Five patients received additional, nonradioactive sten!s. Treated le.~ion lengths were IJ.::!::4 111111. with a reference 
diameter of 2.93:!::0.47 mm. Minimum lumen diameter increased from 0.87:!::O.28 mill preprocedure to 2.84:!::0.J5 lllill 
postprocedure. No in-hospital adverse cardiac events occurred. All patients received aspirin indefinitely and ticlopidinc 
for 4 weeks. Twenty-three patients (88%) returned for 6-month angiographic follow-up; 17'k of them had in-stent 
restenosis, and 13% had repeat revaseularization. No restenosis was observed at the stent edges. Minimum lumen 
diameter at follow-up averaged 1.85:!::0.69 mm, which resulted in a late loss of 0.99:!::O.59 mm and a late loss index of 
0.53:!::0.35. No other major cardiac events occurred during the 6-111onth follow-up. 
Conelusions-The use of radioactive stenls with an activity of 0.75 to 1.5 IACi is safe and feasible. (Circulatio11. 
1999; 100:1684-1689.) 
Key Words: j3-rays • angioplasty • radioactive isotopes _ restenosis _ stents 
Percutaneous transluminal coronary angioplasty (PTCA) is an accepted treatment for coronary artery disease.' However, 
angiographic restenosis is reported in 40% to 60% of p'<1tients 
after a successful PTCA.1.2 The main mechanisms of restenosis 
include late constriction of the arterial wall (vascular shrinkage) 
and neointimal hyperplasia,)-6 which are due to the migration 
and proliferation of smooth muscle cells and myofibroblasts 
after balloon-induced trauma of the arterial wall and the depo-
sition of an extracellular matrix by the smooth muscle cells/i -'J 
Stent implantation reduces the restenosis rateiO.1! by preventing 
elastic recoil and late constrictive remodeling." However, the 
occurrence of restenosis after stent implantation remains ume-
solved. especially in small vessels and long lesions. in which it 
may occur in >30% of cases. JJ Reslenosis is primarily caused 
by neointima! hyperplasia, which occurs due to trauma of the 
arterial wal! by the stent struts.5 
Irradiation is used to decrease neointimal proliferation 
because the actively prolirerating cells lial'e an increased 
sensitivity to tlie )etlml effect~ or radiation. which inhibits 
henign hyperplastic reactions such ns keloid formation (lnd 
heterotopic ossificalion.I~.'.' Scveral experimental and clinical 
trials showed that brachyth~rapy with a radioactivc source 
after PTCA or stent impl~nt~tioll can reduce restenosis by 
inhibiting neointimal hyperplasia,I(,-I') and ;,cveral animal 
studies demonstrated a dose-related reduction of ill-stent 
re.~tenosis with the lise of radioactive stents.1Il-22 Further-
more, II dose-dependent delay in thc endothelial i7.ation or the 
slent occurred. which increased the chance or subacutc 
thrombosis. 2!1.2-' 
This study evaluated the safety and feasibility of radio'lc-
tive stent implantation (activity level. 0.75 to 1.5 MCi) in 
single-lesion. nativc coronary artery disease. 
Received February II. 1999; revision received June 28. 1999; accepled Juty 2. t 999. 
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TABLE 1. Balloon Inflation and Stant Deployment Data 
Predllalalio[j Stelll Deployment Postdi lalation 
Type 01 Lesion 
Palient Slen! Diam, mm AIm Length, mm Diam, mm AIm Diam, mm AIm Length, mm Lenglh, mm 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
Mean 
so 
PSt 3.0 6 20 
PS 3.0 20 
PS 
PS 
BX' 
OX 
PS 
OX 
OX 
OX 
BX' 
BXt" 
OX' 
OX 
OX 
OX 
OX 
OXt 
OX 
OXt 
BX 
OX 
OXt 
3.5 
3.5 
2.5 
35 
3.0 
4.0 
2.5 
3.5 
3.0 
3.0 
3.0 
3.0 
3.0 
3.0 
3.5 
3.0 
3.5 
3.0 
3.5 
3.5 
3.0 
3.2 
0.4 
14 
14 
6 
10 
10 
12 
10 
10 
o 
12 
12 
12 
10 
10 
3 
30 
30 
20 
20 
20 
15 
15 
20 
13 
20 
20 
15 
13 
13 
20 
20 
20 
29 
20 
15 
20 
19 
3.0 10 
3.5 8 
3.5 
35 
30 
35 
30 
35 
35 
35 
3.5 
3.0 
30 
35 
10 
3.0 
3.5 
3.0 
3.5 
3.0 
3.5 
3.5 
3.5 
3.3 
0.2 
10 
12 
12 
10 
12 
12 
16 
11 
11 
12 
o 
12 
10 
10 
10 
18 
10 
11 
3.5 16 30 17 
3.0 16 15 11 
3.5 
NO 
3.5 
4.0 
3.5 
4.5 
2.5 
4.0 
4.0 
3.0 
35 
NO 
4.0 
4.0 
4.0 
4.0 
4.0 
3.5 
NO 
4.0 
4.0 
3.7 
0.5 
16 
NO 
16 
12 
10 
16 
12 
18 
18 
18 
16 
NO 
14 
16 
16 
18 
14 
16 
NO 
12 
16 
15 
13 
NO 
13 
13 
13 
15 
15 
13 
13 
20 
13 
NO 
13 
13 
13 
20 
13 
29 
NO 
13 
20 
16 
10 
15 
15 
12 
11 
10 
14 
19 
17 
17 
14 
10 
" 23 
10 
15 
12 
10 
16 
13 
Aim Indicates maximum atmosplJefes; Diam, maximum diameter; ND, nol done; PS, Palma~·S(;llall. 
'1 additionalllOnradioactive stent implanled; t2 BX stenls implanted; t2 ~dditional nonradioactive stenls implanted. 
Methods 
Patient Population 
The I-,ostent, fur Re~teno~i<; Interventiun Silidy (IRIS) i~ a nonrnn-
domized, multicenter trial evaillating the safety and feasibility of 
radionctive ~tenK The data presented here represent the experiencc 
of the Hearl Center ROllerdam. Pntients who had single coronary 
lesions with a nwximulll lesion length of 2R I11Ill (maxirlHlln, 2 
radioactive stent.'; of IS mm implanted in tandem position) and 
objective evidence or i,<:hemia were eligible. Exclusion criteria 
included the following: a recent myoeartlinl infarction {M!; creatine 
kinnse {CK] isoenlYllle containing M ~nd B suhunits (MB 1 > 3 times 
the upper limit or Iionnal within 5 d~y> of Ihe imefventioll); left 
ventriculnr ejection rnlclion <.jOg,; allergy or comraindi<:iltion to 
~,pirin, licfopjdin~. or ,!ninless steel: and ]e,jOIlS located in the left 
main aTl~fy ()f "lllie oSlium of the right coronary anery. The Medical 
F,lhical Committee of th~ University lim;pil,r\ Rotterdmn ilpproved 
the study. All p~li~n[' prol'ided wril1en. inflllllled con~enl hefore the 
pr",:euurc 
Radioactive Stent, Dosimetry, and Sarety Issues 
Two type, of stellls were implanl~d in this sllldy: thl:' l'allnnz-SchatL 
(Cordis Corp, Johnson und Johll\on intervcmional Systems Co) nnd 
BX stent (lsostentll1L"). Pliosphoru<;-32 ("P), a pllre j3-emi!ler with a 
half-life of 14.3 day.,>. was produced by ncutron irradiation of red 
amorphow; -"p for 10 days to adlieve n concentration of 20X 10-' 
"PI-"P (100 mCi). The inndimed phosphorus was then plnced into a 
mass separator, ionized, and accelerated. A dipole magnet separmed 
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the "p and "P. Sub . ,,,quc/illy, "P was dir"clly implnnted inlo tile 
metal Slent surfncc." The cakul<lted rndioactivity of the Slenl~ at 
implnntation was 0,75 (0 1.5 ~Ci, and the dose ddivered over 100 
days at I mm from the stent surface was ealelilmed for "aell sten!. All 
per,onnel were trained in the nppropriate handling of mdionetive 
materials. During implantation, the lucite shield l:'ndosing the stent 
and the ~heathed introduction system prevented exposure of the 
op~wtOI' to the radiation of the stell!. Background mea<;uremenlS of 
radioactivity were made by means of a Gdger coumer (Model l.jc. 
Ludlum Measlirements ILlC). All disposnble materials that were in 
contact with the stem were immediately disposed of in a plexiglas 
container, and radioactivity measurements were mnde by the radia-
tion technician. 
Quantitative Coronary Angiography 
Quantitative coronary angiography (QCA) was performed preproce· 
uure, pU~lpr()cedure, lind at 6-monlh follow"lIp. Coronary nngiogra-
phy was perform"d after imraeoronary udminislrmion of nilrate,. 
The orf-line annly,is of 2:2 orthogonnl projections was performed hy 
the CAAS II analysis system (Pk Medical BY). Calibration of the 
sy,tcm was based Oil (limen,ions of the catheters not filled Wilh 
COlltlnst medium. Thi~ method of analy~i~ has been exten<;ivciy 
validated and applied in numerous cJinicaltrials.'~-'6 The lullowing 
llleaSlireme~ts were obtained in eadl proj~ction: minimum lumen 
diameter (MLD), referef]<:e dinmeter, percent dinm~ter ;tenosis 
(%DS), nnd lesion length, Lesion length was user-ddined.'6 Proce-
dllral Slleee" was defined as <20% DS as measured by online QCA. 
Short-term gain was defined ns MLD postproeedUfe minlls MLD 
Radioactive Stent Implantation 
preprocedure. Late loss was defined as MLD pustprocedure minus 
MLD al fullow-up. Late loss index was defined a, ,hort-term gain 
dividell by late loss}) Reslenosis was defined as >50% DS at 
follow-up locatell lvitbin the stell! or::55 mm from the stenl ellges. 
The latter represents an area where tissue is subjeded both to 
balloon-induced trauma ami to a lower duse of radiation," which 
may stimulate restenosis. This edge-effect phenomenon has recently 
been described in patients and called the "candy-wrapper effecl.""" 
To quantify an edge effect, a QCA segmentul analysis w~s per-
formed. At both postprocedure ami fullow-up. the tre<lted vessels 
were first divided into segments =5 mm in length; then, the mean 
diameter uf the 5-mm segments distal anll pruximallo the stenl edges 
were calculated using the CAAS II analysi~ systenl. Careful com-
parison of the proximal anll dis1ai edges was perfurmed postprO(:e-
dure and at follow-up. 
Procedure and Follow-Up 
Patients received 250 mg of aspirin and 10000 lU uf heparin at the 
start of the procellure. The activation clotting time was Illaintainell at 
>300 ~. After balloon predilatatiun, the radiollctive ~tent was 
implanted at a numinal deployment pressure of 8 to 10 atm. H 
needed, stent deployment was optimiz:ed using shorter postllilmation 
balluons of longer diameters to higher pressures (Table I). Extreme 
care was taken 10 avoid inflating the balloon outside the edges of the 
sten!. Because of the poor radiopacity of the Palmaz:-Schatz: and the 
FIX ,tellis, the best angiugraphic view was selected. and images were 
rilmed in 1\ magnified field (5 inch) with digital mom enhan<:ement 
to optimize stent visualization. All patients received ticlopilline 250 
mg BID for 4 weeks after stent implaotiltiol1 and ~spirin 80 mg d~ily 
illdefinitely. CK and CK-MB measureme11!S were malle, and the 
ECG was re<:unJed at 6 and 12 to 18 bOllrs pns/procedure in all 
paticnts. 
Patients returned for 1- ami 6-mo!llh clinical folluw-Ilp. An ECG 
was performed at each visit. The 30-day and 6-mollth clinical end 
points were death, Q-wave MI (usirJg the Minnesota code criteria""), 
non Q"wave M! (CK-MB rise >2 times nornwl UppCl" limit), bypass 
surgery. target segment revnscularization, sustainell abrupt closure, 
or subacute thrombosis of the tmget vessel. 
Atthe 6-nJonth visit, an exercise stress (est was perfurmed. Target 
vessel revaseularization w~s performed on the b~sis uf clinical 
~ymptoms andlor evidence of ischemhJ 00 exercise testing. 
Statistical Analysis 
Data are presented as mean;±:SD. Continuous data were <:urnpared by 
2-laiJed Student's I test or linear regression when appropriate. 
Results 
Baseline Characteristics 
Baseline demographics, anginal slatus, and lesion (;haracter-
istics are shown in Table 2. 
Procedural Success 
A tolal of 30 of the 31 stents (97%) were successfu!ly 
implanted (26 were BX lsostent and 4 were Pa!maz~Schatz) 
in 26 palienls. One stent {8X} was Imt in the peripheral 
circulation without clinical sequelae. Eighteen paticnls were 
succcs~fully treated with a single radioactive stcnt, and 4 
required a second radioactive stent to cover lesions> 15 mm. 
five patients received additional nonradioactive stcnts: 2 due 
to procedural dissection nol covered by the radioactive slent, 
2 because a sccond radioactive stent was not available, and I 
be(;atlse a second mdioactive stenl became dislodged when 
trying to implant it distal to Ihc firsl radioactive slen!. All 
procedures were successful, and no complications occurred. 
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TABLE 2. Patient Demographics 
Sex, male/female 
Age, y 
Average 
Range 
Risk factors 
Diabetes mellitus 
Hyperchotesteroiaemfa 
Hypertension 
Smoking 
Family history 
AP CCS 
LeSion type, AHNACC 
B1 
B2 
18t8 (69/31%) 
60 
43-74 
1 (4%) 
16(62%) 
11 (42%) 
15(58%) 
11 (42%) 
3(12%) 
10 (38%) 
13(50%) 
8(31%) 
18(69%) 
Data are n ('Yo) unless olllerwise indicated. AHA indicates American Heart 
Association, and ACC, American College of Cardiology. 
Fullow-Up 
The mean hospital stay w~s I.R days. All paticnb were 
angina-free til hospital discharge. At JU-day follow-up. no 
clinical end points had occurred; 24 p<ltients (92'7rj were 
asymptomatic, and 2 palients (8%) had recurrent angina 
pectoris (AP) or Canadian Cardiovascular Society Classirica-
tion (CCS) I (n=l) and CCS 2 (n=I). All 26 patients 
rcturned for 6-lllonth clinical follow-up. Twenty-one (XI%) 
were asymptomatic, allll 5 patients (19%) had AP CCS I 
(n=I), CCS 2 (n=2), CCS 3 (n=I), or CCS 4 (n=I), 
Six-month angiographic follow-up was performed in 23 
patients (88%). The remaining:l patients (12'7<-) refused; 2 of 
them were asymptmTIatic, and the third had AP CCS I. Four 
patients had angiographic restenosis (17%). All restenotic 
lesions were diffuse (located throughout the entire length of 
the sten!). One of the 4 restenoscs occurred in a patient with 
a single radioactivc stent, I restenosis was in a patient 
receiving 2 radioactive stenl~ in combinalion lVith a nonra-
dioactive stcnl, and 2 restenoses were obscrved in paticnlS 
rccei ving a combination of I radioactive and I nOluaJioactive 
slent. In the restenoti(; patients who rc(;cived an additional 
nonradioa(;tive stent, restcnosis occurred in both. the radioac" 
tive and thc nonradioactive sten!. On QCA, no discernible 
differences existed between the patterns of proliferation 
between the Palrnal.-Schatz and AX stents. No cases of 
restellosis at the stent edges were noted. Two of the 4 
restenotic patients underwent ;\ re-PTCA. One was referred 
for bypass surgery for in-stenl restenosi~ in the proximal left 
anterior descending (;oronary artery and progression of a 
previously nonsignificant Ic~ion in the proximal leI"! circum-
nex artet)' (main stem equivalent). OIlC was treated medi-
cally; thi.~ paticnt wns as),l1lptomalic, with a negative stress 
test. No olher clinical end points existed at 6-rnonth 
follow-up. 
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TABLE 3, Dosimetry and QGA Analyses 
Type of 
Patient Stefll 
10 
11 
12 
13 
14 
15 
16 
17 
18 
18 
20 
21 
22 
23 
Mean 
SO 
PSI 
PS 
PS 
PS 
BX' 
ax 
PS 
BX 
BX 
BX 
BX' 
BXt' 
BX' 
BX 
BX 
BX 
BX 
BXI 
BX 
BXI 
BX 
BX 
BXI 
Activity, 
MCi 
1.07 
1.07 
0,97 
0.97 
1.07 
1.50 
0.75 
1.24 
1,12 
1,73 
0.88 
1.24 
1.36 
1.12 
1,02 
1.06 
1.43 
1.00 
1,02 
0.75 
1.43 
1,06 
0.75 
1.10 
0.25 
Dose, 
cGy 
712 
Artery 
RCA 
712 LAO 
647 LCX 
647 RCA 
712 LAO 
1000 RCA 
500 LAO 
824 RCX 
748 RCX 
1157 LAD 
587 LAO 
827 LAO 
908 LAD 
748 LAO 
678 RCX 
712 LAO 
953 RCA 
678 RCA 
677 ReX 
500 LAO 
953 RCX 
700 RCA 
500 RCA 
743 
165 
Lesion 
Lengtll, 
mm 
17 
11 
10 
15 
lS 
12 
11 
10 
14 
19 
17 
17 
14 
10 
12 
23 
10 
15 
12 
10 
16 
13 
Preinlervenlion Postinlervenlion 
MLO OS RO MLD OS RO 
0.65 76 2.64 2,48 19 3.04 
1.02 52 2,12 2.56 8 2.78 
0,46 85 3.05 2,93 15 3.41 
0.75 79 3.50 2.91 22 3.73 
0.90 59 2.22 2.BO 9 3,07 
1,64 53 3.49 3.08 15 3.59 
0.67 75 2.67 2.64 15 3.12 
0.99 74 3.65 3.51 19 4.31 
0.50 77 2.0B 1.92 12 2.19 
Follow-Up 
MLO OS RO 
1.74 30 2.51 
0.54 77 2.39 
2.77 18 3.36 
1.60 47 3.01 
0.47 87 3.61 
2.45 23 3.18 
1,58 39 2.59 
2.76 44 4.20 
1.77 26 2.39 
Acute late 
Gain Loss LU 
1.83 0.74 0.40 
1.54 
2.47 
2.16 
1.90 
1.42 
1.97 
2.52 
1.43 
2.02 1.31 
0.16 0.06 
1.31 0.61 
2.33 1.23 
0,61 0.43 
1,07 0.54 
0.75 0.30 
0.16 0.11 
0.99 71 3.31 3.18 18 3.B7 2.39 16 2,82 2.19 0.79 0.36 
0.59 79 2.73 3.42 17 4.11 2.65 20 3.32 2.83 0.77 0.27 
1.00 58 2.37 2.36 16 2,81 0.86 55 1.90 1.37 1.51 1.10 
0.69 72 2.45 2.48 14 2.87 1.73 11 1,94 1.80 0.76 0.42 
0.62 79 2.96 2,75 12 3,12 1.61 44 2.86 2,13 1.15 0.54 
0,49 83 2.81 3.03 16 3.59 2.20 25 2,91 2.54 0.83 0.33 
1.10 67 3.36 3.27 10 3.63 1.87 34 2.81 2.17 1.41 0.65 
0.85 75 3,44 2.92 3.19 0.83 70 3.29 2.07 2.09 1.01 
0.83 73 3,09 2.99 3.07 2.51 29 3.47 2.15 0.48 0.22 
0,96 71 3.28 2,90 17 3.50 2.87 17 3.46 1.94 0.03 0.02 
1.13 60 2.81 2.91 17 2.81 1.97 39 3.23 1.69 0.84 0.50 
1.23 62 3,31 2.89 21 3.61 2.03 39 3.34 1.66 0.85 0.51 
1.16 66 3.37 2.91 3.18 1.72 45 3.12 1.75 1,20 0,68 
0.90 68 2.75 2.66 23 3.45 1.73 42 2,99 1.76 0,93 0.53 
0.87 70 2,93 2.84 15 3.31 1.85 38 2.99 1.97 0.99 0.53 
0.28 0.47 0.35 0.48 0.69 20 0.54 0.39 0.59 0.35 
Dose indicates dose over 100 days at 1 mm from lhe stenl surface; OS, percentage diameter stenoses; LAD, left anterior descending artery; LeX, left circumflex 
artery; LLI, lale loss index; PS. Palmal-Schal1 stent; RCA, right coronary artery; and RD. reference diameler. DCA measuremenls are in mm. 
'1 additional nonradioactive stent implanted; t2 ax stents implanted; ~2 additional nonradioactive stenls implanted. 
QCA Measurements 
QCA and procedural data are presenled in Table 3. MLD 
increased from (Ui7;:>:0.1H mm pre procedure to 
2.84;:>:0.35 mm postproceduj'e (P<O.OOOI). MLD at 
follow-up was Ut,);:>:0.69 mm (P<O.OOOJ relative 10 post-
procedure), resulting in a late los~ index of 0.53;:>:0.35. 
Segmental analysis of the mean diameter of the 5-mm 
segmenls distal and proximal to the stent edges showed 
significanl changes. The proximal diameter decreased from 
3.19±0.41 mm postproeedure to 2.78:;'::0.62 mm at follow-up 
(P=O.006). The distal diameter decreased from 
2.69;:>:0.49 mm poslprocedure to 2.45±0.50 mm at follow-up 
(P=O.Ol fi7). 
Radiation Doses 
Stent activity level and the cumulative dose over JOO days 
thai was dclivered to a J mill depth outside the stent arc 
presentcd in Tahle 3, No correlation existed between slem 
activity or delivered dose and MLD or late loss index at 
follow-up. No additiunal environmental radiation was mea-
sured during the procedure. 
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Discussion 
This nonrandomized study illustrates that f3-particle-emilling 
T<ldioactive stent implantation is safe and feasible, with no 
subacute or 30-day clinical events recorded, Subacute throm-
bosis was not ~een, despite the concern regarding delay in 
endothelialization, as previously reported in animal stud-
ies."o,n The embolization of the radioactive stem had no 
clinical sequelae at this level of activity. When stems with 
higher levels of radioactivity are implanted, this may not 
remain true. Detecting an embolized radioactive stent is a 
problem because (1) the f3-radiation of the stent is not 
measor<lbte outside the body and (2) the stents have a 
rdatively low radiopacily. Clearly, there is room 10 increase 
the radiopacity or to add markers to the stents. 
U~ing a multivariate model constructed from the data of 
the Benestent triab that was based on similar lesions, vessel 
size, and short-term result, a predicted restenosis rale of 12'K 
and an MLD at follow-up of 2.05 mm was calculated.J(UI 
Thus, the actual results achieved are somewhat less favorable; 
however, in such a small patient cohort, no definite conclu-
sions can be drawn except that the late results are within the 
Radioactive Stent Implantation 
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Figure 1. Two-d'lmensional dose representation for 1-llCi ~~p 
Palmaz-Schalz sten!. Cumulative dose given over 100 days is 
shown (source, Isostent Inc). 
acceptable limits for safety and feasibility of this sten!. It 
must be noted that 3 of the 4 patients who had in-stent 
restenosis had mUltiple stents implanted, which increases the 
risk of restenosis; in the group of 18 patients who had a single 
radioactive sten! implanted, only I had restenosis. Overall, 
these 6-month clinical and angiographic results are similar to 
the published results of nonradioactive stents. IO• 11 
The Milan group was the first to report restenosis within 
the stent and at the edges of the stent (the candy-wrapper 
phenomenon); this restenosis was possibly caused by in-
creased balloon injury (barotrauma) and the lower radiation 
dose at the stent edges. 21.28 In the Rotterdam series, particular 
attention was paid to avoiding balloon injury outside the stent 
to minimize the edge effect. No cases of edge restenosis were 
seen in this cohort; however, the proximal and distal mean 
diameter at the sten! edges, measured postprocedure and at 
foHow-up, decreased significantly. Because extreme care was 
taken to avoid inflating the balloon outside the stent edges, 
this edge effect may be caused by the lower radiation dose. 
Dosimetry 
Previous work by Jllllicki et aP2 on the 1.0-}LCi Palmaz-
Schatz sten! demonstrated the nonuniformity of dosing in 
areas adjacent to stell! strut wires and those areas between the 
wires. Models showed that for a -'!p stent of 1.0 }LCi that was 
15 mm in length, at a distance of 0.1 mm, dose values of 2500 
cOy were delivercd at the strut wires (peaks) and 800 cGy 
between the wires (valleys) over I half-life (!4.3 days). The 
nonuniforfllity of dosing, reflective of stent geometry, de-
creased at distanl'cs I to 2 mill from the stell! ~urfacc. 
Although these data provide an in-vitro analy,<;is of dosing 
from a radioactive stent, the actual dose distrihution is 
probably affected by variations in atherosclerotic plaque 
morphology and the symmetry of the Icsion and stent cxpan-
sion. The 20 dosimetry represcntation of the Palmaz-Schatz 
and BX stent were done using the Janicki mode]'! (Figures I 
and 2). 
Currently, dose-finding studies examining rc\tcllo<;is after 
implantation of"P BX stents in patient~ with je,iOll morphol-
ogy similar to that described in this study are underway. It i~ 
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Figure 2. Two-dimensional dose representation for 1-/-lCi "p 
BX stenl. Cumulative dose given over 100 days is shown 
(source, Isostent Inc). 
possible that increased doscs will decrease ill-stcnt restenosis, 
as has been descrihed in unimal studies.21 - H Therefore, a 
European Dose Response trial has been started with activities 
ranging from 1.5 10 3, 3 to 6, 6 to 12. and 12 to 20 MCi. 
Conclusion 
This study reporls that the implantation of (3-partie!c-emit-
ling radioactive stents with ,tn activity of n.75 to 1.5 /lCi is 
safe and feasible. 
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Chapter 12 
Compassionate use of intracoronary beta-irradiation for treatment of 
recurrent in-stent restenosis. 
(J Invas Card 199911:582-588) 
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Compassionate Use of Beta-Radiation Therapy 
Compassionate Use of Intra coronary 
Beta-Irradiation for Treatment of Recurrent 
In-Stent Restenosis 
Manel Sabate, MD, I. Patrick Kay, MBChB, Anthonie L, Gijzel, MD, 
Alexander 1. Wardeh, MD, Willem 1. Van der Giessen, MD, PhD, 
'Veronique L.M.A. Coen, MD, Jurgen M.R. Ligthart, BSe, Marco A. Costa, MD, 
Ken Kozuma, MD, P. Serrano, MD, ·Peter. C. Levendag, MD, PhD, 
Patrick W. Senuys, MD, PhD 
ABSTRACT: Recurrent in-stent rcstcnosis after balloon angioplasty poses a serious manage-
ment problcm. Previously y-radiatioll has beell shown to be effective in patients with in-stent 
restcnosis. The aim of the study was to detcrmine the feasibility and safety of p-radiation in patients 
with recurrent in-stent rcstcnosis. From May 1997 to December 1998, 18 patients were treated with 
balloon angioplasty (n = 8) or laser (n = 10), followed by intracoronary p-radiation at a prescribed 
dose of 16 Gray at 2 mm from the source, for reference diameters by quantitative coronary angiog-
raphy < 3.25 mm or 20 Gray for reference diameters 2:: 3.25 mm. Vessels trellted were as follows: left 
anterior descending: (II = 5); circumflex: (n = 4); right coronary artery: (n = 6); saphenous vein 
graft: (n = 3). Average recurrence rate was 2.4 ± 0.7 and the restenotic length was 16 ± 7 mm. p-
radiation was successfully delivered in all patients. Two patients presented complications related to 
laser debulking: a non-Q wave myocardial infarction in one and a rc-angiol)lasty due to uncovered 
distal dissection in another. Geographical miss, defined as an area which has bcen injured but not 
covered by the radiation suuree, was demonstrated in 8 patients. Seventeen patients (94%) complet-
ed the 6-month angiographic follow-up. Restenosis (> 50% Diameter Stenosis) was observed in 9 
patients (53%), leading to target lesion revascularizatioll ill 8 patients (47%). Six of the 9 restenoses 
were located in areas with geographical miss. Intracoronary J3-radiation for recurrent in-stent 
restenosis appears to be a safe and feasible management strategy. However, the mismatch between 
injured and irradiated area may lead to faillire of this therapy. 
J INVAS CARDIOL 1999;11:582-588 
Key words: balloon angioplasty, geographical miss, in-stellt restenosis, laser debulking, 
radiation therapy 
The long-term results of balloon angioplasty are lim-
ited by the occurrence of restenosis in 30-60% of all 
cases.l.2 Mechanisms involved in the restenotic process 
include acute recoil, ncointimal proliferation and late 
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vessel constriction."''' Stcn1 implantation demonstrated a 
beneficial effect by preventing both the acute recoil and 
the late negative remodeling of the vessel.'·· However, 
the restenosis after stent implantation, which is caused 
by neointimal hyperplasia, occurs in 15-20% of the 
cases."! Treatment orin-stent restcnosis is rather disap-
pointing, with recurrence rates of 38-50%,"'11 which 
increase with the number of re-interventions. 11 Radia-
tion therapy appears to be a novel therapy to inhibit the 
proliferative response after balloon-injury.IJ-I. Three 
randomized trials have demonstrated the efficacy of 
gamma-radiation in the treatment of in-stent resteno-
sis. "_'0 A nOll-randomized trial reported favorable 
results with the use of beta-radiation for the treatment 
Compassionate Use of Beta-Radiation Therapy 
Table 1. Baseline chnracteristics (n = 18) 
Gender (male): 
Age (years); 
Coronary risk factors 
Smoking 
Dyslipidemi.l 
Systemic hypertension 
Diahetes mellitus 
Family history of coronary Jisease 
Treated vessel 
Left anterior descending 
Left circumflex 
Right coronary artery 
Saphenous vein graft 
Recurrence Humber 
Stable angina; 
Clllltinllom d.lt;l are presented ~, mea" ± SD 
12 (67%) 
62 ± 10 
5 (28%) 
11 (61%) 
8 (44%) 
3(17%) 
8 (44%) 
5 (28%) 
4 (22%) 
6 (33%) 
J (17%) 
2A±O.? 
15 (83%) 
of in-stent restenosis.'LO To date, no data exist regarding 
the efficacy of brachytherapy in the subgroup of 
patients with recurrent in-stent restenosis. Thus, we 
designed this pilot study to evaluate the feasibility and 
safety of beta-radiation therapy in patients with recur-
rent in-stent rcstenosis. 
METHODS 
Patient selection. Patients eligible for the study 
were those with recurrcnt in-stent restenosis with 
objective evidence of ischemia. The following incitl-
sion criteria were required: the lesion treated involved 
the second episode of restenosis in the same stented 
segment; the lesion length had to measure < 25 mm 
and, the vessel size between 2.5 and 4.0 mm in diame-
ter. Patients were excluded if they had received previ-
ous radiation therapy on the chest; had a left ventricle 
ejection fraction < 40%; suffered from a recent 
myocardial infarction « 3 days), the target lesion 
would not withstand the source dwell time of> 3 min-
utes; the result· after BA was unsuccessful as defined 
by diameter stenosis> 35% or minimal luminal diame-
ter < 1.5 mm; and finally, an allergy or contraindica-
tion to aspirin. Female patients of child-bearing age 
required a negative pregnancy test and undertook not 
to get pregnant during the study. 
Radiation delivery system. The Beta-Cath 
System'" (Novoste Corp., Norcross, Georgia) was used 
to deliver localized beta-radiation at the site of coro-
nary intervention. The device consists of 3 compo-
nents: I) the transfer device which stores the radiation 
source train and allows the positioning of these sources 
within the catheter; 2) the delivery catheter, which is a 
5 French (Fr) multiluillen over-the-wire non-centered 
catheter which uses saline solution to send and rehlrn 
the radiation source train; and 3) the radiation source 
traill consisting of a series of twelve independent cylin-
drical seeds which contain the radioisotope 90Sr/90Y 
sources and is bordered by 2 gold radiopaque markers 
separated by 30 mm." 
Procedure. The Medical Ethics Committee of the 
Erasmus Medical Center, Rotterdam, approved the 
Figure 1. (A) COHmmy angiogra/Jhy of a sewre in-~Ienl restenmi, in a W(lll.lkn(" in a SIlphenollS venoHs bypass graft, (B) treated with 
concelllric laser debljlking, (C) followed by inlracoronary radiation. (DJ Angiogra/Jhic result of rhe /J1ocedllre. (EJ No significant angio-
graphic reslt'nml~· is observed at 6-monrh follow-up. 
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study and all patients signed a written informed con-
sent fonn, Patients received 250 mg aspirin and 10,000 
IU heparin at the initiation of the procedure, and addi-
tional doses of heparin were administered to maintain 
the activated clotting time> 300 seconds, In diffuse 
restenosis, plaque debulking was performed by the use 
ofVitesse II" excimer laser catheters of 1.7 or 2.0 mm 
(Spectranetics International BV., Colorado Springs, 
Colorado) followed by balloon angioplasty according 
to standard clinical practice. In focal restenosis, treat-
ment was performed only wilh ba!1oon angioplasly. 
After successful treatment, the radiation delivery 
catheter was placed at the target site. The radioactivc 
seeds remained in place during a dwell-time of 2.5 to 
4.0 minutes 10 deliver a dose of 16 Oy or 20 Oy for 
lesions with a reference diameter by quantitativc coro-
nary angiography < 3.25 mm or::::: 3.25 mm, respec-
tively. The dose was prescribed at 2 mm from the 
source. Because of thc low penetration force of beta-
energy in tissue, no additional measures were taken to 
protect the patient or slaff. The delivery of the radioac-
tive seeds was carried out by a radiation oncologist. 
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Figure 2. (AJ 
Coronary angiog' 
ra/lhy of a severe 
iws/C1H r('.I/enosis 
ill the rig/)t coro-
llar)' ar/ery, (B) 
treated with bal-
10011 angioplasty, 
(C) followed by 
intl'acoTonary 
radimion. (D) 
DeS/lire a goud 
angiogral,hic 
resulr, (E) a 
sel'ae resrcnosls 
was observed at 
foi/ow-JlII. 
FollOW-Up. Paticnts returned for 6-month clinical and 
angiographic follow-up. A conh'ol ECO was pe!fonned at 
the time of the visit. The following clinical endpoints 
were defined at 6 months: death, Q-wave myocardial 
in/arction {using the Minnesota eode criteria),~n bypass 
surgery, and target lesion revaseularization. 
Definitions. ill-slell! reslenosis was defined as local 
when the restenotic segment measured < 10 mm and dif-
fuse when it mcasured ~ 10 llUll. Procedural slIccess was 
defined as < 35% diameter stenosis post-procedure with-
out acute complications (corolHuy dissection, acute 
myocardial infarction or death). Geographicalllliss is the 
term used in radio-oncology to definc a c,mse offailurc of 
the trcatment due to low-dosage. In such cases, a small 
Palt of the treatmcnt zone has either escaped radiation or 
been inadequately irradiated because the total volume of 
the tumor was not appreciated and hence an insulTicicnl 
margin was taken.!) This concept is translated in intcrven-
tional cardiology for those cases where the radiation 
source cannot lhlly cover the injured area. 8asicalJy, two 
reasons may account for thi:,; phenomenon: coronary 
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Figure 3. Srrit11 COHJ!lt1ry t1ngiognnns sh(Jwing t1 coronary dissection following balloon angioplasty which involved Ihe diswI segment of [ite 
/ef! anterior descendill!: and tile second diagonal. AddilirmaI kissing balloon and stelll implantation were pery'ormed. The radimion SOllree 
could cover only rlie origiJwl re.ltenolic area (geographimI miss). At follOW-lip, a diffuse restenosis at the site of the geographimI miss wa.1 
delllOll,lfW!ed. 
dissection extended to the edges of the radiation source 
which leads to an additional treatment or source shorter 
than the targeted and injured area. Overall, there exist 
traumatized arcas receiving low dose which is potentially 
not able to prevent either neointimal proliferation or ves-
sel shrinkage. To identify those areas with geographical 
miss these steps were followed: during the procedure an 
balloon inflation and laser passes were filmed in the same 
projection as was the radiation source. This approach 
allowed LIS the correct matching of the cinefilms in the 
off-line analysis. By the lise of tile Rubo DICOM Viewer 
(Rubo Medical Imaging, Uithoom, The Netherlands), 
either of the cineloops showing balloon inllation, laser 
passes and radiation source may be displayed simultane-
ously on the screen. By selecting those frames in the same 
part of the cardiac cycle, we were able 10 define whether 
the radiation source completely covered the injured area. 
Quantitative coronary angiography. Quunt;tative 
coronary angiography was performed prior and after 
intervention, and at 6-month follow-up. An angiograms 
were analyzed after intracoronary administration of 
nitrates. The off-line analysis of at least two orthogonal 
projections was performed by means of the CAAS II 
analysis system (Pie Medical BV, Maastricht, The 
Netherlands). Calibration of the system was based on 
dimensions of the catheters not filled with contrast 
medium. This method of anillysis has been previously 
validated."'''' The following measures werc obtained in 
each projection: minimal luminal diameter, reference 
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diameter, percent diameter stenosis and lesion length. 
Lesion Icngth was user defined and not done by an 
algorithm using curvature analysis oflhe diameter func-
tion. ,J Reference diameter was obtained by an interpo-
lated method.'';''· Diameter stenosis post sten! 
implantation and at fonow-up was defined as the mini-
mal luminal diameter within the injured segment relat-
ed to the interpolated diameter measured over the 
length of the stent. Acute gain was defined as minimal 
luminal diameter measured after treatment minus mini-
mal luminal diameter pre-intervention. Late loss was 
defined as minimal luminal diameter post-intervention 
minus minimal luminal diameter at follow-up. Late loss 
index was defined a.s laic loss divided by acute gain.1/> 
Restcnosis was defined as > 50% diameter stenosis at 
follow up and located in the mediated area on either of 
the edges. 
Statistical analysis. Data are presented as mean ± 
standard deviation or proportions. To compare continuous 
data in patients treated with and without laser the 
unpaired two-tailed Student's t-test was perfonned. A 
value of p < 0.05 was considered statistically significant. 
RESULTS 
Baseline characteristics. From May 1997 to Febru-
ary 1999, 18 patients were treated according to the 
above protocol. Baseline characteristics of the study 
population are presented in Table 1. Number of 
Compassionate Use a/Beta-Radiation Therapy 
Table Z, Lesion and quantitative coronary angiography data 
Pat. Laser Stent Stent Lesion Pre !.J:rocedure Post !.J:rocedure Follow III' Acute Lale [ass 
no. Type Length Length MLD DS% RD MLD DS% RD MLD DS% RD GAin Index 
I ye. Wal!stent 39 26 0.45 80 2.28 1.80 30 2.58 1.89 29 2.66 1.35 -om 
2 ye. BARD 19 19 0.82 68 2.51 1.62 36 2.54 1.63 26 2.21 0.80 -om 
3 no Wal!stent 24 24 0.93 52 1.92 1.4 25 1.92 0.00 100 0.51 2.82 
4 ye. Wal!stent 34 6 0.70 70 2.37 1.77 28 2.46 1..38 43 2.41 1.07 0.36 
5 ye. Wallstent 34 26 0.07 97 1.87 1.35 23 1.76 0.70 69 2.24 1.29 0.51 
6 no AVE 39 16 0.95 66 2.76 2.02 30 2.90 1.58 41 2.67 1.07 0.41 
7 no NIR 9 9 0.00 100 2.51 1.95 2! 2.47 0.35 85 2.35 1.95 0.82 
8 no WaJlstcnt 24 14 0.82 70 2.77 1.98 26 2.67 1.79 29 2.54 1.16 0.16 
9 ye. Multilink 35 21 1.49 48 2.86 2,48 25 3.31 2.29 41 3.85 0.99 0.19 
10 ye. NIR 16 5 0.91 63 2.49 2.01 19 2.48 1.05 57 2,47 1.10 0.87 
II no Wallstent 34 7 0.55 74 2.14 2.25 38 3.61 0.1)0 80 4.00 1.70 0.85 
12 no Mullilink 25 23 1.18 51 2.39 1.77 33 2.66 2.30 16 2.74 0.59 -0.89 
!3 yo, BARD 19 2.1 0.92 56 2.\0 1.81 31 2.62 0.88 59 2.13 0.89 1.04 
14 y" Crown 22 19 1.04 46 1.93 1.59 19 1.97 NA NA NA 0.55 NA 
15 yO' Naevius 15 10 0.53 85 3.48 2.64 25 3.51 1.67 45 3.03 2.11 0.46 
16 no NIR 16 16 1.28 56 2.88 2.76 10 3.06 1.34 51 2.80 1.48 0.96 
17 no Bestent 25 9 1.08 47 2.03 1.49 19 1.85 0.81 54 1.76 0.41 1.65 
18 yO' Biodyvisio 15 15 0.70 75 2.79 2.16 17 2.60 0.61 78 2.77 1.46 1.06 
Mean 19 16 0.80 67 2,45 1.94 25 2.61 1.25 53 2.68 1.14 0.64 
SO 4 7 0.38 16 0.42 0,40 7 0.53 0.68 24 0.60 0.48 0.82 
MLD = minimal lumen diameter; DS = diameter steno5is; RD = reference diameter; NA = not Hv~ilablc 
recurrences ofrestenoses were 2 in 10 patients (55%), 
3 in 7 patients (39%) and 4 in 1 patient (6%). 
Procedural data. Lesion characteristics and QCA 
data are presented in Table 2. Laser debullcing was per-
fonned in 10 patients. Lesion length showed a trend to 
be longer in patients pre-treated with laser as compared 
to patients treated only with balloon angioplasty (l7 ± 7 
mm vs. 12 ± 3 mm, respectively;p = 0.06). Examples of 
patients treated either with laser debulking or balloon 
angioplasty alone prior to radiation are depicted in Fig-
ures I and 2. Procedural success was achieved in 16 
patients (89%). In two cases the procedure was compli-
cated by a dissection secondary to laser debulking lead-
ing to a transient occlusion of the vessel: a non-Q wave 
infarction occurred in one case and a re-angioplasty in a 
distal segment was performed in the other patient. Radi-
ation was successfully delivered in all cases. The pre-
scribed dose at 2 nun from the source was 16 Gy in 16 
patients and 20 Gy in 2 patients. Retrospective analysis 
of the angiograms revealed that geographical miss 
occurred in 8 cases: distal dissection in which additional 
stellts were implanted distal to the irradiated area (n = 3) 
and area injured by the balloon but not covered by the 
radiation source (n = 5). An example of the outcome of 
a patient with geographical miss is depicted in Figure 3. 
Ail patients were discharged asymptomatic. 
Follow-up, Seventeen patients (94%) returned for 
angiographic follow-up. One patient refused. Follow-up 
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QCA data are presented in Table 2. Restenosis was 
observed in 9 patients (53%). In 7 patients, the location 
of the restenosis was at the edge of the ilTadiated area, 
whereas in 2 patients it was within the irradiated area. 
The number of recurrences of restenoses were compara-
ble between restenotic and non-restenotic patients. Six 
of the 7 edge restenoses were in areas with geographical 
miss. There were neither deaths nor Q-wave myocardial 
infarctions observed at 6-month follow-up. Total lesion 
revascularization was perf0n11ed in 8 patients (47%): 3 
patients were referred for bypass surgery and 5 under-
went re-PTCA. Progression of atherosclerosis was also 
obseIVed in the non-irradiated vessels in the 3 patients 
referred for surgery. Acute gain, late loss and [ate loss 
index were similar between patients pre-treated wilh and 
without laser debulking (p = NS). 
DISCUSSION 
This study describes the use of bela-radiation thera-
py for the treatment of recurrent in-stent restenosis. 
Although this treatment modality is feasible and safe, 
the observed restenosis rate in this small cohort of 
patients remains rather high (53%), and is comparable 
to conventional treatment either wilh balloon angio-
plasty or debulking techniques. ro.11 The main finding 
was that the vast majority of the rcstenosis were located 
in areas with geographical miss. To date, three ran-
domized placebo-controlled trials have been carried 
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om to evaluate the efficacy of gamma-radiation in 
patients with restl:nosis. 11 '0) Teirstein et aI," random-
ized 55 patients to receive a 0.030" ribbon containing 
192 lr sealed sources or a ribbon containing placebo 
seeds (Best Industries, Springfield, Virginia). Thirty-
five patients were treated due to in-stent restenosis. 
The dosimetry was calculated based on intravascular 
ultrasound measurement in a range of 8-30 Gray to 
the internal elastic membrane. The placebo group 
showed a restenosis rate of70%, as compared to 14% 
in the irradiated group (p = 0.0006). This beneficial 
effect was sustained at 2-year follow-up." Waksman 
et ai, I' evaluated 130 patients who had developed in-
stent restenosis up to 470101 in the Washington Radia-
tion for In-Slent restenosis Trial (WRIST). These 
patienls were randomized 10 radiation using a 192 Ir 
ribbon versus a non-radioactive ribbon delivered into 
a non-centered closed-end lumen catheter (Medtronic, 
Minneapolis, Minnesota). The prescribed dose Was 15 
Gray to a distance of 2 0101 from the center of the 
source for a vessel size of 3.0~4.0 mm, and to a dis-
tance of 2.4 mOl from the center of the source for ves-
sel diameter of 4.0-5.0 l11ill. At 6-l11onth follow-up, 
the irradiated group showed a reduction of 67% in the 
restenosis rate, 79% in total lesion revascularization 
and 63% in major adverse cardiac events. Similarly, 
the multicenter randomized GAMMA-I trial demon-
strated a reduction of 58% in the restcnosis rate within 
the stenl. When considering the edges of the source, 
the reduction in the restenosis rate was 43%.19 Using 
beta-radiation therapy, the non-randomized Bcta-
WRIST trial demonstrated a reduction in target vessel 
revascu!arization of 47% when compared to a 
matched group froill the placebo ann of the WRIST 
trial.'° Although easier to implement in the catheteri-
zation laboratory, the usc of beta-radiation presents 
the potentia! dnlwback of the $teep dose fall-off, 
which might lead to inhomogeneity of the prescribed 
dose to the vessel wall." This phenomenon may be 
more pronounced when non-centered devices are 
used, where the dose reaching the predefined adventi~ 
lial volume might be as less as 30% of the prescribed 
dose." Considering these bela-radiation characteris-
tics, we hypothesize that areas with geographical miss 
may have received a very low dose which has not 
been able to inhibit either proliferation or vessel 
shrinkage. The importance of low-dose radiation in 
injured areas will be addressed in further ongoing ran-
domized shldies (START trial! INHIBIT trial). 
Limitations. This was a non-randomized, non-
placebo-controlIed study with a relatively small num-
ber of patients included. Thus, no conclusions 
regarding effectiveness of the beta-radiation for treat-
ment of this challenging population with restenosis can 
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be drawn. In this regard, the main cause associated to 
the restenosis in this cohort was the presence of injured 
areas not covered by the radiation source. This limita-
tion may be solved with the use of the recently devel-
oped longer radiation sources (up to 40 mOl). 
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Chapter 13 
Europeau C1iuical Trials 
(In: WaksnumR & Serruys pw, eds. Handbook of Vascular 
Brachytherapy 2"" edition. London: Martin Dunitz Ltd.: 191-201) 
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European Clinical Trials 
24. EUROPEAN CLINICAL TRIALS 
TllOraxcenter, University Hospital Dijkzi8t, Rotterdam, The Netherlands 
Mane! Sabate, Marco A Costa and Patrick W Serruys 
The pioneering work in the field of intravascular radiation therapy was originally 
carried out in Europe. In 1992. Liermann et al performed the first four cases of 
brachytherapy after femoral percutaneous angioplasty. I Subsequently, animal 
experiments carried out in the USA2,1 and Europe4 demonstrated the reduction 
of neointimal hyperplasia after endovascular radiotherapy. The insertion of a 
radioactive delivery catheter in human coronary arteries was performed for the 
first time by Con dado et al in Venezuela. 5 As a result of these pioneering 
investigations, the first clinical trials were reported in 1997: in the USA, 
Teirstcin et al demonstrated the effectiveness of gamma therapy for the 
treatment of in-stent restenosis,6 whilst in Europe, Verin et al reported the 
feaSibility of using beta sources after balloon angioplasty.7 
In Europe, most of the trials have been carried out using beta-radiation 
sources, either with catheter-based systems or radioactive stents, Overall, the 
initial target has been the treatment of de novo coronary stenosis. However, 
recent design trials have included patients with restenotic lesions. This chapter 
summarizes the clinical trials carried out in Europe either as a part of larger 
trials designed in the USA or primarily designed in Europe. 
Intracoronary radiation clinical trials using 
catheter-based o/stems 
The clinical trials with catheter-based systems are summarized in Table 24.1. 
Initially, these trials were aimed at demonstrating the safety and feasibility of 
beta emitters in coronary arteries. Currently, results from the dose-finding 
and placebo-controlled trials are pending. 
The GENEVA pilot clinical experience 
This was the first feasibility study performed in Europe (Geneva, Switzerland) 
and also the first in the world to use intracoronary beta-radiation in humans. 7 
A pure 90y beta-emitter source delivered via a centering catheter (Sclmeider 
Endovascular Radiation System, Schneider Worldwide, BiilIach, Switzerland) 
was used to deliver 18 Gy at the surface of the balloon in 15 patients with de 
novo coronary stenoses treated with balloon angioplasty. At follow-up the 
restenosis rate was 40%. The investigators considered these to be unfavorable 
results owing to an insuflicient dose administered at the adventitia « 4 Gy). 
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Intracoronary beta-radiation following PTCA for reduction of 
restenosis using the Boston Scientific/Schneider system: Dosc-
Finding Study 
This multi-center, prospective, randomized, non-controlled study aimed to 
determine the effect of four different doses of beta-radiation, using the 90y 
pure beta-emitting source via a centering catheter (Schneider Irradiation 
Therapy System, Biillach, Switzerland) on coronary stenosis. In five 
European centers, 181 patients were randomized to receive 9, 12, 15, or 
18 Gy at 1 mm tissue depth. The preliminary analysis demonstrated a dose-
dependent reduction in angiographic rcstenosis with an extremely low 
restenosis rate in the 18 Gy arm: 8.3% in all patients (stented and trealed 
with balloon alone) and 4.2% in patients treated with balloon alone (V 
Verin, personal communication, Congress of the European Society of 
Cardiology Barcelona, August 1999). Final results will be available by 
November 1999. 
BERT I.S (Beta Energy Restenosis Trial-1.5): the Rotterdam 
experience 
BERT 1.5 stands for the European arm of the BERT trial. This trial was 
conducted at the Thoraxcentcr in Rotterdam in 31 patients Crom April 1997 
to June 1998. This feasibility study was designed to test the 90Sr j90Y source in 
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a hydraulic system (Beta-Cath ™ system, Novoste Corporation, Norcross, GA, 
USA). The dose was randomized to 12, 14 or 16 Gy prescribed at 2-mm 
depth from the source axis. Twenty-three patients were treated with balloon 
angioplasty, whereas eight patients received a stent after radiation. Delivery of 
radiation was successful in all patients but one. At 6 months, the restenosis 
rate was 28% and target vessel revascularization 23%. Two thrombotic 
occlusions in patients receiving a stent after radiation were observed at the 
2.5- and lO-month follow-up.14 
Beta-Cath Trial 
This prospective, randomized, placebo-controlled trial aims to evaluate the 
safety and effectiveness of the 90Sr /90y source (Beta-Cath ™ system) versus 
placebo in de novo and restenotic lesions of native coronary arteries: Three 
centers in Europe are participating in this trial. Complete 8-month follow-up 
data will be available in 2000. 
BRIE Trial (Beta Radiation in Europe) 
This non-randomized trial is designed to evaluate the safety and performance of 
the 90Sr/90y source (BetaCath™ system) in de novo and restenotic lesions of 
native coronary arteries up to two vessels. This study is being carried out only in 
Europe (20 sites). Complete 8-mont-h follow-up ,data will be available in 2000. 
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START Trial (STents And Radiation Therapy) 
This prospective, randomized, placebo-controlled trial aims to evaluate the 
safety and performance of thc 90Sr/90y source (Beta-Cath ™ system) in the 
treatmcnt of in-stent restenosis of native coronary arteries. Two sites in 
Europe are involved in this study. The enrollment phase will be completcd by 
the end of 1999. One site in Europe will be involved in the START 40-20 
Trial, which is designed to assess the feasibility and efficacy of the 40-mm 
long 90Sr /90y source for the treatment of in-stent restenotic lesions. 
RENO Trial (European surveillance Registry with the Novoste Beta-
Cath ™ system) 
This prospective multi-center, multi-national surveillance registry is designed 
to assess the clinical event rate of 90Srj9oy source (Beta-Cath ™ system) 
combined with approved PTCA techniques (balloon angioplasty, rotablator, 
laser, and stenting) in patients with coronary artery disease (native or bypass 
grafts). This study is being carried out only in Europe (50 sites) and multi-
vessel treatment up to three vessels is allowed. 
PREVENT (Proliferation REduction with Vascular ENergy Trial) 
Prospective, randomized, blinded, multi-center study aimed to determine the 
safety of the Guidant (Santa Clara, CA) beta-radiation system in human 
coronary arteries following PTCA or stent implantation. The system consists 
of a 32p 27-mm source wire, a centering spiral balloon and an automatic 
computerized afterloader (Nucletron BV, Waardgeldcr, Veenendaal, The 
Netherlands). The enrollment phase has been completed in Europe and 6-
month angiographic and clinical follow-up data are expected by the first 
quarter of 2000. 
INHIBIT (INtimal Hyperplasia Inhibition with Beta In-stent Trial) 
A randomized, multi-center, double-blind, sham-controlled study started in 
the USA and Europe to demonstrate the clinical safety and efficacy of thc 
Guidant beta-radiation system for treatment of in-stent restenosis. The 
enrollment phase will be completed by the end of 1999 and 9-month 
angiographic and clinical follow-up will be available by the end of 2000. 
DURABLE Trial (DUtch RAndomized Brachytherapy study for 
Long-term evaluation of Efficacy) 
This randomized, placebo-controlled, double-blind study is aimed to assess 
the effect of brachytherapy by means of the Guidant intravascular 
brachytherapy system, after optimal balloon angioplasty (stenosis diameter 
< 35%), elective stenting, and indicated stenting (bail-out and suboptimal 
result) in patients with multi-vessel stentable lesions (up to two vessels) with 
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respect to MACE-free survival at 1 year. Nine hundred patients will be 
randomized in nine centers in The Netherlands. The enrollment phase started 
in October 1999. 
MARS (Mallinckrodt Angiopla~ty Radiation Study) 
This is the first European prospective registry to assess the feasibility and 
safety of the I 86 Re liquid-filled balloon (Mallinckrodt System) for the 
treatment of de novo coronary lesions. Results at the 6-month follow-up will 
be available by the end of 1999. 
The GRANITE Study (Gamma-Radiation to Atheromatous 
Neointima using IntracoronaryTherapy in Europe) 
This is the first trial utilizing gamma-radiation for the treatment of coronary 
in-stent restenosis in Europe. Patients will be followed up for 3 years at 11 
sites in Europe including France, Germany, Italy, and The Netherlands, as well 
as one site in Australia. The radiation system (Gamma IRTTM Delivery System, 
Cordis, Miami, FL) consists of a ribbon of radioactive 192Ir seeds (up to 
55 mm in length) that will be delivered to the target lesion via a delivery 
catheter with a closed end lumen and using a hand-cranked 
containment/delivery device. The radioactive ribbon will be left at the 
angioplasty site for between 15 and 25 min to deliver the prescribed dose. 
Intracoronary radiation clinical trials using 
radioactive stents 
The clinical trials utilizing radioactive stents have demonstrated safety and 
effectiveness in preventing neointimal proliferation in a dose-related manner. 
Hmll/cver, a new phenomenon has become evident: restenosis at the edges of 
the high activity radioactive stent, coined the 'candy wrapper' effect. 8 The 
clinical trials using radioactive stents are summarized in Table 24.2. 
IRIS Trial (Isostent for Restenosis Intervention Study) 
This feaSibility registry involved three centers in Europe in which 40 
radioactive stents with an activity of O. 75~1.5 /-LCi were implanted. This trial 
demonstrated feasibility and safety with a restenosis rate that ranged between 
17% (Rotterdam)9 and 50% (Milan).l0 
European 12p Dose-Response Study 
This dose-finding study is being conducted in five centers in Europe. 
Radioactive stents of four ranges of activity have been utilized; 1.5-3.0; 
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3.0-6.0; 6.0-12; and 12-20 fLCi. The Milan group (n = 82 patients) reported 
a suppression of the neointimal hyperplasia in a dosc~relatcd manner (between 
1.5 and 12 fl-Ci). Edge restenosis (,candy wrapper') was observed in 36% for 
1.5-3.0 fLCi, 38% for 3.0-6.0 fLCi, and 50% for 6.0-12-fLCi activity 
levels. 10 Currently, the Milan group is evaluating the use of stent activities up 
to 20 p,Ci. ,The Heidelberg group enrolled 11 patients for radioactive stent 
implantation of activity levels between 1.5 and 3.0 fJ..Ci. larget vessel 
revascularization was 36%, mainly at the articulation of the Palmaz-Schatz 
stent. II In Rotterdam, 40 patients have been evaluated after 6. 0-12 .0~/-LCi 
radioactive stent implantation. To date, 18 patients have returned for 
angiographic follow-up. No restenosis (> 50% diameter stenosis) was 
observed within the stent. However, at the edges of the stent the restenosis 
rate reached 55%, leading to target vessel revascularization in 30% of the 
patients (AJ Wardeh, personal communication). Data from the Vienna 
experience will be available at the end of 1999. 
Two trials have been deSigned to address the problem of edge restenosis. 
The Cold End Study is aimed to determine the efficacy and safety of the 
32p 2S-mm Fischell BX stent, of which both 5-rnm ends are inactive ('cold 
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ends'). Conversely, the Hot End Study is aimed to determine the efficacy 
and safety of the 32p 18-mm Fischell BX stent, of which both 2-mm ends 
present with higher activity (,hot ends') as compared with the inner 14 mm, 
which has a total activity ranging from 4.5 to 9 /-I>Ci. These two studies are 
still in the enrollment phase. 
Conclusions and future perspective 
The use of endovascular beta-radiotherapy in Europe demonstrated that this 
therapy is safe and feasible. Furthermore, preliminary results of a dose-finding 
study with the Roston Scientific/Schneider system have been very promising (V 
Verin, personal communication). This beneficial effect of radiation in preventing 
restenosis may be explained partially by the positive influence of brachytherapy 
on the remodeling process. 12,13 However, some detrimental clinical 
consequences of intracoronary radiation may also be recognized from the 
European experience. The edge effect, also named' candy 'lVrapper effect', was 
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reported by Albiero et al after radioactive stent implantation. lO Further, the 
occurrence of late coronary thrombosis has been associated with radiotherapy. 14 
This phenomenon may be the consequence of delayed endothelialization, 
persisting russections l5 or the inability of tubular stents to follow vessel 
enlargement promoted by radiation leading to late stent malapposition. 16 
Potential solutions for these problems include the use of new designs of 
radioacti~e stents or hybrid techniques (catheter-based + radioactive stent)!7 
in addition to the use of prolonged anti thrombotic therapy. Also, the 
avoidance of conventional stent implantation may be considered in the setting 
of catheter-based endovascular radiotherapy. 
There are still several unanswered questions which should be resolved 
before determining the potential of this new technique. First, the usc of beta 
or gamma sources or a combination of both. Secondly, the use of centering or 
non-centering devices. Further, to determine the best vehicle for radiation: 
solid (wire or train of seeds), liquid (filled-balloon) or gaseous. Equally, the 
clinical effect of the dose-rate (radioactive stent-Iow dose-rate versus 
catheter-based radiation-high dose-rate). Finally, the target tissue must be 
dermed, as well as the minimal effective dose to be delivered. Hopefully, after 
the completion of ongoing trials in Europe, as well as in the USA, many of 
these issues will be answered. 
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Summary and Conclusions 
Vascular brachytherapy is the technically most innovative and exciting recent development in 
Interventional Cardiology. 
The part I of this thesis, reports on the structural and functional changes that intracoronary 
beta-radiation therapy induces in coronary tissue when delivered either by catheter-based 
systems or radioactive stent. After plain balloon angioplasty catheter-based radiotherapy 
induces vessel enlargement which is able to acconnnodate the increase in plaque volume that 
occurs after this coronary intervention (Chapter I). Furthermore, the use of conventional stent 
before or immediately after brachytherapy does not preclude the development of this positive 
remodeling ofthe vessel wall.(Chapter 2 and 3) Potentially, this phenomenon may lead the stent 
to become malapposed during the follow-up period which may account for the development of 
late thrombotic occlusion as witnessed in excess in this population (Chapter 8). This vessel 
enlargement may be explained by inhibition of migration but not of cellular proliferation that 
occurs at low dose of radiation. Further, the production of a-actin by the adventitial 
myofibroblasts is decreased after brachytherapy. Therefore, cells may remain in situ unable to 
migrate but able to grow in the presence of positive vascular remodeling. After one week, the 
effect of radiation diminishes and cellular proliferation as a reaction to the presence of the 
stent, occurs behind the stent in the context of positive remodeling. In stark contrast to what is 
observed after catheter-based radiotherapy, vessel enlargement is not seen after radioactive 
stent implantation. (Chapter 3) In such cases, it is hypothesized that the continuous and low 
dose rate provided by the stent creates a "radioactive fence" which prevent the migration and 
invasion of myofibroblasts from the adventitia through the stent struts and into the lumen. 
Thus, adventitial cells remain intact without upregulation of growth factors and inhibition of 
contractile proteins. 
Another important structural finding demonstrated during the follow-up in patients who 
received either catheter-based radiation or high activity radioactive stent is the development of 
the so-called "edge effect". (Chapter I and 3) The combination of increase in plaque volume 
and absence of vessel enlargement or even vessel shrinkage was the common structural change 
observed at the edge of the irradiated coronary segment. 
Finally, irradiated coronary segments were functionally tested at 6-rnonth follow-up after 
plain balloon angioplasty. The endothelium-dependent vasodilator acetylcholine was selectively 
infused in the coronary segments of patients in stable condition formerly irradiated by means of 
catheter-based system. A vasodilatory response was observed in most of these patients which 
was indicative of restoration of the endothelial function. This favorable functional response 
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may play an important role in the potential beneficial efiect of the radiation therapy on the 
restenosis process. 
The part n of this manuscript reports on dosimetry calculated from intravascular ultrasound 
studies performed in patients treated with catheter-based brachytherapy systems (Chapters 5 
and 6). The first, main finding demonstrated in those studies is the inhomogeneity of the 
radiation dose demonstrated when non-centered devices are used. Further, the effective dose to 
be delivered to the adventitia volume, as considered to be the target volume in intracoronary 
radiotherapy, has been determined to range between 4 and 6 Gy. However, this optimal 
radiation dose was delivered in less than 50% of the irradiated coronary segments. In addition 
to these findings, residual plaque burden, delivered dose and tissue composition have been 
identified as independent predictors of plaque volume at 6-month follow-up, as assessed by 
intravascular ultrasound. (Chapter 5) All the above mentioned factors have to be taken into 
account when intracoronary radiation treatment is planned. 
The part ill of the thesis describes a new methodological approach based on quantitative 
coronary angiography, in order to homogenize the interpretation of results from clinical studies 
aimed to define the effectiveness of brachytherapy. Since vessel enlargement frequently occurs 
at the site of the previous target lesion, minimal luminal diameter may be relocated at follow-up 
in a different coronary subsegment. As a result, discrepant results may be obtained depending 
on the region subject to the analysis. The definition and identification of the target segment, 
irradiated segment, injured segment and vessel segment, may be helpful to understand the 
mechanism of action of this new treatment modality. (Chapter 7) 
The part IV ofthis manuscript reports on the potential complications derived from the use of 
beta-radiation therapy. The development of late thrombotic occlusion occurs in excess either 
after plain balloon angioplasty or after stent implantation in the context of catheter-based 
brachytherapy system. (Chapter 8) The use of double antiplatelet regimen (aspirin and 
clopidrogrel) for long-term may reduce this undesirable effect. Several mechanisms are 
hypothesized to be involved in this phenomenon: first, a delay in stent re-endothelisation may 
occur after brachytherapy. Furthermore, baUoon-induced coronary artery dissections may not 
be resolved during the follow-up period as witnessed in a great proportion of patients treated 
with balloon angioplasty and catheter-based radiation therapy. (Chapter 9) Finally, as 
discussed in previous chapters, the vessel enlargement may induce late stellt malapposition 
which is a we1l known subtract for stent thrombosis. 
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Another complication which may be linked to the development of the "edge effect" is the 
occurrence of geographical miss. This concept has been genuinely used in radio-oncology to 
define that cause of treatment failure due to low dose radiation. Radiation dose at the edge of 
the source is rather low due to the steep decay of beta radio-isotopes. This feature when 
combined with the stimulus of the injury (balloon or stent-induced injury) has been 
demonstrated to provoke a higher-than-expected late loss as compared to those non-injured 
edges. (Chapter 10) 
The knowledge of all the above sources of complications may help to improve the 
performance and safety of intra coronary radiation therapy. 
In the part V of the thesis the results of some clinical trials performed by this new therapy 
are described. The implantation of low activity radioactive stent has been demonstrated to be 
safe and feasible. However, the restenosis rate was comparable to conventional stent 
implantation. (Chapter II) The use of catheter-based beta radiation is also feasible in recurrent 
in-stent restenosis. Nevertheless, the occurrence of restenosis in this cohort of patients 
appeared to be rather high probably due to the presence of geographical miss. (Chapter 12). 
Finally, a summary of the trials currently under way in Europe is described in the Chapter 13. 
FUTURE DIRECTIONS.- There are still several unanswered questions which should be 
defined before determining the potential of this new technique. First, the use of fi- or y- sources 
or a combination of both. Secondly, the use of centering or non-centering devices. Further, to 
determine the best vehicle for radiation: solid (wire or train of seeds), liquid (filled-balloon) or 
gaseous. Equally, the clinical effect of the dose-rate (radioactive stent-Iow dose-rate versus 
catheter-based radiation-high dose-rate). And, finally, to define the subgroup of patients which 
will benefit most from this new technique. 
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Samenvalling en Conclusies 
Vasculaire brachytherapie is de meest vernieuwende en veelbelovende recente technische 
ontwikkeling in interventie cardiologie. 
In het eerste deel van dit proefschrift vermelden we de structurele en functionele 
veranderingen die ontstaan in coronair weefsel, na bestraling door middel van intracoronaire 
katheters of radioactieve stents. Na klassieke ballonangioplastiek induceert radiotherapie een 
vergroting van het lumen waardoor de toename in plaquevolume na coronaire interventie 
geneutraliseerd wordt ('positive remodeling'). (Hoofdstuk I) Verder verhindert het gebruik van 
een conventionele stent voor of onmiddellijk na brachytherapie deze 'positive remodeling' van 
de vaatwand niet (hoofdstuk 2 en 3). Dit fenomeen zou kunnen leiden tot malappositie van de 
stent tijdens follow-up, wat de oorzaak kan zijn van late thrombotische occlusie, zoals 
veelvuldig beschreven in deze populatie. (Hoofdstuk 8). 'Positive remodeling' kan worden 
verklaard door het voorkomen van migratie van cellen, maar niet door de inhibitie van cellulaire 
proliferatie welke zich voordoet bij lage stralingsdoses. De productie van alfa~actine door de 
myofibroblasten in de adventitia neemt af na brachytherapie, waardoor cellen zich niet 
verplaatsen maar ~el kunnen groeien tijdens de 'positive remodeling'. Na een week neemt het 
effect van de bestraling af en als reactie op de stent ontstaat celvenneerdering achter de stent, in 
samenhang met 'positive remodeling'. In tegenstelling tot eerdere observaties wordt 'positive 
remodeling' niet waargenomen na het implanteren van een radioactieve stent (Hoofdstuk 3). In 
dergelijke gevallen is het mogelijk dat een continue lage dosis bestrating vanuit de stent een 
'radioactieve aftastering' vonnt, die de migratie en het binnendringen van myofibroblasten in 
het lumen vanuit de adventitia door de stentstruts belemmert. Zo blijven adventitiacellen intact 
zonder stimulatie van groeifactoren en inhibitie van contractiele eiwitten. 
Een andere belangrijke bevinding tijdens de follow-up van patienten behandeld met 
brachytherapie, zowel door katheter systemen dan wei door radioactieve stent, is het 
zogenaamde 'edge'effect (Hoofdstuk I en 3). De combinatie van plaque toename en het 
uitblijven van vaatverwijding of zelfs het optreden van vaatvemauwing, was de meest 
voorkomende structurele verandering die werd geobserveerd. 
Ook testten we de functie van de bestraalde coronaire segmenten 6 maanden na de klassieke 
ballonangioplastiek. Warmeer we acetylcholine (endotheel afhankelijke vasodilator) selectief 
infuseerden in de coronaire segmenten van stabiele patienten, eerder behandeld met 
brachytherapie (katheter systemen), zagen we in de meeste gevallen vasodilatatie optreden, 
suggestief voor het herstel van de endotheelfunctie. Deze gunstige res pons kan een belangrijke 
rol spelen in het potentieel positieve effect op het restenose proces. 
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In het tweede deel van dit proefschrift beschrijven we de dosimetrische berekeningen uit 
intravasculaire ultrageluid studies, bij patienten behandeld met brachytherapie (hoofdstuk 5 en 
6). De eerste belangrijke bevinding is dat de stralingsdoses bij gebruik van niet-gecentreerde 
katheter systemen niet homogeen zijn. Wij vonden dat de effectieve dosis die de adventitia, het 
doelwit van brachytherapie, dient te ontvangen, tussen 4 en 6 Gy bedraagt. Deze optimale dosis 
werd echter bij minder dan 50% van de bestraalde coronair segmenten toegediend. De 
hoeveelheid resterende plaque, de toegediende dosis en de samenstelling van het weefsel, zijn 
voorts onafhankelijke voorspellers van plaque volume bij 6 maanden follow-up zoals gezien bij 
intravasculair ultrageluid (hoofdstuk 5). 
In het derde deel beschrijven wij een nieuwe methodologische benadering gebaseerd op 
kwantitatieve coronaire angiografie, teneinde een standaard interpretatie van studieresultaten 
van de effectiviteit van brachytherapie te verkrijgen. Omdat vaatverwijding vaak optreedt op 
de plaats van de behandelde stenose, zou bij een vervolgstudie een rninimale lumendiameter 
gesitueerd kunnen worden in een ander coronair segment. Dit kan tot gevolg hebben dat er 
tegenstrijdige resultaten gevonden worden, afhankelijk van de geanalyseerde gebieden. Het 
definieren en identificeren van het te behandelen segment, het bestraalde segment, het 
beschadigde segment en het vaatsegrnent kan behulpzaam zijn bij het begrijpen van de 
werkingsmechanismen van deze nieuwe behandelingsmethode (hoofdstuk 7). 
In het vierde deel bespreken we de mogelijke complicaties die verband houden met het 
gebruik van beta bestraling. De ontstaan van late thrombotische occlusie wordt frequent gezien 
na ballon angioplastiek of stent implantatie, gecombineerd met brachytherapie (hoofdstuk8). 
Het gebruik van een gecombineerd langdurig anti-plaatjesregime met aspirine en clopidogrel 
kan deze complicatie voorkomen. Verscheidene mechanismen kunnen bijdragen tot het optreden 
van late thrombotische occlusie: een vertraging in de stent re-endothelialisatie, persisterende 
dissectie 6 maanden na ballon angioplastiek in combinatie met brachytherapie (hoofdstuk 9) en 
het optreden van vaatverwijding met mogelijke stent malappositie. Een andere cornplicatie, die 
te maken kan hebben met het 'edge' effect is het optreden van 'geographical miss". Dit concept 
is oorsprookelijk gebruikt in de radio-oncologie, om het falen van een te lage stralingsdosis te 
beschrijven. De stralingsintensiteit aan de randen van de bron is laag, vanwege het hoge verval 
van beta radio isotopen. Deze eigenschap is samen met de ballon- of stent gelnduceerde 
beschadiging verantwoordelijk voor de onverwacht grotere reduktie van lumen in vergelijking 
met de onbeschadigde randen. (hoofdstuk 10) 
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Kennis van boven beschreven complicaties kan helpen bij de verbetering en uitvoering van 
brachytherapie. 
In het vijfde deel beschrijven we de resultaten van een aantal klinische studies, met deze 
therapie. De implantatie van laag-actieve radioactieve stents is mogelijk en veilig gebleken. Het 
restenose percentage echter was te vergelijken, met dat van conventionele stentimplantatie. 
(Hoofdstuk 11). Het gebruik van brachytherapie is ook mogelijk bij recidiverende in-stent 
restenose. Desalniettemin blijft het percentage restenose in deze groep patii!nten vrij hoog, 
waarschijnlijk ten gevolge van het optreden van 'geographical miss' (Hoofdstuk 12). In 
hoofdstuk 13 tenslotte, geven wij een overzicht van de lopende Europese studies op dit gebied. 
TOEKOMSTVERWACHTINGEN.- Verscheidene vragen dienen te worden beantwoord, 
voordat het nut van deze techniek detinitief kan worden vast gesteld: het gebruik van beta- of 
ganuna bronnen of een combinatie van beiden; gecentreerde versus niet-gecentreerde bronnen; 
het bepalen van het beste medium om de straling toe te dienen; vast (draad of een reeks van 
radioactieve zaden), vloeibaar (een met radioactieve vloeistof gevulde baIlon), of in gasvonn; 
het klinische effect van de dosis (radioactieve stent met lage dosis ten opzichte van hoge dosis, 
toegediend met het kathetersysteem); de bepaling van de subgroep van patienten die het meest 
gebaat zijn met deze nieuwe techniek. 
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